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ABSTRACT 
The role of HLA class I molecule interaction with their receptors in NK cell education is 
well established, but the molecular mechanism behind it as well as the role of these ligands on 
their receptors acquisition during NK cell development, are still unclear. Trying to give more 
insight to these questions, two different studies were performed on NK cells derived from 
patients presenting a genetic defect in the transporter associated with antigen processing (TAP), 
leading to a strongly reduced surface expression of HLA class I molecules. 
In our first paper, the expression of HLA class I receptors (three killer immunoglobulin-
like receptors (KIR) - KIR2DL1/DS1, KIR2DL2/3/DS2 and KIR3DL1 - NKG2A, CD8) and the 
maturation marker CD57 were dissected in seven TAP-deficient patients and a panel of healthy 
donors (HD). A comparison of the two NK cell statuses (healthy and TAP-deficient) showed a 
significant increase in HLA class I receptors’ co-expression in TAP-deficient compared to 
healthy NK cells. Functionally, hyporesponsiveness was confirmed for TAP-deficient NK cells: 
no cytotoxicity, degranulation nor IFN-γ production following co-culture with K562 cells. Only 
one patient presented functional NK cells with HLA class I receptors’ co-expression pattern 
being different form HD’s one. 
In parallel, whole genome microarrays were performed on TAP-deficient vs HD’s NK 
cells, aiming to identify the maturation (from CD56bright to CD56dim) as well as cytotoxicity 
pathways which may be affected by HLA class I expression. The comparison of both statuses 
showed similar maturation processes (with different CD56bright and CD56dim gene profiles). 
Following 5 hours of CD56dim NK cells co-incubation with K562 cells, different gene clusters’ 
evolution lead to identical final profiles contradicting the significant functional difference. 
Taken together, our data demonstrate a strong effect of HLA class I molecules on NK 
cell maturation and functionality as well as on their KIR repertoire formation. 
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INTRODUCTION 
1. Antigen Processing and Presentation 
1.1. Introduction 
During their lives, mammals are threatened by numberless pathogens (parasites, fungi, 
bacteria and viruses) as well as malignantly transformed cells. As a protection, evolution 
developed a sophisticated system of adaptive and innate immune cells, capable of differentiating 
the “self” from the “non-self” and defending the organism. This recognition is based on a turnover 
of cellular peptides which are presented on the surface of each nucleated cell by Major 
Histocompatibility Complex (MHC) class I molecules. The expression of MHC class I molecules 
is peptide dependent. Peptides resulting from the degradation of proteins by the proteasome are 
translocated into the Endoplasmic Reticulum (ER) lumen by the Transporter Associated with 
Antigen Processing (TAP). Once in the ER, these peptides are loaded on the MHC class I 
molecules by the Peptide Loading Complex (PLC), then processed to be expressed on the cell 
surface (Fig. 1). 
In this first chapter, we will present the different steps implicated in the peptide processing 
and presentation, on the cell surface, by MHC class I molecules, with an emphasis on TAP 
protein, around which the PLC is centred. 
 
1.2. MHC class I molecules 
MHC class I molecules are expressed on the surface of almost all nucleated cells and play 
a very important role in the immune system function. Gene products encoded in the MHC complex 
region were first identified as being important in rejection of transplanted tissues. Different crystal 
structures of MHC class I molecules have been determined [14-17] showing the existence of two 
conserved domains, homologous to Immunoglobulin (Ig) constant region domains, which 
constitute the membrane-proximal region. The first one is a transmembrane glycoprotein with 
short cytoplasmic domains: the heavy chain, and the second is a soluble product of a non-MHC-
linked gene: β2-microglobulin (β2m) (Fig. 2A). MHC class I genes exhibit enormous allelic 
polymorphism especially in the amino acids (aa) constituting the peptide binding structure (the 
membrane-distal groove) formed by two antiparallel α-helices overlaying an eight-strand β-sheet 
(Fig. 2B). These variations allow the specific binding of a wide range of 8-11 mers peptides [13]. 
MHC class I molecules are directly translated, by the ribosome, in the ER lumen. It first encounters 
two different chaperones: BiP (binding Ig protein) and calnexin (CNX). After the assembly of β2m, 
CNX is replaced by its soluble form, calreticulin (CRT) and the complex CRT-MHC/β2m joins the 
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PLC [18] (Fig. 1). This last step allows the stabilisation of the empty MHC class I molecule and 
the maintenance of its binding groove in a favourable conformation for the high-affinity peptide 
loading. 
 
Figure 1: Antigen processing and binding to MHC class I molecules in the Endoplasmic 
Reticulum (ER). 
MHC class I (MHC-I) molecules are synthesized in the Endoplasmic Reticulum (ER), folded by Calnexin 
(CNX), then assembled with β2-microglobulin (β2m). The MHC-I/β2m complex is then recruited to the 
Peptide Loading Complex (PLC) by Calreticulin (CRT). In the cell cytoplasm, endogenous proteins and 
Defective Ribosomal Products (DRiPs), originated from the translation of either self or foreign (i.e., viral) 
RNA, are degraded into peptides by the proteasome and then translocated into the lumen of the ER by 
Transporter Associated with Antigen Processing (TAP). These peptides may further undergo trimming 
by ER aminopeptidases known as ERAAP/ERAP1 and ERAP2 before being loaded on the MHC-I 
molecules by Tapasin and ERp57. The resulting complex, MHC-I/β2m-peptide is then expressed on the 
cell surface. Taken from [11], permission number 11163370. 
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In human, MHC class I molecules, or Human Leukocyte Antigen (HLA) class I molecules, 
can be divided into two groups: HLA class Ia comprising HLA-A, HLA-B, HLA-C, and HLA class 
Ib, for HLA-E, HLA-F and HLA-G. The same subdivision exists in mice, where the 
H-2D, H-2K and H-2L subclasses are part of the MHC class Ia molecule group, and H-2Q, H-2M 
and H-2T subclasses belong to the MHC class Ib, or the non-classical MHC molecules, group. 
 While MHC class Ia molecules bind to peptides resulting from the degradation of cytosolic 
proteins by the proteasome, MHC class Ib molecules, specifically HLA-E in human and Qa-1 in 
mice, bind to peptides derived from the leader sequence of MHC class Ia molecules. Both 
subclasses’ expression depends on the translocation, into the lumen of the ER by TAP, of the 
specific peptide [19]. 
Figure 2: Crystal Structure of a MHC class I molecule complexed with a peptide. 
(A) Shown is the crystal structure of a MHC class I molecule (HLA-A2) formed by the 
heavy chain (green) and the β2-microglobulin (β2m) (blue), complexed with a peptide 
(HCMV pp65-495-503 nonapeptide A7H variant) (red). (B) Shown is the membrane-distal 
groove formed by 2 α-helices and 8 β-sheets (green) presenting the HCMV pp65-495-
503 nonapeptide A7H variant (red). PDB fi le 3MRB. 
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1.3. The Proteasome and Protein Degradation 
The proteasome, a 26S barrel-shaped structure formed by the assembly of one 20S with 
two 19S structures, is responsible of the protein degradation in the cytosol. The 20S structure is 
a four axially stacked rings of seven subunits each (α7β7β7α7) (Fig. 3). Each of the two outer rings, 
composed of α-subunits, is capped by a 19S multisubunit complex which recognises, 
deubiquitinilate then unfold the ubiquitinilated proteins directed for degradation. The resulting 
proteins are then processed into the centre of the proteasome where the active sites reside. 
These proteolytic sites are formed by the middle two rings constituted by seven β-subunits, three 
of which are the active ones: β1, β2, and β5, whose genes (LMP1, LMP2, and MECL1) are MHC-
linked [11, 20]. Under interferon-γ (IFN-γ) and interferon-β (IFN-β) induction, these three 
β-subunits are replaced by other variants (β1i, β2i, and β5i) and form the immunoproteasome [13, 
21]. Compared with the proteasomes, immunoproteasomes show a different cleavage pattern 
resulting in peptides that are more favourable to the MHC class I presentation [13, 22]. 
 
 
Figure 3: The 26S proteasome structure. 
The 26S proteasome is formed by 3 different components, a 20S barrel shaped 
proteasome caped with two 19S multisubunits. The latter component being essential for 
the opening of the 20S proteasome as well as the recognit ion and binding of 
ubiquit inilated proteins, both functions requiring ATP hydrolysis. The 20S proteasome is 
an assembly of two inner heptameric r ings (β-subunits) containing the catalytic sites, 
and two outer r ings comprising seven different α-subunits. Adapted from [1], permission 
number 3326560776967. 
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Peptides presented by MHC class I molecules can have different sources, the major one 
being endogenous proteins and ones derived from viral genetic material. Another important 
source of peptides are defective ribosomal products (DRiPs) [23, 24] that include: defective 
polypeptides resulting from alternative/defective mRNAs, ribosomal frameshift and different 
translation errors [25, 26]. Other possible sources of MHC class I molecules’ binding peptides are 
specific epitopes generated by nardilysin, thimetoligopeptidase and the insulin-degrading enzyme 
(IDE) present in the cytoplasm [13]. 
The products resulting from the proteolysis by the 26S proteasome (20S plus two 19S) 
are generally 3-22 mers [27], most of them being either too long either too short to be loaded on 
MHC class I molecules (cf. chapter 1.2. MHC class I Molecules). Further trimming, in the cytosol 
of long peptides is possible by aminopeptidases: leucine aminopeptidase, puromycin-sensitive 
aminopeptidase, bleomycin hydrolase and the tripeptidyl peptidase II (TPP II) [13, 28, 29]. The 
role of these aminopeptidases is controversial, especially TPP II that was supposed to be the 
source of many peptides’ generation [30]. These studies where later on contradicted when TPP 
II knockout (KO) mice were shown to present no major defects in antigen presentation [31, 32]. 
One clear effect of these aminopeptidases seems to be more negative for the antigen 
presentation, as they destroy more MHC class I ligands then they create [33]. 
 
1.4. TAP protein 
1.4.1. History, Structure and Characterisation 
Studies on cells with MHC class I expression deficiency revealed deletion of one or several 
genes in the MHC class II locus region [34, 35]. Mapping of this locus by gene deletion analysis 
allowed the identification of different candidates involved in the peptide translocation [36]. Four 
different genes were characterised [37-40] and were later renamed to TAP by the World Health 
Organization (WHO) nomenclature committee for factors in the HLA system [41]: RING4, PSF1, 
mtp1 and HAM1 are now called TAP1, and RING11, PSF2, mtp2 and HAM2 were renamed TAP2. 
TAP belongs to the ATP-binding cassette (ABC) transporter family, which under 
consumption of adenosine triphosphate (ATP), translocates various substrates across 
membranes. ABC transporters present a common structure formed by two hydrophilic nucleotide-
binding domains (NBD), located in the cytosol, and two hydrophobic transmembrane domains 
(TMD). The NBD are characterised by highly conserved sequences: Walker A, Walker B, the C, 
D and Q loops, involved in the ATP binding and/or hydrolysis [4] (Fig. 4A). 
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TAP is a heterodimeric protein composed of 2 subunits: TAP1 (ABCB2) and TAP2 
(ABCB3) [42], whose genes are 8 and 12 kb respectively. This protein is anchored in the ER 
membrane and the cis golgi, and transports peptides from the cytosol to the lumen of the ER. No 
functional homodimers of TAP1 and TAP2 were found [43, 44]: deletions of either or both genes 
results in a dramatic decrease in MHC class I surface expression which can be corrected by the 
Figure 4: TAP membrane topology, and peptide translocation to the ER lumen. 
(A) Shown is TAP1 membrane topology (similar to TAP2). EL1, EL2 and EL3 are the ER-
luminal loops, CL1 and CL2 the two cytosolic loops, NBD for Nucleotide binding domain, 
and TMD0 the four transmembrane domains. (B) Peptide translocation into the ER lumen 
requires the hydrolysis of two ATP molecules into two ADP molecules. The cycle starts 
by TAP loaded with two ATP molecules. Following the peptide binding, a conformational 
change occurs in TAP leading to the engagement and tr iggering of the NBDs. The 
hydrolysis of the two ATP molecules results in the peptide release in the ER lumen and 
disengagement of the NBDs, restoring the init ial TAP conformation. After the ADP 
exchange to ATP, the cycle starts again. Adapted from [4], permission number 
3356010086623. 
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addition of exogenous class-I binding peptides [34]. Each of the two TAP subunits can be 
dissected into: the core TAP complex, or the COOH-terminal NBD, and the NH2-terminal TMD 
domain, called TMD0 which is involved in Tapasin (Tsn) recruitment. 
 
1.4.2. Role of TAP protein in Peptide Translocation 
TAP protein translocates peptides into the lumen of the ER by 2 successive steps: the 
ATP-independent peptide binding [45] followed by its transport into the ER which requires ATP-
hydrolysis into adenosine diphosphate (ADP) [46] (Fig. 4B). 
The peptide binding to TAP is not a random mechanism as this protein was revealed to 
be stereospecific [47]: the introduction of D-amino acids leads to a drastic decrease of the peptide 
binding and translocation. Other peptide characteristics are also important: the peptide’s first three 
N-terminal and the last C-terminal residue are critical for TAP recognition. Such anchor positions 
allow TAP to bind aa with various lengths (up to 40 residues), as only the two peptide ends are 
fixed in the TAP binding pocket, the central part being mobile and free of TAP interaction [48, 49]. 
During the peptide transport, both ATP and the peptide bind TAP independently, leading 
to two different conformational changes. ATP biding is sensed by the Q loop, inducing the 
movement of the NBD, resulting in the NBDs dimerization. Structural rearrangement of both TAP1 
and TAP2 TMDs is induced by the peptide binding, leading to the peptide release in the ER lumen. 
Following ATP hydrolysis and the phosphate release, the NBDs dimers are weakened and 
dissociated. ADP is then released form the complex and replaced by ATP, and the cycle restarts 
[50]. 
 
1.4.3. TAP Protein and Human Diseases 
Peptides’ presentation by MHC class I molecules is essential for the immune system 
function. The control of peptide processing and presentation is a key method which enables 
different pathogens and malignant cells to escape the immune surveillance. 
 
1.4.3.1. Viral Infections 
Throughout evolution, different viruses developed ingenious methods to avoid the immune 
system surveillance by interfering with the antigen processing and presentation and thus, down-
regulate MHC class I molecule expression [51, 52]. Till today, 5 different virus-encoded peptides 
were identified as inhibitors of TAP-mediated peptide transport [52]. 
The immediate early protein infected cell peptide 47 (ICP47), a Herpes simplex virus 
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(HSV)-1 and -2 encoded protein, acts as a substrate of TAP and prevents peptide binding [53]. It 
blocks the essential and first step of the peptide translocation pathway by binding, with high 
affinity, to the peptide binding site of TAP. This interaction is species-specific and depends 
essentially on the ICP47 affinity for TAP. Other Herpes viruses, like bovine herpesvirus 1 (BoHV-
1), equine herpesvirus 1-4 (EHV-1/4), pseudorabies virus (PRV) also known as Aujeszky's 
disease, as well as feline Herpesvirus-1 (FeHV-1), encode UL49.5, a protein which interacts with 
TAP, preventing it from binding to ATP, or targeting it for proteasomal degradation [52]. 
Human cytomegalovirus (HCMV) encodes gpUS6, an ER-resident glycoprotein. By 
binding to the ER luminal part of the TAP complex, gpUS6 stabilises the conformation of TAP1 
preventing it from binding to ATP [54, 55]. This inhibition can be overridden by IFN-γ-induced TAP 
overexpression. 
Human papilloma virus (HPV) and Epstein-Barr virus (EBV) developed another method to 
reduce MHC class I surface expression. Once they infect the cell, HPV proteins, as well as the 
EBV protein vIL-10 (the sequence of which is similar to the human IL-10) down-regulate TAP1 
but not TAP2 protein by interfering with its gene expression [56]. Another EBV protein, BNLF2a 
interacts with the cytosolic domain of TAP1 and inhibits the ATP binding. 
E3/19K, an adenovirus protein, interferes with the MHC class I pathways using two 
different mechanisms: (i) by binding MHC class I molecules and trapping them in the ER lumen, 
(ii) by binding to TAP protein, preventing its association with MHC class I molecules [57, 58]. 
Cowpox virus (CPXV) encodes CPXV12, a type II membrane protein, inhibits TAP and 
down-regulates MHC class I molecule expression [59]. The inhibition mechanism is still to be 
determined. 
 
1.4.3.2. Tumour Development 
Escaping the immune surveillance is the main mechanism of tumour resistance, often 
ensured by controlling the antigen presentation pathways thus down regulating surface 
expression of MHC class I molecules [60, 61]. Each of the different antigen processing and 
presentation steps can be targeted by this regulation, but the most frequent mechanism is TAP 
malfunction [62]. Some mouse small cell lung carcinoma (CMT.64) and human breast cancer 
cells showed highly reduced to non-detectable levels of TAP1 or/and TAP2 mRNA [63, 64]. Such 
a decrease can be restored by IFN-γ treatment, except in some metastatic melanomas where 
TAP expression increase was not correlated with a higher cytotoxicity [65]. In a study by Johnson 
et al, matched TAP1-negative and TAP1-positive cell lines were generated [66]. Mice inoculated 
with TAP1-negative cells presented larger and more persistent tumours compared to the TAP1-
positive cells. These results were confirmed in a TAP1 deficient mouse lung carcinoma model 
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(CMT.64) where IFN-γ treatment or infection with a virus encoding TAP1 decreased the tumour 
growth in vivo [67]. 
 
1.4.3.3. Transplantation and Autoimmunity Diseases 
The role of TAP in autoimmune disease and transplantation is discussed controversially. 
A varying degree of TAP1 and TAP2 mRNA reduction was observed in many MHC-linked 
autoimmune diseases, like Sjogren’s syndrome, Hashimoto’s disease, Graves’ disease and 
others [68]. These observations would presume that such low mRNA levels would reduce the 
surface expression of HLA class I molecules thus transforming the cells into potential Natural 
Killer (NK) cell targets. 
MHC class I molecules are important players in transplantation as they can induce strong 
alloreactions directed toward the transplanted tissue. The role of TAP polymorphism in acute 
cellular rejection is poorly understood. Some TAP2 polymorphisms were found to be correlated 
with the rejection incidence and severity in the case of renal transplantation [69]. Donors 
presenting the TAP2*0103 allele were found to be less efficient in presenting allospecific antigens 
to the recipients T cells. Other studies on patients undergoing liver transplantation associated the 
increase of early acute cellular rejection to the TAP-1 p.697Gly allele [70]. Further studies in this 
field are necessary to evaluate the significance of such correlations. 
 
1.4.3.4. Genetic Diseases 
Bare lymphocyte syndrome (BLS) is a rare disorder, described for the first time in 1978 
[71], and resulting in a reduction of the surface expression of HLA class I, class II, or both classes’ 
molecules (BLS type, I, II or III respectively). Works in 1994 by de la Salle et al. [72] have shown 
that mutations in the TAP1 or TAP2 genes are responsible of the HLA class I defective surface 
expression in BLS type I patients. Several other patients were later described and grouped under 
the name of TAP-deficiency (cf. chapter 2. TAP-deficiency). 
 
1.5. Peptide Loading Complex (PLC) and Peptide Binding to MHC Class I Molecules 
The PLC is a macromolecular machinery responsible of the peptide translocation into the 
lumen of the ER then its loading on the MHC class I molecule. It is centred on TAP protein and is 
composed of: the MHC class I heavy chain and β2m (the peptide presenting molecules), Tsn  
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Figure 5: The assembly and disassembly dynamics of the PLC. 
The model is assembled based on the crystal structures of HLA-B*4402 (PDB 3KPL), 
Tsn-ERp57 (PDB 3F8U), CRT (PDB 3RG0), and the homology model of coreTAP1/2 [4]. 
The different molecules are named in the f igure. In the cell cytoplasm, endogenous 
proteins are degraded by the proteasome into peptides which are then translocated to 
the ER lumen by TAP1/2. In the ER lumen, the CRT binds to the MHC-I/β2m complex 
and escorts it to the PLC, composed of the Tsn-ERp57 complex as well as TAP1/2. Once 
the CRT-MHC-I/β2m complex joins the PLC, the translocated peptides (tr immed by the 
ER aminopeptidases, not shown) are loaded on the MHC-I/β2m complex and are aff inity 
proofread by Tsn-ERp57. The newly formed, stable MHC-I/β2m-peptide complex 
dissociates from the PLC, making way for a new, peptide-receptive MHC I to be 
incorporated into the PLC. MHC I, major histocompatibili ty complex class I; β2m, beta-
2-microglobulin; CRT, calreticulin; Tsn, tapasin; PLC, peptide-loading complex; TAP, 
transporter associated with antigen processing. Adapted from [13], permission number 
3356010828121. 
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the adapter chaperone, Erp57 the ER-resident oxidoreductase, CRT the lectin-like chaperone 
and CNX. Both, MHC class Ia and Ib molecule expression is TAP dependant [19, 73, 74]. For 
optimal peptide loading, the PLC needs to be assembled directly after the peptide translocation 
to the lumen of the ER by TAP. During the peptide loading process, a sequence of required events 
have to be fulfilled [13] (Fig. 5). 
i. A suitable peptide, for MHC class I loading has to be provided. 
TAP is known to translocate peptides with a wider range of length than the ones optimal 
for MHC class I loading [73]. Further amino-trimming of these peptides can be performed 
in the ER by ER aminopeptidase-1 (ERAP1) in human, and ER aminopeptidase 
associated with antigen processing (ERAAP) in mice [75, 76]. ERAP2, a second 
aminopeptidase present in humans but not in mice, can play a role in this peptide length 
optimisation [77]. These aminopeptidases’ activity was shown to be crucial, as ERAAP-
KO mice produce highly immunogenic and unstable peptides [76]. 
ii. The TAP/Tsn-ERp57 complex formation. 
An important component of the PLC is Tsn, a type I membrane glycoprotein which plays 
the role of linker between the MHC class I molecule and TAP. ERp57, an ER-resident 
oxidoreductase, presents a redox activity which is not essential for the PLC function. Its 
main and essential role is the PLC complex integrity maintain [78]. In fact, Tsn and ERp57 
are covalently linked by a disulfide bond forming a conjugate [79]. This conjugate is then 
bond to the TMD0 domain of TAP by the intermediate of Tsn, forming the TAP/Tsn-ERp57 
complex which plays a crucial role in the peptide loading. TAP presents two TMD0 domains 
allowing the assembly of two different Tsn-ERp57 conjugates. 
iii. MHC class I molecule retention in the PLC and the creation of a spatial proximity between 
TAP and the MHC class I molecules. 
After its formation, the CRT-MHC-I/β2m complex joins the Tsn-ERp57/TAP complex and 
form the PLC. In fact, Tsn binds strongly to the monoglycosylated N86 of the MHC class I 
heavy chain, retaining the latter molecule in the PLC [80]. This step is of high importance 
as the Tsn-ERp57 complex is responsible for the spatial proximity creation between the 
peptide donor (TAP) and the peptide acceptor (MHC class I molecule) allowing the peptide 
binding.  
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iv. High-affinity binding of peptides to MHC class I molecules. 
The main function of MHC class I molecules is to present the peptide turnover on the cell 
surface for a relatively long time (3-7 days). The stability of this complex is crucial for the 
immune system function, which explains why MHC class I molecules that are associated 
with low affinity binding peptides are retained in the PLC. The peptide editing/optimisation 
is ensured by Tsn, leading to a preferential loading, on the MHC class I molecules, of the 
high-affinity peptide [81] resulting in a kinetically stable complex.  
v. The last step of the peptide loading is the dissociation of the peptide-MHC class I complex 
from the PLC, a mechanism that is still not completely understood. 
 
2. TAP deficiency 
2.1. History and Discovery 
In 1978, Touraine et al. described the first case of defective surface expression of HLA 
class I molecules [71]. Similar cases were identified in the following years, and were all grouped 
under the name of “Bare Lymphocyte Syndrome” (BLS) [82-91]. Depending on the HLA molecule 
presenting a defective expression, BLS patients were divided into three different types (cf. chapter 
1.4.3.4. Genetic Diseases). Clinical and immunological parameters allowed the subdivision of 
BLS type I patients into three distinct groups [72], [92]. (i) Group 1 includes patients presenting 
the most severe symptoms and are heterozygous for their HLA haplotype, ruling out the possibility 
that the disease responsible gene(s) are encoded in the HLA locus. (ii) Patients in the group 2 
are completely asymptomatic with heterozygous HLA haplotype. The third group is the best 
characterised and comprises 30 cases (till today). These patients are homozygous for the HLA 
haplotype and present HLA class I molecule down-regulation caused by mutations in the TAP-1 
[93-97], or the TAP-2 gene [72, 98-103]. 
 
2.2. Symptoms 
TAP-deficient patients express very low levels of HLA class I molecules leading to immune 
system’s malfunction problems. No disease-specific phenotype was found among all the 
described patients. While some were reported to be asymptomatic [101], others developed 
symptoms resembling Wegener’s granulomatosis syndrome [96, 104]. Nasosinusal involvement 
and nasal polyposis were among the most frequent symptoms. Based on patients’ age, we can 
distinguish (i) late childhood chronic inflammations of the respiratory tract which could culminate 
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in respiratory insufficiency resulting from bronchiectasis, emphysema, panbronchiolitis, or 
bronchial obstruction [92, 105], and/or (ii) adulthood granulomatous skin lesions with no particular 
pathogen involved [92, 101, 104]. No severe viral infections were reported, suggesting that 
immune responses by cell-mediated cytotoxicity are, to some extent, efficient [106]. In the 
opposite, bacterial infections, like with Staphylococcus aureus, Haemophilus influenza, 
Escherichia coli, Pseudomonas aeruginosa etc… are considered to be a real threat for TAP-
deficient patients. In some cases, facial lesions eventually lead to complete destruction of the 
nasal cartilage, and after a generalised vasculitis accompanied with cerebral involvement and 
seizures, the patient passed away [96, 97, 104]. 
 
2.3. Treatments 
As mentioned in chapter 2.2. Symptoms, no truly specific symptoms exist for this disease, 
making TAP deficiency diagnosis difficult. The family’s medical history and consanguineous 
marriages may be of great importance during the early diagnosis. Till today, most of the 
treatments are mainly restricted in the symptoms developments’ prevention (rhinosinusitis, 
bronchiectasis, skin lesions…). In severe cases, bone marrow transplantation was envisaged, but 
performed only once. The concerned patient seem to recover well, her CD4:CD8 ratio became 
normal, but her NK cells were still not functional, which is consistent with works, on a mouse 
model, by D. Raulet group [107]. Such an approach is very risky. Taking in consideration the 
patient’s chronic infections, released cytokines may activate NK cells, leading to a potential 
cytotoxicity towards autologous cells, already HLA class I low making them a perfect target for 
activated NK cells [108]. 
 
2.4. Effect on the Immune System 
Cells derived from TAP-deficient patients express very low surface expression levels of 
HLA class I molecules (95% to 99% compared to HD). Nevertheless, patients have normal 
numbers of NK cells, CD8+ α/β T cells exist among their PBMC, and an expansion of γδ T cells 
was observed in some cases [72, 100]. NK cells derived from TAP-deficient patients were shown 
to be hyporesponsive against HLA class I negative target cells (no missing-self recognition) 
[72, 105, 106, 109], which can be reversed after activation with rhIL-2 [106]. Antibody dependent 
cellular cytotoxicity (ADCC) activity was present for these NK cells, but at lower levels than HD 
[109], suggesting that TAP-deficient NK cells still have their killing machinery intact. Such data 
implicate that in vivo, TAP-deficient hyporesponsive NK cells may be activated by endogenous 
interleukins (like IL-2 and IL-15), thus developing a response following viral infections, as 
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demonstrated in a β2m-KO mouse model [110, 111]. 
 
3. NK cells 
3.1. Discovery and Characterisation 
Till the 1970th, lymphocytes were divided into two main cell types: T cells and B cells. In 
1974, then 1975, two independent groups identified a third immune cell type capable of 
spontaneously killing P-815-Y mastocytomas [112] or the mouse Moloney leukemia cells [113, 
114]. This killing, or cytotoxicity, did not require any prior activation nor a host immune 
sensitisation, so these cells were named Natural Killer (NK) cells. The lymphoid cells’ division 
(B cells, T cells and NK cells) was recently modified, and NK cells are now considered to be part 
of the innate lymphoid cells (ILCs) subset 1 (ILC1) [115] (Fig. 6). 
NK cells constitute 5% - 15% of peripheral blood lymphocytes (PBL) [116] and are present 
in many other tissues, like bone marrow (BM), thymus, lymph nodes, lung, brain, liver and spleen. 
In humans, NK cells are defined as CD3- CD56+ (CD56bright or CD56dim), and in C57BL/6 mice as 
CD3- NK1.1+ cells. These receptors, and others, will be discussed in chapter 3.3. NK Cell 
Receptors. Although NK cells are known as “killers”, other functions were later discovered, like 
cytokine production and control of the adaptive immunity cells’ functions, making NK cells more 
than just natural killers, but immune cells with a complete and unique role in the organism defence. 
In this third chapter we will discuss the main aspects of NK cells: their functions, receptors, 
development and differentiation as well as their education mechanisms. 
 
3.2. NK Cell Functions 
NK cells are part of the innate immune system and are involved in early defence 
mechanisms. They can spontaneously kill stressed, infected and malignant transformed target 
cells by degranulation or Antibody Dependent Cellular Cytotoxicity (ADCC), produce cytokines, 
and control adaptive immunity functions. Reverse Antibody Dependent Cellular Cytotoxicity 
(rADCC) is a specific in vitro function of NK cells. 
 
3.2.1. Cytotoxicity 
NK cell activities are regulated by a surface detection system composed of a large panel 
of activating and inhibitory receptors (AR and IR respectively), (cf. chapter 3.3. NK Cell 
Receptors). The balance of the different activating and inhibitory signals transmitted through the 
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these receptors determines the target cell’s fate [117]. Absence or down-regulation of MHC class 
I molecules (IR ligands) lead to NK cell activation and target cell killing. This mechanism, called 
the “missing-self” recognition [118] (cf. chapter 3.5.1. Missing-self Recognition), is a result of NK 
cell cytotoxicity which can be natural (spontaneous) or antibody dependant. 
 
3.2.1.1. Natural Cytotoxicity 
Mature NK cells are specialised in target cell killing without any prior stimulation nor 
antibody recognition [119], and can be mediated through two different mechanisms: 
perforin/granzyme-mediated cytotoxicity, and the engagement of death receptor pathways [120]. 
After NK cell activation, both cytotoxicity mechanisms lead, within minutes, to apoptotic cell death 
by activating caspases, thus limiting the pathogen spread and replication [121]. 
 
Figure 6: Lymphocytes’ subdivision. 
Common lymphoid progenitors (CLPs), originated from the haematopoietic stem cell 
(HSC), give r ise to T cells and B cells, as well as innate lymphoid cells (ILCs). The latter 
cells do not express antigen receptors and can be divided into three major classes: group 
1, group 2 and group 3, NK cells being part of ILC group 1. Adapted from [5], permission 
number 3356480192775. 
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i. Perforin/granzyme-mediated cytotoxicity. 
This mechanism, implicating cytotoxic granules (CG), is the major mechanism of target 
cell killing by NK cells. CG are specialised secretary lysosomes containing the cytotoxic 
molecules necessary for target cell killing [122], three of which are: (i) perforin, responsible 
of target cell membrane disruption [123, 124], (ii) granzymes (Grz) which are related to 
the serine protease family, responsible of target cell apoptosis triggering by caspase 
cleavage [121], (iii) and granulysin, a lytic molecule belonging to the saponin-like protein 
family [125]. NK cell killing by perforin/granzyme-mediated cytotoxicity is evoked by 3 
subsequent processes [10, 126] (Fig. 7): 
a. Immunological synapse formation. 
Once a NK cell encounters a potential target cell, a ligand/receptor interaction occurs 
leading to the formation of an immune synapse between the two cells. This synapse 
contains two distinct domains: the peripheral supramolecular activation cluster 
(pSMAC) and the central supramolecular activation cluster (cSMAC) [127]. The 
pSMAC containing adhesion molecules (LFA-1 or CD11a/CD18) and rich in actin 
filaments (F-actin), forms a ring around the cSMAC where the cytotoxic molecules’ 
secretion site is found. This conformation allows an intimate contact between the 
plasma membranes of both, the effector and the target cell. A former hypothesis has 
suggested that the cSMAC is an actin free zone, but studies demonstrated that the F-
actin is not depleted, it contains openings just wide enough to let the CG pass [128]. 
The importance of the F-actin formation in this step is demonstrated by the NK 
cytotoxicity block following cytochalasin D or jasplakinolide treatment, which disrupts 
or inhibits the actin cytoskeleton rearrangement/polymerisation [129]. 
b. Microtubule-organising centre (MTOC) polarisation and CG docking to the plasma 
membrane. 
The second step consists of the MTOC and the CG polarisation towards the immune 
synapse formation site. This step is of great importance as it allows the NK cells to kill 
specifically the target cell while keeping the surrounding cells unharmed. 
Cytoskeleton polarisation is induced by the NK AR triggering of Ca2+ signalling [130]. 
In human NK cells, myosinIIA was reported to be essential for the last step of CG 
release as it promotes their transport through the last layer of F-actin to the site of  
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the immune synapse [131, 132]. Once they approach the cytosolic side of the cell 
membrane, CG dock with the latter membrane, leading to the two membrane fusion 
and the CG’ content release. 
c. Cytotoxic molecule release upon fusion of cytosolic and CG’ membranes. 
In order to release their content, CG have to fuse with the cytosolic membrane, a step 
catalysed by soluble N-ethyleimide-sensitive factor attachment protein receptors 
(SNAREs) [133]. SNAREs present a lipid tail allowing them to anchor membranes. 
Once four different SNAREs, belonging to two different membranes, come together, 
the result is a fusion of the two corresponding membranes. Cytotoxic molecules are 
then released in the immune synapse interface leading to the target cell death and 
the exposure of the CG membrane residing proteins on the cell surface. The most 
abundant ones are lysosome-associated membrane protein (LAMP) 1 and LAMP2, 
from which, LAMP1 (CD107a), is widely used as a NK cell degranulation marker [134]. 
Inactive forms of the cytotoxic molecules are stocked in CG as a result of the low pH 
and Ca2+ concentration. Once they are released in the immune synapse, they become 
Figure 7: Sequences of events in cytotoxic granules-mediated NK cell cytotoxicity. 
Following a l igand/receptor interaction between a NK cell and a potential target cell, an 
immune synapse is formed. Two different domains can be distinguished in the immune 
synapse: the peripheral and the central supramolecular activation clusters (pSMAC and 
cSMAC respectively), allowing an intimate contact between the two cells. Microtubule-
organizing centre (MTOC) and the entire microtubule network, as well as the cytotoxic 
granules (CGs) are polarised towards the immune synapse site. Once the CGs fuse with 
the NK cell cytosolic membrane, their content (perforin, granzymes…) is released into a 
small secretory cleft (yellow) formed between the NK cell and target cell, leading to the 
target cell death by apoptosis. Taken from [10], permission number 3326560924949. 
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active and can mediate only target cell killing, leaving the NK cell protected from lysis. 
Recent works on human NK cells have shown two different and important roles of 
LAMP1. In fact, this protein is important for lymphocytes’ protection from cytotoxic 
molecules’ mediated death [135], and its silencing results in a mobility disturbance of 
CG leading to an inhibition of NK cell cytotoxicity [136]. 
ii. Death receptor pathways. 
A second mechanism of target cell killing by NK cells involves the activation of the death 
receptor pathways. These pathways are induced by IFN-γ and result in caspases-
dependent apoptosis. Two different pathways will be highlighted in this part: Tumour 
necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL).  
a. TRAIL mediated cell death. 
TRAIL, a type II transmembrane protein, belongs to the TNF superfamily. Two of the 
five TRAIL receptors found in humans, TRAIL-R1 (DR4) and TRAIL-R2 (DR5), are 
capable of transducing apoptosis signals [137]. In both, humans and mice, TRAIL 
expression can be induced by IL-2, -15 and type I IFNs. In this cytotoxicity 
mechanism, IFN-γ play two different roles: TRAIL expression regulation on NK cells, 
and target cell sensitising to TRAIL-mediated cytotoxicity [138]. 
b. FasL mediated cell death. 
The in vivo contribution of the FasL expression by NK cells in tumour growth 
suppression was demonstrated, even though most of the tumour cells do not express 
Fas [139]. NK cells, by secreting IFN-γ, induce Fas expression on target cell surface, 
which needs a direct contact between both cells, demonstrated by double-chamber 
experiments [140]. FasL is expressed on the inner layer of NK cell CG thus delivered 
at the same time as perforin to the immune synapse. This may implicate a common 
and complementary role of both FasL and perforin-mediated cytotoxicity in NK cell 
target cell killing [141]. 
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3.2.1.2. Antibody Dependent Cellular Cytotoxicity (ADCC) 
Upon recognition of antibody-opsonised target cells, NK cell cytotoxicity can be triggered 
by ADCC [142] which is mediated, in both humans and mice, by the low-affinity IgG receptor, 
FcγRIII or CD16 [143] (Fig. 8). The resulting triggering signal is high enough to overcome KIR 
molecule inhibition [144] and leads to NK cell degranulation, cytokine secretion, proliferation, 
activation marker expression, and apoptosis for some NK cell subsets [145]. Contrary to 
perforin/granzyme-mediated cytotoxicity, CD16 mediated ADCC induces exocytosis of CG and 
not their polarisation [146]. 
 
 
3.2.1.3. Reverse Antibody Dependent Cellular Cytotoxicity (rADCC)  
rADCC is an in vitro NK cell function, never occurring in vivo and allows the study of 
specific receptors’ effect on NK cell functions [2] (Fig. 8). The NK cell receptor of interest is 
recognised, through one of its epitopes, by an antibody. The Fc part of the antibody is then 
Figure 8: Antibody dependent cellular cytotoxicity (ADCC) and reverse ADCC mechanisms. 
Through the recognition of the antibody Fc fragment by their Fc receptor (FcγRIII or 
CD16), NK cells are able to kill  antibody-opsonised cells by antibody dependent cellular 
cytotoxicity (ADCC). Redirected lysis and redirected inhibit ion (also known as reverse 
ADCC or rADCC) are in vitro properties of NK cells used to study the effect of specif ic 
receptors on NK cell functions. The Fc fragment of a specif ic NK cell receptor antibody 
is recognised by the target cell Fc receptor. If the studied receptor is activating, the 
target cell kil l ing is increased, whereas if the receptor is inhibitory, the target cell kil l ing 
is reduced. Taken from [2], permission number 3367210630236 
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recognised by the FcγR expressed on the target cell surface. This interaction mimics the one 
occurring between the studied marker and its receptor on the target cell surface. When implicating 
a NK AR, rADCC induces the target cell lysis. On the contrary, when the studied marker is a NK 
IR, the result is a reduction or absence of the target cell lysis.  
 
3.2.2. Cytokine and Chemokine Production 
Following their stimulation, NK cells are capable of synthesising and secreting different 
cytokines which can be implicated in their cytotoxicity functions [147]. These cytokines include 
IFN-γ, TNF-α, transforming growth factor (TGF)-β, granulocyte-macrophage-colony stimulating 
factor (GM-CSF), several interleukins as well as the chemokines MIP-1α and MIP-1β [148-150]. 
During inflammation in a murine model, for example with Listeria monocytogenes bacteria, and 
as a response to high levels of type I IFN or IL-12 and IL-18 secreted by dendritic cells (DCs) and 
macrophages [151], NK cells are able to secrete high levels of IFN-γ [152, 153], thus activating 
macrophages and resulting in early Listeria monocytogenes clearance [154]. Secretion of 
cytokines by NK cells also occurs upon target cell recognition and AR triggering and depends on 
the strength of the stimulation [155] (cf. chapter 3.3.4.9. Activating Receptors and their Synergistic 
Combinations). Cytokine stimulation and target cell recognition can result in a different NK cell 
response. In human upon cytokine stimulation, the cytokine secretion faculty was found to be 
higher in CD56bright NK cells compared to the CD56dim subset. The opposite is being true following 
target cell recognition in which CD56dim NK cells were found to be more potent than the CD56bright 
subset [155]. 
As a parallel to T cells which are divided into two sub-types according to their secreted 
cytokine profile, Th1 (T helper 1) and Th2 (T helper 2), NK cells were also divided into NK1 and 
NK2 subset regarding their cytokine secretion profile [156]. When NK cells are stimulated with 
IL-12, a type I cytokine, they produce IFN-γ, another type I cytokine, and they are called NK1. In 
contrast, NK2 cells secrete type II cytokines like IL-5 and IL-13 upon stimulation with the same 
type of cytokines, like IL-4. 
 
3.2.3. Adaptive Immunity Control 
Alongside their cytotoxicity and cytokine production, NK cells mediate effects on the 
adaptive immune system by producing a range of immunoregulatory mediators [157-160], as well 
as interacting with other immune cells. This effect was clearly shown in a NK cell-depleted mouse 
model where a decrease in the antibody and cytokine response was observed [161]. During early 
phases of the immune response, a cross-talk between NK cells and antigen presenting cells 
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(APCs), like DCs and macrophages was suggested [162, 163], leading to both, NK cells’ and 
DCs’ or macrophages’ activation [164]. Early resistance to bacteria can be mediated by the 
secretion of IFN-γ, killing of infected cells, and mediating an effect on T regulatory (Treg) response 
[165, 166], and driving a Th1 polarisation [167]. Upon stimulation with antibody coated target cells, 
NK cells can produce chemokines which can recruit T cells to the corresponding site [168]. In a 
murine model, NK cells were found to present a cytotoxic activity against activated CD4+ T cells 
that do not express sufficient amount of MHC class I molecules. This strategy can be used by 
blocking the CD94/NKG2A IR, leading to increase of NK cell cytotoxicity against activated 
CD4+ T cells-dependent autoimmunity [169]. In a mouse solid organ transplantation, graft-resident 
DCs were found to be eliminated by host NK cells [170]. 
 
3.3. NK Cell Receptors 
Throughout their developmental process, NK cells acquire, progressively, a mature 
phenotype and express a large panel of AR and IR, cytokine and chemokine receptors, adhesion 
molecules (AM) and maturity markers (Fig. 9). These receptors give NK cells the ability to perform 
their different functions (cf. chapter 3.2 NK Cell Functions) and migrate between tissues. 
 
3.3.1. NK Cell Identification Markers 
NK cells, originally characterised as ‘‘naturally occurring killer lymphocytes with specificity 
for tumour cells’’ [113, 114], are not defined using a specific surface receptor like T cells and B 
cells. Since their discovery, many efforts were deployed in finding a specific NK cell marker 
allowing their identification. NK cells are considered as being non-monocytes, non-B cells, non-T 
cells, expression CD56 in human, and NK1.1 in C57BL/6 mice. These two receptors are not 
restricted for NK cells, but are also expressed on subsets of T cells and appear late during NK 
cell development [171]. One marker, present in basically all species, NKp46, was proposed as a 
common and specific NK cell marker [172], but the discovery of NKp46+ innate lymphoid cells 
(ILC) re-launched the search for the ultimate NK cell receptor [173]. Until this specific marker is 
found, NK cells will still be defined by their surface expression of a certain combination of 
non-NK-restricted surface antigens; human NK cells will still be defined as CD3- CD56+ (CD56bright 
or CD56dim), and C57BL/6 mice NK cells as CD3- NK1.1+ (Fig. 10). CD56 will be developed in the 
chapter 3.3.5. Adhesion molecules, and NK1.1 in the chapter 3.3.4.6. NK1.1 or NKRP-1C. 
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Figure 9: NK cell receptors. 
A larger panel of receptors is expressed on NK cell surface and can be mainly grouped 
in activating (green), inhibitory (red), adhesion (blue), cytokine (black) and chemotactic 
receptors (purple). Not all NK cell inhibitory receptors are specif ic for MHC class I 
molecules. In the activating receptors’ l ist, the adaptor molecules involved in signall ing 
cascades are indicated. Unless indicated (h, human; m, mouse), receptors are conserved 
in both species. Taken from [7], permission number 3265762809244. 
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3.3.2. Activating and Inhibitory Signal Transduction 
As previously stated, NK cell functions are controlled by a balance between inhibitory 
signals and activating ones transmitted through a large panel of cell surface AR and IR 
respectively. These receptors present different transmembrane domains allowing the 
transduction of their signal to the cell cytosol. Due to their importance in the NK cell function, two 
different domains as well as their mechanism will be discussed in this paragraph: the 
immunoreceptor tyrosine-based inhibition motifs (ITIM) and the immunoreceptor tyrosine-based 
activating motifs (ITAM) 
The ITIM motif (consensus sequence S/I/V/LxYxxI/V/L) present in the cytosolic part of 
most of the immunological IR, is responsible for the inhibitory signal transmission to NK cells in 
both humans and mice [174, 175] (cf. chapter 3.3.3. Inhibitory receptors). IR can contain up to 
four ITIM motifs. Other immune receptors do not present an ITIM motif, but recruit tyrosine-based 
motifs for the pathways’ effector molecules’ activation. AR, in both human and murine species, 
lack the ITIM motif which is substituted by a positively charged residue (lysine or arginine). This 
residue, present in the cytosolic tail of the receptor, is required for the interaction with an adaptor 
Figure 10: NK cell identification in humans and C57BL/6 mice. 
NK cells do not express a specif ic marker allowing their direct identif ication. In humans, 
a combination of CD3 and CD56 is necessary for the identif ication of two NK cell 
populations: CD56br ight and CD56dim in the CD3 - cells, but also an NKT like population 
identif ied as CD3+ CD56+.  In C57BL/6 mice, NK1.1 alone is not suff icient for the 
identif ication of NK cells, as a CD3+ NK1.1+ population (NKT like cells) needs to be gated 
out in order to get pure NK cells (CD3 - NK1.1+). 
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molecule containing an ITAM motif (consensus sequence YxxI/Lx6-12YxxI/L) [176]. Both ITIM and 
ITAM motifs, upon their surface receptor engagement in an interaction with its specific ligand, can 
be phosphorylated by SRC (a family of non-receptor tyrosine kinases) leading to other molecules’ 
recruitment and signal transduction. 
Once phosphorylated, ITIM motifs recruit phosphotyrosine phosphatases (PTP), like SHP-
1 and SHP-2, or SHIP, the inositol-phosphatase. This PTP recruitment leads to a decrease in the 
phosphorylation of the activation pathway effectors: the spleen tyrosine kinase (SYK), the 
phospholipase C (PLCγ), the B-cell linker (BLNK/SLP-76) and VAV-1, as well as transmembrane-
associated adaptor proteins, like the Fc receptor common gamma chain (FcRγ), CD3ζ (linker for 
activation of T cells), and cytoskeletal structures. This signalling pathway results in the prevention 
of calcium signalling and protein kinase C (PKC) activation, thus inhibiting NK cell activation [177, 
178]. 
The phosphorylated sites of ITAM motifs are docked by the tandem SH2 domains of SYK 
family protein tyrosine kinase (PTK), like the zeta chain-associated protein kinase 70 (ZAP-70). 
Following this recruitment, a series of substrates, including phosphatidylinositol 3-kinase (PI3K), 
PLCγ, as well as VAV-2 and VAV-3 are phosphorylated by SYK family PTK. This pathway leads 
to Ca2+ signalling, as well as cellular activation through Ras activation and stimulation of the 
extracellular signal-regulated kinases (ERK) pathway [179]. 
 
3.3.3. Inhibitory Receptors (IR) 
All known NK cell IR are part of the inhibitory receptor superfamily (IRS). Most of them 
carry one or more ITIM motifs in their cytoplasmic tail [174, 175]. The binding of these receptors 
with their ligand, mostly MHC class I molecules, results in an inhibitory signal delivery allowing 
the immune cells to spare the target cells. Several ITIM-baring receptors are expressed on NK 
cells. They include the killer cell immunoglobulin-like receptor (KIR) and immunoglobulin-like 
transcript (ILT) in humans, Ly49 in mice, and CD94/NKG2 family as well as other receptors in 
both species. This receptor superfamily can be subdivided into two main groups according to their 
molecular structure: the immunoglobulin-superfamily inhibitory receptors (ISIR), and the C-type 
lectin inhibitory receptors (CLIR). 
 
3.3.3.1. Immunoglobulin-Superfamily Inhibitory Receptors (ISIR) 
The ISIR family receptors, members of the Ig superfamily type I membrane glycoproteins, 
include KIR molecules and ILT, both expressed only in humans.  
 
  25   
 
3.3.3.1.1. Killer Immunoglobulin-like Receptors (KIR) 
KIR molecules were first discovered in 1995 and designated as “NK-associated 
transcripts” [180, 181]. This family contains both IR and AR. 
i. KIR genes, nomenclature and alleles. 
Till today, fourteen genes and two pseudogenes have been identified for KIR molecules, 
which were mapped to chromosome 19q13.4, the leukocyte receptor complex [182]. 
These allelic and haplotypic variation are the result of extensive intergenic sequence 
exchange implicating unequal crossing over, deletions and/or insertions [183, 184]. Their 
evolution and diversity is highly comparable to MHC class I molecules, their main ligands 
(especially for the inhibitory KIRs). Each of the genes can encode either an inhibitory or 
activating KIR, explaining the KIR designation in the literature, for example 
KIR3DL1/DS1… The subcommittee of the WHO Nomenclature Committee for Factors of 
the HLA System reported the naming rules of the KIR genes which is based on their 
structure [185] (Fig. 11). After the KIR acronym, a digit indicates their extracellular Ig-like 
domains number (2 or 3) followed by the letter “D” for Domain, and another letter indicating 
this domain characteristics which can be Short “S” (presenting activating functions), Long 
“L” (presenting inhibitory functions) or a Pseudo-gene, “P”. The final digit indicate the gene 
number. When many genes have the same structure, a “final letter” can be added in order 
to distinguish them, for example the two genes KIR2DL5A and KIR2DL5B. Like HLA 
molecules, KIR nomenclature contains information about the genetic characteristics of the 
different alleles. After their classical name, a set of first three digits indicate the alleles’ 
differences in the exon region that lead to nonsynonymous changes. The next two digits 
indicate the alleles’ differences in the exon region that lead to synonymous changes, and 
the last two digits designate the differences in the alleles’ intron regions, promoter or any 
other noncoding sequence. 
With the rapid evolution of molecular biology techniques, including sequencing, a wider 
scan of populations’ KIR allele’s polymorphism was possible. The Immuno Polymorphism 
Database of KIR (IPD-KIR) reported 87 alleles in 2002, 292 alleles in September 2008, 
then 678 alleles in October 2013, the highest number of polymorphism being for the 
inhibitory (KIR_DL_) molecules. This high number can be explained by, a correlation 
between the HLA class I molecules polymorphism and their receptors, KIR molecules’, 
polymorphism, or simply by the fact that some laboratories have concentrated their effort 
on studying some specific KIR genes and not others. 
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ii. Haplotypes 
Two different KIR haplotypes are determined according to the gene content, namely 
haplotype A and haplotype B. The KIR region, in the chromosome 19, is divided in two 
parts: from KIR3DL3 at the centromeric end to KIR3DP1, followed by KIR2DL4 till 
KIR3DL2 at the telomeric part. These four genes, or framework genes, are present in all 
humans. The presence of other KIR is used to determine the two known haplotypes. 
Haplotype A uses eight genes: the four framework genes and four other KIRs (KIR2DL1, 
KIR2DL3, KIR2DS4 and KIR3DL1), and present mainly allelic polymorphism. The 
Haplotype B is based on the presence of at least one activating KIR (KIR2DS1/2/3/5, 
KIR3DS1) as well as KIR2DL5A/B and KIR2DL2. Its variability is mainly determined 
according to the presence/absence of these genes. 
iii. Ligands 
HLA class I molecules are the ligands for most of the KIR molecules, especially inhibitory 
KIRs, with different binding affinities. Inhibitory KIR molecules present a long cytosolic 
domain with one or more ITIM motifs. Some HLA class I residues favour certain 
interactions to others. HLA-Cw alleles are present in all humans, making it the most 
important regulator of NK cell functions. HLA-C molecules can be divided in two different 
groups. HLA-C group 1, which includes HLA-Cw1, 3, 7 and 8, can bind KIR2DL2 and 
KIR3DL2 using the Asp (asparagine) at position 80, whereas HLA-C group 2, which 
Figure 11: KIR nomenclature. 
Shown is the KIR nomenclature rule based on their structure. 
Source http://www.ebi.ac.uk/ipd/kir/alleles.html 
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includes HLA-Cw2, 4, 5 and 6, uses the Lys (lysine) 80 to bind KIR2DL1 [186]. Whereas 
the KIR2DL1 interaction with the Lys80 of HLA-C2 group is very specific, one report 
showed that KIR2DL2, and to a weaker extend KIR3DL2 can bind HLA-C2 group [187]. 
Other KIR molecules, like KIR3DL1 specifically bind the Ile/Thr80 of HLA-Bw4 and HLA-
A molecules [188]. KIR3DL2 selectively bind HLA-A3 and -A11 alleles only when they are 
loaded with specific viral peptides [189]. Finally, KIR2DL4 is the specific receptor for HLA-
G [190]. 
 
3.3.3.1.2. Immunoglobulin-like Transcripts (ILT) 
Immunoglobulin-like transcripts (ILT), or leukocyte immunoglobulin-like receptors (LIR), 
are genetically related to KIR molecules [183]. They both possess isoforms with different cytosolic 
signalling functions. ILT/LIR receptors with long cytoplasmic tails recruit SHP-1 phosphatase to 
the ITIM motifs thus inhibiting cellular activation [175]. The ILT/LIR family includes several 
receptors, like ILT2 (LIR-1), ILT3 (LIR-5), ILT4 (LIR-2), ILT5 (LIR-3) and LIR-8 [22, 191]. 
ILT2, LIR-1 or CD85j presents four extracellular Ig domains and four cytoplasmic ITIM 
motifs [192]. It is expressed on basically all PBMC and is able to inhibit the Ca2+ flux in B cells, 
monocytes, macrophages and DCs [193]. T cell and NK cell cytotoxicity is also inhibited by ILT2 
[193, 194]. ILT2/LIR-1 binds a wide range of HLA class I molecules: HLA-A1, -A2, -A3, HLA-Bw4 
and -Bw6, HLA-Cw3 and -Cw4 as well as HLA-G [194]. It can also bind molecules with a similar 
structure to HLA class I molecules, like the CMV protein UL18 [195]. However, ILT2 does not 
seem to play a role in NK cell education, and more evidence is needed in order to demonstrate 
its real role in NK inhibition in vivo [196]. 
Other ILT/LIR family members were detected only as transcripts in NK cells, no surface 
expression was found, like ILT3 (LIR-5), ILT4 (LIR-2) and LIR-8 [191]. Their expression on other 
PBMC allowed the identification of the ILT3 ligand only, being HLA class I molecules, with the 
same wide range of binding as ILT2/LIR-1 [197]. 
 
3.3.3.2. C-type Lectin Inhibitory Receptors (CLIR) 
The CLIR family are members of the lectin C superfamily, type II membrane glycoproteins. 
Some are specific for mice, like Ly49 family and NKR-P receptors, whereas others are common 
for both humans and mice, like the inhibitory CD94/NKG2 family, and KLRG1. 
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3.3.3.2.1. Inhibitory CD94/NKG2 
The NKG2 gene complex, located on the chromosome 12p13.2 in humans and 
chromosome 6 in mice, presents inhibitory and activating receptors. Both inhibitory and activating 
forms are represented by a disulfide-linked heterodimer formed by two molecules, CD94 and 
NKG2 [198]. (for CD94, cf. chapter 3.3.6. Other NK Cell Phenotypic markers). The NKG2 
receptors are always expressed on the cell surface as CD94/NKG2 complex. This complex, in its 
inhibitory as well as activating form, recognise the non-classical MHC class I molecule, HLA-E in 
humans [199], and Qa-1 in mice [200]. In humans, the two inhibitory forms of this complex are 
CD94/NKG2A and CD94/NKG2B, NKG2B being a splicing variant of NKG2A missing 18 aa 
between the transmembrane domain and the carbohydrate recognition domain [201]. 
CD94/NKG2A and CD94/NKG2B recognise HLA-E or Qa-1 molecule loaded with specific 
peptides, and transduces an inhibitory signal through its one or two cytosolic ITIM motifs, in mice 
and human respectively [19, 199, 200]. Both CD94 and NKG2A chains are implicated in the 
interaction with HLA-E: while NKG2A interacts with the α2-helix of HLA-E, the α1-helix of the latter 
molecule and the C-terminal part of the peptide are oriented toward CD94. This last interaction, 
CD94-peptide, is important for inducting the inhibitory signal [202-204]. 
 
3.3.3.2.2. Killer Cell Lectin-like Receptor G1 (KLRG1) 
KLRG1 is a type II transmembrane molecule present in humans and mice, and is 
preferentially expressed by NK cells and antigen-experienced T cells [205, 206]. It binds the highly 
conserved region of E-, N- and R-cadherins [207] and acts as an IR. The cytosol tail of KLRG1 
contains an ITIM motif which recruits the phosphatases SHP-2 and SHIP-1 conferring its inhibitory 
functions [208, 209]. Different infections (bacterial, viral and parasitic) result in an expression of 
KLRG1 on NK cells and T cells [210, 211]. An increase of KLRG1 expression levels was observed 
on human NK cells after chronic HCV infection as well as NK cells co-cultured with hepatocytes 
expressing HCV. [212].  
 
3.3.3.2.3. Inhibitory Ly49 
Unlike humans, mice do not present KIR and ILT/LIR molecules, but instead they express 
proteins belonging to the type II glycoproteins, the Ly49 family. Ly49 proteins are expressed on 
the cell surface as disulfide-linked homodimers [213]. They recognises MHC class I molecules, 
the H-2 molecules, and can be activating or inhibitory depending on the intracellular domain they 
express or interact with (ITAM or ITIM respectively). Although human KIR molecules and murine 
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Ly49 receptor family have analogous functions and recognise MHC class I molecules, they are 
both structurally distinct. The difference between these two molecules’ families is that big that 
they cannot have shared a common evolutionary descent [188]. 
The Ly49 family includes up to 30 different genes encoding inhibitory, activating, and many 
pseudogenes. Based on homology, genomic organisation, and function, groups of Ly49 genes 
can be clustered as shown in Fig. 12 [214]. Ly49A, or T lymphocyte activation marker, was the 
first one to be described [215]. Not all murine strains share the same set of Ly49 receptors, and 
when they do, the same receptor may present: allelic variants depending on the strain, like 
Ly49AB6 and Ly49ABalb/C, specific for the C57BL/6 and Balb/C strain respectively, or homologues 
in the different strains, like Ly49EBalb/C and Ly49ENOD present in the Balb/C and the Non-obese 
Diabetic (NOD) strain respectively. 
Most of the Ly49 proteins, especially the inhibitory ones, recognise the different MHC class 
I molecules, H2-D, H2-L and H2-K, with different affinity, the latter three molecules being specific 
for each of the murine strain [214, 216, 217]. For example, Ly49A can bind to the two MHC class 
I molecules present in C57BL/6 mice, H2-Kb and H2-Db, but it can also recognise, with higher 
affinity, the H2-Dd and H2-Ld molecules expressed in Balb/C mice [218]. This interaction can occur 
in cis, when both, the receptor and the ligand, are expressed on the same cell surface, or in trans, 
when each is expressed on a different cell. These two different interactions involve molecular 
shifts in the receptor and ligand conformation leading to different signal transduction [219], 
developed in the chapter 3.5.5. Cis and Trans Interactions.  
 
3.3.4. Activating Receptors 
NK cell killing does not occur just in the absence of inhibition, but next to that, it requires 
activating signals which are generally transmitted through a panel of surface AR associated with 
adaptor proteins carrying ITAM motifs. AR belong to many different receptor superfamilies, but 
most of them, like IR, belong to the Ig and the C type lectin families. Many of the IR have activating 
counterpart, like KIR, ILT/LIR, CD94/NKG2 and Ly49. AR can be autonomous, capable of 
stimulating NK cells upon their unique engagement with their ligands, or co-stimulatory, when a 
second stimulus is needed to ensure their activating signal transduction. They have a much wider 
range of ligands compared to IR as they can bind constitutive cellular molecules as well as stress-
induced proteins.  
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3.3.4.1. Natural Cytotoxicity Receptors (NCR) 
NCRs belong to the Ig superfamily type I membrane proteins [220]. Structurally, they are 
composed of three different domains: an extracellular binding-domain containing the membrane 
distal and the membrane proximal, the latter being important for ligand binding, a transmembrane 
domain associated with an adaptor molecule (possessing an ITAM motif), and a short cytosolic 
domain [154, 221, 222]. Cellular heparin, or heparin sulphate proteoglycans, upregulated on 
cancer cells, are a common ligand for all the NCRs [223]. NCRs can also recognise pathogen 
associated ligands [224]. An overview of three different NCRs, and their ligands will be presented 
below. 
i. CD337 (NKp30 or NCR3) 
CD337, expressed only in humans, is associated with an adaptor protein bearing an ITAM 
motif, such as homodimers of CD3ζ chains linked with disulfide bonds, or CD3ζ and 
γ-chain of the high-affinity Fc receptor for IgE (FcεRI) [225, 226]. Three different isoforms 
Figure 12: Ly49 genes’ clusters and mouse strain expression. 
(A) Ly49 genes can be subdivided into different clusters. After each gene name, the 
corresponding mouse strain is indicated as a superscript. Blue is used to indicate 
inhibitory Ly49 genes, and red for activating Ly49 genes. Ly49 gene number differs 
between strains as shown in (B). Adapted from [3]. 
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exist for NKp30: NKp30a and NKp30b, both stimulatory, and NKp30c which is 
immunosuppressive [227]. NKp30-mediated NK cell killing results of its binding to one of 
two different surface proteins: B7-H6, which was exclusively found on tumour cell surface 
[228], and BCL-2-associated athanigene 6 (BAG6 or BAT3), found on immature DCs 
surface [229, 230]. NKp30 can also bind the HCMV protein pp65 which inhibits NKp30-
mediated NK cell killing by dissociating the AR from its adaptor molecule, CD3ζ [231]. 
ii. CD336 (NKp44 or NCR2) 
NKp44, encoded by the human NKC2 gene, is only detected on activated NK cells [232]. 
It has a cytosolic ITIM motif, which does not seem to be functional, and its signal 
transduction is mediated by the ITAM-containing adapter DNAX-activation protein 
(DAP)12 [233].  Many ligands were described for NKp44, including influenza virus HA and 
other viral HA-neuraminidase (HN) proteins [221, 234], sialylated and sulphated cellular 
proteoglycans [235], and bacterial wall elements [236]. Proliferating cell nuclear antigen 
(PCNA) is an intracellular protein, but is sometimes recruited on tumour cell surface where 
it is recognised by NKp44. This protein acts as an inhibitory receptor for NKp44 allowing 
the tumours to escape NK cell killing [237]. NKp44-mediated killing of noninfected 
CD4+ T cells was reported. In fact, after an aborted viral fusion, the conserved 3S motif 
(SWSNKS) of the HIV-1 gp41 envelope protein, binds to the complement receptor gC1qR 
on CD4+ T cells, which is then recognised by NKp44 [238, 239]. Recently, a new NKp44L 
has been found, an isoform of mixed-lineage leukemia-5 (MLL5), not detectable in normal 
tissues, but present on a broad range of tumour and transformed cells [240]. 
iii. CD335 (NKp46 or NCR1) 
NKp46, the only NCR expressed in humans and mice, was long thought to be the specific 
NK cell marker, but a subset of ILCs expressing NKp46 was discovered [241]. Its short 
cytosolic tail is associated with CD3ζ and the FcεRI γ-chain [233]. NKp46 ligands are 
unknown to date, but are expressed on many cell types, like tumour cells [242, 243], 
pancreatic β-cells, inducing type I diabetes [244], and liver stellate cells, protecting from 
liver fibrosis [245]. Some viral Hemagglutinin (HA) (form influenza and Sendai virus) were 
found to be NKp46 ligands [222]. Resting NK cells stimulation with NKp46 is not sufficient 
to induce degranulation. Combination of NKp46 signal with other receptors’ signals (CD2, 
CD244, DNAM-1 or NKG2D) was necessary for NK cell activation [246]. Among the three 
NCRs, only NKp46 functions can be studied in vivo. Two different NKp46 mutants were 
generated: the Ncr1gfp/gfp, in which the exons 5-7 were replaced by eGFP [234], and the 
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Ncr1Noé/Noé, presenting a substitution of the residue 32 to arginine [247]. Ncr1gfp/gfp mice 
developed tumour metastasis and were vulnerable to influenza virus infections [248, 249], 
whereas NK cells from Ncr1Noé/Noé mice presented NKp46 receptor-independent hyper-
responsiveness [247]. The intact NKp46 DNA, RNA and protein are present in Ncr1Noé/Noé 
mice, but lack in Ncr1gfp/gfp mice. This major difference may explain the discordance in 
these two models’ responses. Whatever the differences between these two models are, 
they both demonstrate an important role of NKp46 in the recognition/elimination of 
tumours, viruses and bacteria. 
 
3.3.4.2. Activating CD94/NKG2 
The activating form of the CD94/NKG2 complex consists of two different molecules: 
CD94/NKG2C and CD94/NKG2E which exist in human and mice. The activating CD94/NKG2 
adaptor molecule is DAP12 which presents two ITAM motifs that transduce the activating signal. 
Both CD94/NKG2C and CD94/NKG2E, like their murine inhibitory counterparts CD94/NKG2A 
and CD94/NKG2B, bind Qa-1. In human, CD94/NKG2E ligand is still unknown, whereas 
CD94/NKG2C binds HLA-E molecule with 6 fold weaker affinity than CD94/NKG2A and 
CD94/NKG2B [250]. This might be due to the difference in the aa residues 167-170 of the 
NKG2/CD94 interface [250, 251]. In the opposite, the HLA-E molecule expressing the signal 
peptide of HLA-G is equally recognised by both inhibitory and activating CD94/NKG2 complexes 
[252]. The HCMV protein, gpUL18, is a MHC homologue which can be recognised by 
CD94/NKG2C with a weak affinity [251]. gpUL18 can also bind ILT2/LIR-1 (cf. chapter 3.3.3.1.2. 
Immunoglobulin-like Transcript (ILT)). Both interactions are opposed as the gpUL18 interaction 
with CD94/NKG2C leads to NK activation, whereas its interaction with ILT2/LIR-1 inhibits NK cell 
functions [195, 253]. In the CD94/NKG2 family, other AR exist, like CD94/NKG2F and 
CD947NKG2I, but they will not be developed in the thesis introduction. 
 
3.3.4.3. NKG2D or CD314 
NKG2D is one of the most studied NK cell AR, and its activating role is largely 
demonstrated. Contrary to what its name may suggest, NKG2D is different from the NKG2 family. 
It is expressed as a homodimer, not associated with CD94 molecule [254]. In humans, NKG2D 
binds MICA and MICB, expressed upon cellular stress and in some epithelial tumours. MICA and 
MICB are structurally similar to MHC class I molecules, but do not associate with β2m molecules 
nor bind peptides [255]. UL16-binding proteins (ULBP) or retinoic acid early transcripts 1 (RAET1) 
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are also ligands for NKG2D [256, 257]. UL-16 is a CMV protein which binds to ULBP1 and ULBP2 
as well as MICB and retain them in the ER, preventing their recognition by NKG2D, thus inhibiting 
cell lysis by NK cells. In normal conditions, ULBP transcripts are generally present in many cell 
types, but not expressed on the cell surface [256]. This expression is restricted to many tumours 
and infected cells [254, 257]. In mice, NKG2D recognises, the family of Rae I (homologue of the 
human RAET1), as well as the histocompatibility 60 protein (H-60), similar to the MHC class I 
molecules, and the murine ULPB-like transcript 1 (MULT1) molecules [254]. 
In human, the NKG2D adaptor molecule is DAP10 which carries a tyrosine based motif 
(YxxM) different than ITAM motifs [258], and recruits the phophatidylinositol-3 kinase (PI3K) 
resulting in an activation pathway leading to CG polarisation toward the target cell and 
degranulation [259]. Two different isoforms of NKG2D were found in murine NK cells. The 
difference is based on their cytosolic tail length: NKG2D-L having a Long cytosolic tail, associated 
with DAP10 and expressed on both resting and activated NK cells, and NKG2D-S, presenting a 
Short cytosolic tail, an isoform only expressed on activated NK cells and associated with DAP10 
or DAP12 adaptor molecules [260]. 
 
3.3.4.4. Activating KIR and LILR/ILT/LIR 
Activating and inhibitory KIR and LILR/ILT/LIR receptors exhibit high degrees of sequence 
identity especially in their extracellular part suggesting a comparable ligand specificity. Activating 
KIR interaction with their ligands seems to be very weak making these latter molecules’ 
identification very difficult. Some activating KIR ligands are still unknown, like those of KIR2DS3, 
2DS5 and 3DS1. KIR2DS1 and 2DS2 were found to bind to the same ligands as their inhibitory 
counterpart (KIR2DL1 and DL2), HLA-Cw4, but with a much weaker affinity [261]. KIR2DS4, using 
soluble Ig-Fc molecules, recognises HLA-Cw4 (but not –Cw6) molecules [262]. Activating KIR 
and LILR/ILT/LIR receptors present short cytoplasmic tails. Their transmembrane region has a 
charged residue associated with signalling adaptor proteins possessing ITAM motifs 
(TYROBP/DAP-12) which is responsible of the activation signal transmission [263]. An exception 
for this rule is KIR2DL4, with soluble HLA-G as ligand, presents atypical domains. Although its 
two extracellular Ig domains are connected to an intracellular ITIM motif, KIR2DL4 exhibit 
activating functions mediated by a positively charged aa (arginine), located in the amino-terminal 
part of the transmembrane domain) and connected to an adaptor molecule, FcεRIγ. 
 
3.3.4.5. Activating Ly49 
Like the human KIR and ILT/LIR molecules, murine Ly49 proteins can also be activating 
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receptors. Both activating and inhibitory forms are highly similar in their extracellular portion 
especially their ligand recognition domain [213]. Unlike the inhibitory Ly49 proteins (which are 
expressed on NK cells, NKT cells and a part of T cells), the activating Ly49 proteins are restricted 
to NK cells [264]. It was demonstrated that the transgenic expression of Ly49D and its interaction 
with its ligand (H2-Dd, H2-Dr and H2-Dsp2) are incompatible with NKT cells’ development [265]. 
Act Ly49 protein are coupled to the adapter molecules DAP12 and DAP10 [266] and are 
implicated in direct recognition, on infected target cells, of viral proteins resembling MHC class I 
molecules [267]. A good example of the act Ly49 molecules in the NK cell-mediated antiviral 
defence is Ly49H, which recognises the CMV protein m157, structurally close to the MHC class I 
molecules. This interaction, Ly49H-m157, induces NK cell cytotoxicity and IFN-γ secretion [268]. 
Following CMV infection, a preferential expansion of Ly49H+ NK cells is detected, which stops 
once the adaptive immune response appears [269]. Till today, no MHC class I capable of 
interacting with Ly49H was found, indicating that this AR is specific of a virus-encoded protein 
[270]. 
 
3.3.4.6. NKRP-1C or NK1.1 
NK1.1, CD161c or NKRP-1C belongs to the type II C-lectin superfamily and does not have 
an ITIM nor an ITAM motif in its cytosolic tail. It is expressed as a homodimer on the surface of 
C57BL/6 murine NK cells and a small subset of T cells [271]. NK1.1 is used as C57BL/6 
identification marker. Unlike TCRα/β+ cells, NK1.1+ T cells are able, like NK cells, to 
spontaneously lyse several kinds of tumour cells in vitro [272, 273]. The inoculation of anti-NK1.1 
antibodies to C57BL/6 mice results in NK cells death by apoptosis, but NK1.1+ T cells proliferation 
and IL-4 secretion [274], whereas in rADCC experiments, the anti-NK1.1 antibody stimulates NK 
cells for cytotoxicity and IFN-γ secretion [275, 276].  
 
3.3.4.7. CD16 and CD32 
CD16 or FcγRIII, expressed in both human and mice, is part of the Ig superfamily, presents 
two extracellular Ig domains, a transmembrane charged aa and a short cytosolic tail that does not 
have an ITIM nor an ITAM motif [277]. It presents two different isoforms:  CD16a, expressed on 
NK cells and co-localising with homodimers or heterodimers of CD3ζ and Fc-εRI-γ in human, and 
only with Fc-εRI-γ homodimers in mice, and CD16b, expressed on neutrophils [278, 279]. CD16a 
is one of the most important NK cell AR as it induces ADCC (cf. chapter 3.2.1.2. Antibody 
Dependant Cellular Cytotoxicity (ADCC)) by recognising the Fc fragments of IgG1 and IgG3 but 
not IgG2 nor IgG4 and inducing NK cell activation [143]. It has been shown that after human NK 
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cell co-culture with malignant target cells, a down-regulation of CD16a occurs, which might be 
important for NK cell function modulation [280, 281].  
NK cell ADCC can also be induced by another Fc receptor, FcγRIIc1, an isoform of CD32 
which recognises Fc parts of IgG3, IgG1 and IgG4 as well as IgG2 but with a much weaker affinity. 
This AR is a part of the Ig superfamily, like CD16, but differs in the fact that it presents a cytosolic 
ITAM motif responsible of its activating signals transduction. Two different isoforms, resulting from 
allelic polymorphism, are generated. One is truncated and non-functional, and the other is 
complete and expressed on NK cell surface [282, 283].  
 
3.3.4.8. Other Activating Receptors 
i. CD7 
CD7, belonging to the Ig superfamily, is expressed on the surface of all NK cells and T 
cells. Its specific ligand, K12, is a protein secreted by epithelial cells [284, 285]. In rADCC 
experiments using an anti-CD7 antibody, an enhancement of NK cell cytotoxicity, IFN-γ 
secretion, and proliferation was observed [286, 287]. CD7 classification as a co-activation 
receptor is based on the finding that NK cells in CD7-KO mice are normal in quantity and 
cytotoxicity function [288]. Milush et al. identified novel subsets of peripheral blood (PB) 
CD3/14/19neg NK cells and monocyte/DC-like cells. In fact, using CD7 and CD56 as 
surface markers, it is possible to distinguish two different cell types: CD7negCD56+ 
monocyte/DC-like cells, lacking the expression of NK cell-associated markers as well as 
NK cell functions, and CD7+CD56+, common NK cells [289]. 
ii. CD27 
CD27 is a co-stimulatory molecule, a type I transmembrane glycoprotein, belonging to the 
TNF receptor superfamily [290] which recognises another member of the same family, 
CD70 [291, 292]. In mice, CD27 interaction with its ligand, or the use of an anti-CD27 
antibody (ADCC) increases NK cell secretion of IFN-γ, but not their cytotoxicity [292]. 
Combined to CD11b, CD27 defines different stages of murine NK cell differentiation (cf. 
chapter 3.4.2. Late Stages of NK Cell differentiation) [293, 294]. In humans, more 
specifically in T cells, CD27 is a co-stimulatory receptor that enhances signals through the 
T cell receptor (TCR) upon engagement with its ligand, CD70 [295]. Loss of CD27 on 
human and murine T cells was correlated with an increase in their cytotoxic capacity [296]. 
In human, by using CD27, NK cells can be sub-divided into two main subpopulations 
differing in their compartmentalisation. This subdivision overlaps with the expression of 
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CD56: high or positive expression of CD27 on CD56bright, and low to negative expression 
of CD27 on CD56dim NK cells [297, 298]. 
iii. CD69 
CD69 is a type C lectin expressed as a disulfide-linked homodimer on most of the 
hematopoietic cells. Absent from non-activated NK cells, CD69 is a functional triggering 
molecule on activated NK cells [299]. In rADCC tests, an anti-CD69 induces NK cell 
cytotoxicity, proliferation, and cytokine production [300].  
iv. DNAM-1 or CD226 
DNAM-1 is a surface glycoprotein belonging to the Ig-superfamily and expressed on 
human NK cells, platelets, monocytes and a subset of T cells. It binds to CD155, a 
poliovirus receptor, and CD112, a nectin adhesion molecule [301] which are both 
upregulated on tumour cells. A physical and functional association between DNAM-1 and 
both, the adhesion molecule Lymphocyte function-associated antigen 1 (LFA-1), and the 
tyrosine-kinase Fyn was found [302]. This association is necessary for DNAM-1 mediated 
NK cell triggering. DNAM-1 plays an important role in spontaneous formation prevention 
and growth controlling of tumour cells [248, 303, 304]. NK cells also use DNAM-1 in their 
cross-talk with DCs since the latter cells express this receptor’s ligands [305]. 
v. CD244 or 2B4 
CD244 (2B4), expressed in human and mice, is a member of the Signalling Lymphocyte 
Activation Molecule (SLAM) receptor family [306]. Contrary to other SLAM receptors, 2B4 
does not bind to itself in trans, it recognises another Ig-like hematopoietic molecule, CD48. 
In their cytosolic tail SLAM receptors present a tyrosine based motif (S/TxYxxL/I), similar 
to the ITIM motif, and called Immunoreceptor Tyrosine-based Switch Motif (ITSM) [307]. 
ITSMs transduce an activation signals through the SLAM-associated proteins (SAP) 
followed by the recruitment of the tyrosine kinase Fyn. 2B4-dependant activation signal in 
NK cells is ensured by two different ways: VAV-1 phosphorylation by Fyn, and SH2 
recruitment blocking [308, 309]. Another SAP adaptor molecule is expressed in NK cells, 
Erwing’s sarcoma-associated transcript-2 (EAT-2), which does not bind Fyn, but combines 
to SAP in NK cell activation upon 2B4 recognition of CD48 [310]. An inhibitory function is 
also attributed to the 2B4 receptor. This inhibition occurs during lymphocytic 
choriomeningitis virus (LCMV) infection in mice and protects activated CD8+ T cell against 
NK cell-mediated killing [311]. The balance between both activation and inhibitory 
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functions of 2B4 receptor are still unknown. 
vi. NKp80 
NKp80 belongs to the C-type lectin family and presents in its cytosolic part two ITIM-like 
motifs [312]. It is expressed as a homodimer on all NK cells (activated or not) as well as 
CD56+ T cells [313]. NKp80 binds to the genetically linked activation-induced C-type lectin 
(AICL) and stimulates NK cytotoxicity by using an atypical hemi-ITAM and the Syk-kinase 
pathway [314]. This interaction promotes cross-talk with monocytes, and increases the 
responses of effector memory CD8+ T cells (4, 5). 
 
3.3.4.9. Activating Receptors and their Synergistic Combinations 
To secrete cytokines or kill target cells, NK cells require activation signals transmitted 
through their AR. But is each of the above mentioned receptors sufficient for triggering activation? 
rADCC experiments, with antibodies against each of these receptors, showed that only 
CD16 cross-linking can lead to degranulation in resting NK cells [246] whereas other receptors 
(NCRs, NKG2D, DNAM-1 and 2B4) were found to activate NK cells only in combination with 
others. The rADCC resulting activation is different from the receptor/ligand interaction occurring 
in vivo. One solution would be to express the corresponding ligand on Drosophila cells, or 
attaching it to an artificial lipid bilayer. In such experiments, results similar to rADCC were 
obtained: not one single natural cytotoxicity receptor was able to induce degranulation alone. 
Specific AR synergistic combinations were important for such activation [315]. These experiments 
show that the NCRs, NKG2D, DNAM-1 and 2B4 have equal activation status, at least in 
degranulation (Fig. 13). 
AR ligation and its effect on cytokine secretion was found to be more complicated and 
different than degranulation. Some receptors ligation were enough to induce IFN-γ secretion, like 
2B4. This effect was additive, meaning that the ligation of more than one receptor could increase 
the cytokine secretion [155]. 
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3.3.5. Adhesion Molecules (AM) 
NK cells express a large number of AM like, CD2, CD11a/CD18 (LFA-1), CD11b, CD31, 
CD44, CD49d/CD29 and CD62L. These molecules are implicated in different functions: 
endothelial adhesion, extravasation, migration, homing, tissue infiltration, conjugates formation 
with target cells, and cytotoxic activity co-stimulation [316]. In this part, we will develop the role of 
some of the above mentioned AM. 
i. CD2 
CD2 is a surface protein belonging to the Ig superfamily, expressed by human T cells and 
a subset of NK cells. It binds CD48, and CD58, a ligand widely expressed on 
hematopoietic cells [317, 318]. Only a fraction of CD2+ NK cells that does the engagement 
of CD2 molecules with their ligands can result in NK cell activation. Such observations 
suggest that CD2 is a co-receptor during NK cell mediated cytotoxicity [319-321]. This was 
Figure 13: NK cell activating receptors (AR) synergistic combinations. 
Shown is a table summarising NK cell responses following their activating receptors (AR) 
engagement with their specif ic l igands expressed on insect S2 cells. Not one single AR 
was able to induce a complete NK cell response, demonstrating the AR synergistic 
combination necessity for NK cell degranulation and target cell kil l ing. Adapted from [6], 
no permission needed. 
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explained by the fact that CD2 plays an important role in nanotubes’ formation on NK cells, 
enabling them the exploration of their local environment and interaction upon target cell 
encounter [322]. 
ii. LFA-1 or CD11a/CD18 
LFA-1, or leukocyte function associated molecule-1, is a heterodimer, expressed by all 
leukocytes, and formed of the two integrins, αL and β2 (CD11a and CD18 respectively) 
[323]. LFA-1, or CD11a/CD18, binds three different AM: intercellular adhesion molecule 
(ICAM)-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50) [324]. LFA-1 play an important 
role in the NK cell cytotoxicity mechanism [316]. NK cells derived from LFA-1 KO mice are 
phenotypically normal, present normal cytokine secretion properties, and have the 
necessary CG for degranulation, but upon target cell encounter less conjugates are 
formed (60% to 80% reduction), and their cytotoxicity activity is reduced [325]. This 
cytotoxicity requires both cells (NK and target cell) adhesion, which is mainly mediated by 
the interaction of LFA-1 and its ligand, ICAM-1 [326]. Such a cytotoxicity reduction was 
also observed when LFA-1 was blocked by an antibody [327]. LFA-1 was found to promote 
degranulation but not polarisation [146, 315]. 
iii. CD11b (MAC-1) 
Like LFA-1, CD11b (or macrophage-1antigen (MAC-1)) is part of the heterodimeric 
integrin αMβ2 molecule, β2 being CD18. In mice, CD11b devises NK cells into two subsets, 
CD11blow subset, present in foetal and neonatal mice [328] as well as adult mice’s BM, 
and CD11bhigh NK cells, present in peripheral sites, such as spleen, peripheral blood 
mononuclear cells (PBMCs), and lung [329]. Along with CD27, CD11b determines four 
different stages of murine NK cell maturation [294], (cf. chapter 3.4.2. Late Stages of 
Differentiation). In human, nearly all PBMC NK cells are CD11bhigh. By comparing these 
NK cells (phenotypically and functionally) to the decidua NK cells, known to be less mature 
and having a CD11bneg CD27neg phenotype, it was proposed that both markers, CD11b 
and CD27, can determine, like in mice, different human NK cell differentiation steps [330]. 
iv. CD56 
CD56, a binding glycoprotein, is an isoform of the neural cell adhesion molecule (NCAM), 
expressed in human but not in mice. This AM is expressed on the surface of neurons, 
skeletal muscle and NK cells [331-333]. Although CD56 is the main human NK cell marker, 
it does not seem to be implicated in these cell’s functions and its role is still unknown. The 
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use of anti-CD56 antibodies does not induce NK cell activation, nor inhibition, on the 
contrary, it is used as a negative control when studying other receptors’ effect upon 
antibody recognition [323, 334]. NK cell subpopulations’ division is based mainly on the 
CD56 expression into two main subsets: CD56bright and CD56dim. In response to interleukin 
stimulation, CD56bright cells produce IFN-γ and proliferate, whereas CD56dim produce 
cytokines and become cytotoxic upon their AR triggering [335-337]. After few days of IL-2 
activation, CD56 density increases on CD56dim NK cells. A third population, CD56neg 
CD16+, rare in healthy donors, represent up to 40% of NK cells in HIV-1 and hepatitis C 
virus (HCV) patients [338, 339]. Phenotypically, CD56neg cells express NKp46, at low 
levels under certain conditions, as well as molecules which are associated with NK cells 
[340]. This third subset shares the phenotype features of immature NK cells, high 
expression of CD94/NKG2A and low expression of CD57, but also of mature NK cells, 
high expression of KIR molecules [341, 342]. Functionally, they are skewed towards 
cytokine production suggesting a role in virus infection control [340]. All these 
characteristics make CD56neg CD16+ cells a possible third subdivision of NK cells, thus 
reducing the specificity of CD56 and calls for the use of multiple approaches to reach the 
NK cell definition.  
v. CD62L 
CD62L, a member of the selectin family (L-selectin), is a homing molecule important for 
the recruitment of NK cells to the lymph nodes [343]. It can also initiate leukocyte tethering 
while rolling along the endothelium [344]. CD62L expression was suggested to be a part 
of the NK cell development in mice and humans. Kerstin et al. have shown that human NK 
cell development can be divided into three different steps using CD56 and CD62L: 
CD56bright, CD56dim CD62L+ and CD56dim CD62L-, where the CD56dim CD62L+ is the only 
subset retaining both CD56bright and CD56dim functions (cytokine production and 
cytotoxicity) [345]. In mice, CD62L is expressed at higher levels in CD11b+ than CD11bneg 
NK cells, suggesting a correlation between its expression and NK cell development [293]. 
 
3.3.6. Other NK Cells Phenotypic Markers 
i. CD8 
CD8 is a transmembrane glycoprotein belonging to the Ig superfamily. Two different 
isoforms were identified, CD8α and CD8β, encoded by two different genes. While CD8α 
is associated with a short cytosolic tail that interacts with a SRC-like tyrosine kinase, 
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p56lck, CD8β’s 15 aa cytosolic tail has no identifiable protein binding motif [346, 347]. CD8 
is expressed on the surface of T cells, in both human and mice, mainly as a disulfide-
linked heterodimer composed of a CD8α and CD8β chain, and serves as a co-receptor for 
the T cell receptor (TCR) when binding to MHC class I molecules [348-350]. While it is 
absent on resting murine NK cells, CD8 is expressed on a subset of human NK cells, and 
a small subset of T cells, as a CD8α/α homodimer [351, 352]. The interactions of both 
CD8α/α and CD8αβ with the MHC class I molecules were found to have identical affinities 
[347, 353]. Functionally, resting and IL-2-activated human CD8+ NK cell subsets were 
found to be more cytotoxic than their CD8- counterparts [354, 355]. Addison et al. have 
shown that CD8+ NK cells are less prone than CD8- NK cells for apoptosis after target cell 
ligation and lysis, allowing them to perform multiple target cell killing [356]. 
ii. CD57 
CD57 represents a carbohydrate epitope containing a sulfoglucuronyl residue. The 
enzyme processing this epitope is beta-1,3-glucuronyltransferase 1 (B3GAT1), a type 2 
transmembrane protein with a relatively short cytoplasmic region [357]. This epitope is 
widely expressed in mouse brain [358], on human neurons and retina cells [359] as well 
as on NK cells, subsets of T cells, B cells and monocytes. In T cells, CD57 is a marker of 
high differentiation, indicating cells capable of IFN-γ and IL-5 production and cytotoxicity, 
but reduced proliferation [360]. Only CD56dim NK cells express CD57, an expression which 
increases by age [361]. In fact, CD57+ CD56dim NK cells, compared to their CD57- 
counterparts, express less CD94/NKG2A, CD27, CD62L, NKp30, NKp46 and NKG2D, 
and more KIR molecules. Functionally, CD57+ NK cells produce less IFN-γ than CD57- NK 
cells, the opposite being observed in ADCC assays. As for the proliferation capacity and 
response to IL-2 and IL-15, the expression of CD57 makes NK cells less prone to these 
functions. All these characteristics, which occur independently from NK cell education, 
associate the expression of CD57 on NK cells with a unidirectional differentiation, leading 
to a final maturation step [361, 362]. 
vii. CD94 
CD94 is a glycoprotein, part of the C-type lectin superfamily, and has a very short cytosolic 
tail that does not transduce any signal. It can be disulfide-linked with the different inhibitory 
and activating members of the NKG2 family (NKG2A, B, C, E, and H), but not with NKG2D 
[198]. The CD94/NKG2 complex recognises HLA-E in human and Qa-1 molecule in mice. 
CD94 is considered to be an invariant chain serving as a chaperone for the NKG2 
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receptors’ transport to the cell membrane [363] and is acquired during the late stages of 
NK cell development. The depletion of KLRD1 gene in mice (the CD94 gene), did not 
affect NK cell development and maturation, nor their cytokine production and lytic 
functions against the YAC-1 target cell line [364]. Like CD62L [345], CD94 was reported 
to subdivide human NK cell into 3 distinct subsets according to their maturation process: 
CD94high CD56bright, more potent in IFN-γ secretion, less cytotoxic, and expressing less 
perforin and Grz B than their CD94low CD56dim counterparts, and CD94high CD56dim, 
showing intermediate properties between the two latter cell types [365]. This subdivision 
was also proposed by Moretta et al. where CD56, CD94, KIR, CD16, CD57 and perforin 
were used to identify four different stages in NK cell transition from CD56bright to CD56dim 
[366]. 
 
3.4. NK Cell Development and Differentiation 
In mammals, PBMC derive from bone marrow (BM) self-renewing pluripotent 
hematopoietic stem cells (HSCs) which give rise to the common myeloid progenitor (CMP) and 
the common lymphoid progenitor (CLP). A series of maturation and differentiation steps, following 
various hierarchical fashion pathways, leads to functionally competent cells. Thrombocytes, 
erythrocytes, mast cells, basophils, neutrophils, eosinophils and monocytes are derived from the 
CMP, whereas T cells, B cells, and NK cells are derived from the CLP. Dendritic cells can be 
derived from both progenitors, CMP and CLP [367]. 
NK cell development studies constitute a large area of investigation. The elucidation of the 
immunophenotypes of the different NK cell developmental intermediates (NKDIs) is of high 
importance as NK cell application in cancer therapy, and other diseases’ treatment, is growing by 
time. NK cell development, which starts by the HSCs differentiation, is divided into 6 different 
stages, based on multi-parameters’ cell surface markers [368] (Fig. 14A, B). In this section, we 
will present the main cellular intermediates, the developmental pathways as well as the 
anatomical sites of human and mouse NK cell development. 
 
3.4.1. Early Stages of Differentiation 
NK cells, like all lymphocytes, are derived from BM HSCs. In humans, HSCs and CLP are 
part of the CD34+ BM population and defined as lineage negative [367]. During the early stages 
of development, stages 1, 2 and 3 in humans, and, CLP, pre-NK precursors (pre-NKP) and NK 
precursors (NKP) in mice, NK cells become gradually committed to the NK cell lineage. An 
important step in both human and murine NK cell development is the acquisition of the 
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interleukin (IL)-15 receptor (IL-15R) [369] more specifically the β chain, common with the IL-2R 
(cf. chapter 3.4.3. i. Cytokines and Chemokines). 
The definition of early NK cell precursors is based on different characteristics. These cells 
lack the phenotypic features of mature NK cells, are unable to produce IFN-γ nor mediate 
cytotoxicity, and have, under IL-15 stimulation, the potential to develop into NK cells [370, 371]. 
Figure 14: Representation of the different NK cell developmental intermediates (NKDI) in human 
and mice. 
(A) Human NK cell development from hematopoietic stem cells (HSCs) to mature CD56dim 
ones (stage 5) is represented as a linear pathway. Memory NK cells (stage 6) are 
depicted here as one possible terminal stage of NK cell development/maturation, 
although different pathways are known to lead to this stage. (B) Mouse NK cell 
development from hematopoietic stem cells (HSCs) to mature CD11bhi ghDX5+ NK cells is 
represented as a l inear pathway. As in humans, memory NK cells are depicted here as 
one possible terminal stage of NK cell development/maturation, although different 
pathways are known to lead to this stage. Shown under each developmental stage, 
different surface markers which can be used to distinguish NKDI population. 
Abbreviations: CLP, common lymphoid progenitor; iNK, immature NK cell; mNK, mature 
NK cell; NKP, NK cell precursor. Expression is designated as ‘+’ (expression), ‘–’ (no 
expression), ‘hi’ (high expression), or ‘lo’ (low expression). Adapted from [8], permission 
number 3326560423995. 
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Committed NKDIs are cells lacking lineage specific antigens (like CD3, CD14 and CD19) with the 
potential of becoming NK cells but no other hematopoietic cell lineages (T cells or DCs). These 
cells were believed to belong to the stage 3 of differentiation as the latter stage cells are not able 
to revert to the previous stage 2 NKDIs [370]. Recent studies showed an overlapping between 
the stage 3 committed NKDIs and some ILC populations in the human secondary lymphoid tissue 
(SLT) [372]. The main difference between these two cell types are the specific development 
requirements. ILCs require the nuclear receptor RORγt for their development, whereas NK cells 
never express this gene during their in vivo lifespan [373]. Another factor, IL-7, is essential for 
ILC3 development, but not NKDIs, the opposite being true for IL-15 [374]. 
 
3.4.2. Late Stages of Differentiation  
During the next 3 stages of NK cell development, stage 4 (CD56bright), 5 (CD56dim) and 6 
(memory NK cells) for human, and immature NK (iNK), mature NK (mNK) then memory NK for 
mice, NK cells undergo functional maturation, become cytotoxic, and gain the ability to secrete 
different cytokines and chemokines. The acquisition of the different receptors, in both humans 
and mice, follows a certain specific order. In humans, CD161 is acquired first, followed by CD56, 
CD94/NKG2A, NKp46 then KIR and CD16 [119, 171, 361, 375]. Mouse NK cells follow a parallel 
expression order: NK1.1 is the first to be expressed, CD94/NKG2A, NKp46 then the Ly49 receptor 
family and finally CD11b [329]. During their lifespan, NK cells partially downregulate or lose some 
of these receptors, like CD56 in humans, CD27 in mice, and CD94/NKG2A in both species [376]. 
Based on their functionality, mature NK cells, in both species, can be divided into at least two 
different populations. 
Human CD56bright and CD56dim are the main two NK cell populations [336, 377]. While the 
CD56bright subset is more potent for cytokine production upon soluble factors’ stimulation, CD56dim 
cells represent the main cytotoxic NK cell population, and are capable of strong cytokine response 
resulting from a cell surface ligands engagement [6, 119]. NK cell differentiation, as well as 
telomere length studies indicate that CD56bright are the precursors of CD56dim NK cells [378-380]. 
This notion is supported by the fact that the CD56bright subset is the first to appear in PB following 
stem cell transplantation [381] whereas CD56dim NK cells appear later and accumulate during life 
[362]. Other receptors were also investigated and found to have a certain progression pattern 
during NK cell maturation, like CD94, CD62L, CD27, NKG2A, KIR and CD57 [345, 361, 362, 365]. 
Among the mNK in mice, there can be determined different subpopulations with different 
functional competence. Stimulation of CD27high murine NK cells leads to a higher cytokine 
production and cellular cytotoxicity compared to their CD27low counterparts [382]. The notion that, 
like human CD56bright and CD56dim NK cells,  CD27high NK cells are CD27low precursors, was 
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confirmed by adoptive transfer experiments, showing that CD27high can give rise to CD27low NK 
cells, the opposite not being possible [382]. These data lead to a 4-steps murine NK cell 
maturation pattern based on CD11b and CD27 expression: CD11blow/CD27low  
CD11bhigh/CD27low  CD11bhigh/CD27high  CD11blow/CD27high [294]. 
Traditionally, immunological memory is restricted to T cells and B cells, NK cells being 
considered as part of the innate immunity with short lifespan. In the past few years, several studies 
provided evidence of specific NK cell features of adaptive immune memory induced by MCMV 
infection [383, 384], exposure to cytokines [385], and a liver-restricted NK memory cells directed 
towards specific antigens [386].  
 
3.4.3. Factors Influencing NK Cell Differentiation  
During their development and differentiation process, NKDIs are subject to many factors 
which play an important role. These factors can be extrinsic, like cytokines, chemokines and the 
surrounding environment, or intrinsic, like transcription factors. 
i. Cytokines and Chemokines 
By directing the NKDIs into specific tissues and distinct microenvironments, chemokines 
play an important role in NK cells differentiation and maturation [387]. Most of the available 
data dealing with the role of cytokines and chemokines on NK cell development were the 
result of in vitro studies. It is still unclear when, how and at what concentration these 
molecules play their role in vivo. 
One of the most important IL in NK cell development is IL-15, and its action through its 
receptor IL-15R, downstream the CLP differentiation [369, 388]. This receptor is 
composed of 3 subunits: the high affinity α chain (CD215), the β chain (CD122) which is 
shared with IL-2 (IL-2/IL-15R), and the common γ chain (CD132) present in IL-2, -4, -9, -
15 and -21 receptors [389]. While in vitro the soluble IL-15 drives NK cells development 
from BM-derived HPCs [390], in vivo IL-15 is coupled to CD215 then presented in trans to 
the CD122 and CD132 expressing cells [391]. 
Some cytokines, like flt3 ligand can play an indirect role in NK differentiation by promoting 
expansion of an important IL-15 source, DCs [392]. The tyrosine kinase receptor Axl/Gas6 
(adhesion-related kinase/growth arrest-specific gene 6) positively regulates flt3 and thus 
participates in NK cell development [393]. In contrast, other cytokines are known to 
repress or decrease the development of NK cells, like TGF-β [394]. IL-1β, in the presence 
of IL-15 favours the expansion of ILC3 compared to NK cells [395]. 
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ii. Environmental Cells 
NK cells can be found in most tissues, as well as blood. In human and mice, these tissue 
resident NK cells are shaped by their environment and may present unique roles during 
the immune response as well as tissue integrity. In case of malignant cell growth, infection 
or inflammation, specific PB NK subsets can be recruited to the concerned organ and 
perform their specific and necessary functions. For a long time it was thought that CLP 
were only present in BM, but CD34+ precursors were found in many other tissues, like 
thymus [396], cord blood (CB), SLT, lymph nodes [397] and blood. These cells can, in 
vitro and under IL-2 or IL-15 stimulation, differentiate into mature NK cells [171, 398, 399], 
an interaction mediated by the IL-2/IL-15R β chain, and the common γ chain. BM stromal 
cells were reported to play an important role in NK cell differentiation, mediated by 
receptor-ligand interactions between these two cells. Deletion of the three Tyro3 family 
receptor members (Axl, Tyro3 and Mer), expressed either on NK cells or stromal cells, 
resulted in a NK development and function alteration [400]. T cells, DCs and monocytes 
were also found to mediate NK cell differentiation by secreting IL-15 and/or IL-2 [401, 402] 
iii. Transcription Factors 
Transcription factors (TFs) are important players in the hematopoietic lineage specification 
[403, 404]. E4BP4/NFIL3, a basic leucine zipper transcription factor, plays a role in 
different immune processes [405]. In E4BP4-deficient mice, NK cells number are highly 
reduced in different organs (LN, liver, spleen and BM) indicating that E4BP4 is absolutely 
required for NK cell development in the BM [406, 407]. Ets-1, known to play a role in T cell 
and B cell development, is critical for NK cells differentiation as it is implicated in the very 
early stages of development by inducing other TFs expression [408]. Ets-1 KO mice 
showed a normal CLP count, but NK cell committed precursors number was decreased 
leading to a 5-fold to 10-fold reduction in mature NK cells’ number [408]. Helios, belonging 
to the Ikaros zinc-finger family of TFs, is highly expressed in murine CD11bneg NK cells. 
Studies on Ncr1Noé/Noé mice suggested a possible link between the up regulation of Helios 
and the absence of NKp46 expression [247]. Splenic NK cell maturation, but not 
specification, was found to be stopped in GATA-3 KO mice. While immature GATA-3 KO 
splenic NK cells had normal cytotoxicity, the secretion of IFN-γ was reduced compared to 
WT NK cells [409]. GATA-3 was also reported to be indispensable for the generation of 
murine CD127+ thymic NK cells [396]. Loss of KLF4 affected NK cell number in PB and 
spleen but not in the BM, Lymph Node (LN) and liver. Functionally, only splenic NK cells 
showed increased apoptosis. Interestingly, these defects were compensated after 
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adoptive transfer of KLF4-deficient NK cells in WT mice [410]. 
 
3.5. NK Cell Education 
In contrast to T and B cells, the term “education”, for NK cells, does not systematically 
imply a defined development mechanism taking place in the thymus or BM, but more the adaptive 
process(es) that a NK cell undergoes to achieve functional competence. This process(es) results 
from the NK cell interaction with MHC class I molecules, and allows it to sense the absence or 
differences in these molecules’ expression on surrounding cells, termed “missing-self”. To 
achieve such functions, the IR expression on NK cells should be regulated in a way such that NK 
cells can recognise and eliminate the non-self or altered-self, while remaining tolerant to the 
autologous (self) cells.  
NK cell educational mechanisms have not been yet entirely elucidated, and are still 
intensively debated. In this section we will discuss the different models of NK cell education, 
including the original one, the missing-self hypothesis and how it gave rise to the other models, 
as well as the role of MHC class I molecules (Fig. 15).  
 
3.5.1. Missing-self hypothesis 
Early studies by Georges Snell in 1958 [411, 412], demonstrated that following a bone 
marrow transplantation, an irradiated F1 hybrid individual (with a genotype A/B) rejects the tissue 
if derived from AA or BB genotype individuals, a rejection controlled by MHC class I molecules. 
Years later, Cudkowicz et al. [413] showed that such tissues’ rejections are controlled by a bone 
marrow derived and thymus independent cell type. Such observations correlate with the initial NK 
cell description and led K. Kärre to elaborate the missing-self hypothesis in 1981: the absence or 
reduced expression of MHC class I molecules would render target cells susceptible to NK cell 
attack. Mechanistic models explaining the initial hypothesis were published in the following years 
by K. Kärre’s team, suggesting the existence of unknown structures allowing NK cells to detect; 
(i) the self and transmitting negative signals, or (ii) the absence of self (missing-self) resulting in 
a triggering of the NK cell which could lead to the target cell lysis [118, 414]. The work of L. and 
A. Moretta, starting in 1994, allowed the identification of different NK cell IR and AR as well as 
their ligands, HLA class I molecules [415-420]. In 1997, Valiante et al. [421] showed that a NK 
cell should express at least one self-specific MHC class I receptor to be able to detect the 
presence or absence (missing) of self. 
During the following years, the identification of NK cell subsets lacking the expression of 
IR or any MHC class I receptor [422, 423], as well as the different requirements for a correct NK 
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cell function, took the NK cell education beyond the missing-self hypothesis. Although the 
missing-self hypothesis has been proven to be incomplete, it provided an important platform for 
the generation of other models. 
 
3.5.2. Licensing, or Arming Model 
In a mouse model, on the C57BL/6 background, the comparison of Ly49C+ NK cells (which 
bind H2-Kb, a self-MHC class I ligand), showed that they are more cytotoxic and produce more 
cytokines than NK cells expressing only Ly49A (which has no MHC class I ligand in the C57BL/6 
mice) [424]. The same results were observed on human NK cells expressing KIR3DL1 and its 
ligand, HLA-Bw4 [425]. An explanation for such differences is that IR provide an ITIM-dependent 
instructive signal to the NK cells rendering them responsive, or “licenced”, “armed” [424, 426]. NK 
cells are initially hyporesponsive and their AR are inactive. When a NK cell acquires a self-specific 
IR, the signal transmitted by its ITIM motif instructs them and renders their AR competent, giving 
NK cells their responsiveness. Hyporesponsiveness caused by a lack of ITIM-dependent 
signalling can be overcome by cytokines [424]. During inflammation, the NK cell licensing lack is 
not a handicap, as the secreted IL can induce NK cell activation and overcome their 
hyporesponsiveness, such as the case with MCMV infection [427, 428].  
The licensing model is compatible with the hybrid resistance, described by Georges Snell 
[411, 412]. In a F1 hybrid individual, H2-KbDd, Ly49A+ and Ly49C+ NK cells are separately 
licensed by both MHC class I molecules, H2-Kb and H2-Dd respectively. Once they encounter a 
parental cell, H2-Kb or H2-Dd, the lack of one of the two MHC class I molecules will be detected, 
and the NK cell will attack the corresponding cell, causing the rejection. The work of Elliott et al. 
[429] in 2010 provided another proof of the licensing model. When transferred into a MHC class 
I sufficient environment (WT mice), MHC class I deficient (β2m KO) NK cells lost their 
hyporesponsiveness and exhibited functional properties comparable to NK cells derived from WT 
mice. Such results suggest that neither exposure to MHC class I ligands during NK development 
in the BM nor endogenous MHC class I expression by NK cells themselves is absolutely required 
for licensing (cf. chapter 3.5.5. Cis and Trans Interactions, and chapter 3.7. Trogocytosis) 
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Figure 15: NK cell education models. 
Depicted are the different NK cell education models. In the arming model (a), NK cell 
functional competence is ensured by the inhibitory receptor (IR) signall ing: NK cells are 
hyporesponsive in the absence of this inhibitory signal. (b) In contrast, according to the 
disarming model, NK cells are init ially activated. In the absence of a self-MHC class I 
specif ic IR, the NK cell becomes hyporesponsive. In the cis interaction model (c), NK 
cell education is ensured by the interaction of IR with its cognate MHC class I molecule 
in cis , that is on the same cell membrane. Such binding can reduce the available IR that 
can interact in trans  in the immune synapse, thus making NK cells responsive. The 
rheostat model (d) is based on the inhibitory signal strength during NK cell education. 
The activating threshold is balanced as a rheostat, allowing the NK cell maturation to be 
optimally tuned by the inhibitory input, making the rheostat model a dynamic NK cell 
education mechanism. Taken from [9], permission number 3356030822296. 
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3.5.3. Disarming Model 
Contrary to the licensing model, the disarming model highlights the effect of activation on NK cell 
education, in other words, NK cell responsiveness is tuned down. Hyporesponsiveness is an 
induced state, caused by an overstimulation of NK cells that present a lack in inhibitory signalling 
[422]. Initially, NK cells are responsive and have their functional competence retained by the 
activation pathways, allowing them to respond in the case of missing- or altered-self. When NK 
cells fail to ensure the expression of a self-specific IR, the continuous stimulation results in a 
withdrawal of their responsiveness, leading to a state of hyporesponsiveness [430]. In this model, 
the only requirement of IR is to do their assigned job; inhibiting NK cells in the presence of their 
ligands, MHC class I molecules. 
Consistent with this model, the AR NKG2D became dysfunctional after an in vitro 
prolonged exposure of NK cells to tumour cells expressing a ligand for NKG2D [431]. This chronic 
engagement of NKG2D did not only affect the latter receptor, but cross-tolerised other receptors 
with activating pathways independent of NKG2D, like NK1.1 and CD16 [431]. Similar observations 
were made when Ly49H+ NK cells were transferred into a transgenic mouse model expressing 
the MCMV-encoded peptide, m157. Responsiveness of Ly49H+ NK cells was found to be reduced 
although they express IR and MHC class I molecules at normal levels [432, 433]. The adoptive 
transfer of mature responsive NK cells into MHC class I deficient mice (β2m KO mice) resulted in 
their loss of responsiveness, providing another evidence in favour of the disarming model [107]. 
Such results presume that NK cells, once chronically exposed to MHC class I-deficient host cells, 
may develop a state of induced hypo-activity. NK cells derived from a Dd transgenic H-2b mouse 
model, in which some cells do not express the Dd transgene, were unable to kill Dd- target cells 
[434, 435]. In contrast, murine NK cells chronically exposed to tumour cells, or MHC class I 
deficient splenocytes, were unable to become hyporesponsive in vivo [431]. 
In the above mentioned situations, by adding cytokines and culturing them in vitro in the 
absence of the stimulatory cells, hyporesponsive NK cells gained their functions [431, 432, 434, 
435]. This clearly shows that hyporesponsiveness is reversible and needs continuous stimulation 
in order to be maintained. 
 
3.5.4. Rheostat Model 
The main differences in the two NK cell education models (licensing and disarming) is the 
default/initial state of uneducated NK cells. NK cells can have their functions (i) gained and 
licensed by inhibitory signals, or (ii) withdrawn and disarmed following their over-stimulation in the 
absence of inhibitory signals. But these two models fail to answer one question, are all MHC class 
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I molecules equally efficient in the NK cell education process? Especially that both, human and 
mice, can express up to six different MHC class I molecules. 
Using a murine transgenic system, the effect of H2-Ld, H2-Dd and their chimeric form, 
H2-Dd/Ld, on NK cell response was studied. The results showed that the chimeric form H2-Dd/Ld 
had the same impact as the H2-Dd transgene on NK cell response, although Ly49G can efficiently 
bind both MHC class I molecules [436]. These results were confirmed by a more detailed study 
investigating the effect of Kb, Db, Ld and Dd as well as many chimeras on NK cell functions [437]. 
The four MHC class I molecules, when expressed individually, were able to educate efficiently 
NK cells. Once expressed as chimeras, the Kd and Dd molecules induced a better missing-self 
response than the Db and Ld molecules. Not only MHC class I molecules have a strong effect on 
NK cell education, their receptor expression and ligation strength can also be determinant. Using 
a detailed multicolour flow cytometry staining, including functional readout, Brodin et al. showed 
that the IR co-expression influences the functional responses’ results in an individual NK cell. In 
a mouse model expressing MHC class I molecules of low educating impact, IR co-expression 
lead to a synergistic effect on NK cell functions. The more a NK cell expresses self-specific IR, 
the better its missing-self response is [438, 439]. NK cell capacity of missing-self response is also 
directly correlated to the MHC class I expression level: once it drops to half, NK cell rejection of 
MHC class I-deficient cells also drops to half [438]. 
In the line of the above mentioned studies, both licensing and disarming models are 
validated, but fail to explain the quantitative feature of the NK cell education. A quantitative tuning 
model was proposed, the rheostat model, in which the NK cell can be tuned up (licensed) or tuned 
down (disarmed) during its development and adapt to its MHC class I environment [438]. MHC 
class I molecules can educate NK cells, and their interactions with their receptors (IR) sets the 
threshold for NK cell activation, resulting in a gradual responsiveness in which a higher inhibition 
leads to a higher and more efficient NK cell response. Such tuning can be perturbed during cellular 
stress, inflammation, or any other situation, leading to an efficient NK cell response. 
  
3.5.5. Cis and Trans Interactions 
The different models were able, in different ways, to give more insight to the 
tolerance/education of NK cells, but the molecular mechanism behind is still unclear. They all 
agree on the importance of the NK cell IR interaction with the surrounding cells’ MHC class I 
molecules (in trans), ignoring another feature of these receptors: their interaction in cis with MHC 
class I molecules expressed on the surface of the same NK cell [219, 440-443]. The existence of 
these two binding capacities of the IR to the MHC class I molecules (Fig. 16A, B) lead to a 
questioning whether these two types of interaction have a role in NK cell education. 
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Figure 16: Cis and trans interactions between NK cell inhibitory receptors (IR) and their specific 
MHC class I ligands. 
(A and B) Shown are the interactions of MHC class I molecules (H2-Kb) with Ly49C. Such 
interactions can occur in trans (A) when each of the two molecules is on different cells, 
or in cis (B) when both molecules are expressed on the same cell surface. By comparing 
both interaction types, stalk regions do not adopt the same conformation: back-fold 
conformation when in trans, and extended conformation when in cis. MHC class I 
molecule is shown in cyan, β2m in purple, Ly49C in red, and the stalk regions of both 
molecules (green) are represented in an arbitrary way as no crystal structure is available. 
(C) The association of IR with their specif ic MHC class I molecule in cis reduces the pool 
of available IR that can engage in trans with target cell MHC class I molecules. Following 
an encounter with a potential target cell, the balance between the inhibition and activation 
signals becomes more sensible, thus activating the NK cell and leading to the target cell 
lysis. When cis interactions are absent (D), trans interaction between NK cell IR and 
target cell MHC class I molecules leads to a strong inhibition signal. When a NK cell 
encounters a target cell, the activating signal may not be suff icient to overcome the 
inhibition signal, and may not induce target cell lysis. Adapted from [12], permission 
number 3326561281597. 
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To date, cis interactions have exclusively been demonstrated for MHC class I receptors with 
inhibitory functions, like the Ly49 family members on NK cells (the most studied one being Ly49A 
which binds H2-Dd) [219, 441-443] and the ILT receptor family on mast cells [444], whereas no 
evidence of such interaction between KIRs or CD94/NKG2 receptors and MHC class I molecules 
was found. It was shown that cis interaction, between Ly49A and H2-Dd, regulates the 
accessibility of the Ly49A receptor. (cf. chapter 3.7. Trogocytosis). This accessibility, measured 
by the anti-Ly49A antibodies, correlates more with NK cell licensing than trans interactions [219, 
442]. In fact, the cis interaction modulates Ly49A accessibility thus regulating the NK cell inhibitory 
signal. 
Once a NK cell encounters a target cell, the latter is killed when the activating signal 
exceeds the inhibitory one, meaning that the necessary threshold for NK cell activation is set by 
the inhibitory signal strength (Fig. 15C, D). In the case where the available IR number is limited, 
NK cell inhibition is consequently affected and can lead to target cell killing following a minor 
reduction of host MHC class I molecules’ expression [445]. When NK cells, not expressing H2-
Dd, interact with H2-Dd+ target cells, Ly49A receptors are recruited to the immunological synapse 
where they achieve their role: inducing inhibitory signal following their engagement with their 
ligand [446, 447]. In contrast, when NK cells express H2-Dd, the Ly49A recruitment to the 
immunological synapse is reduced due to their interaction in cis with their ligand, leading to a 
higher NK cell responsiveness by restricting the inhibitory capacity of Ly49A [219, 440, 441]. 
By considering the cis interaction model, more insight can be given to some previous 
works’ conclusions, notably the work by Elliott et al. in 2010 [429]. As exposed in the chapter 
3.5.2. Licensing, or Arming Model, MHC class I deficient NK cells (β2m KO) were adoptively 
transferred into WT mice resulting in a gain of function for these NK cells. These results call for 
questioning the role of the endogenous expression of MHC class I molecules (which results in cis 
interactions) in NK cell education, but forget to take in consideration an important NK cell property, 
trogocytosis (cf. chapter 3.7. Trogocytosis). 
 
3.6. NK cell’s HLA class I Receptor Repertoire Formation and Evolution 
It is clearly established that NK cell education is highly dependent on their IR expression, 
referred to “NK cell repertoire”, and its interaction with MHC class I molecules. It shapes these 
cells’ functionality and defines their response following their encounter with surrounding cells and 
potential target cells. NK cells expressing all the available IR (KIR in humans, Ly49 molecules in 
mice, and NKG2A in both species), cannot acquire efficient immunosurveillance functions, as this 
requires from the potential target cell a complete loss of MHC class I molecules. The wide 
expression of the latter molecules, up to six different in humans, requires a clonal distribution and 
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selectivity of the NK cell repertoire. Indeed, individual NK cells express only a subset of the 
available IR, generating specialised NK cells, able to detect specific and particular alterations of 
MHC class I molecules. As a result, the NK cell repertoire expression is of great importance in 
these cells’ functions. Its expression and development can be influenced by epigenetic factors, 
molecular interactions, and can follow different developmental time-courses. 
3.6.1. Epigenetic influence on NK Cell Repertoire Expression 
MHC class I molecules and their receptors, more specifically the IR, are not genetically 
related. NK cells from both species, humans and mice, are able to express IR which do not have 
specific MHC class I ligands [448]. NK cell repertoire distribution may be based on an efficient, or 
inefficient, activation of the corresponding IR gene. From the epigenetic side, two different factors 
play an important role in this process of (in)efficient gene activation : 
i. DNA methylation 
In active genes, DNA is hypo-methylated, giving the RNA polymerase full accessibility to 
the corresponding genes, whereas silent genes have methylated DNA. Consistent with this, 
the KIR and Ly49 molecules’ expression was found to be epigenetically ensured by this 
DNA methylation process [449-451].  
ii. Role of Promoters and Transcription Factors 
In T cells, B cells, and olfactory cells, only a single receptor is selected from a large 
repertoire, and expressed per cell [452, 453]. In contrast, NK cells present a unique case of 
selective transcriptional activation, and are able to express several KIR or Ly49 molecules. 
For instance, the transcription factor T-cell factor (TCF)-1 was found to regulate the 
acquisition of Ly49A receptor in a dose-dependent manner during NK cell development 
[454, 455]. Other epigenetic factors, like promoters, were found to have an important impact 
on the IR expression. In KIR and Ly49 clusters, gene activation is controlled by several 
promoters, including some of which are bi-directional and can act as probabilistic switches 
[456-458]. One of these bi-directional promoters, Pro1, was found to have a correlation 
between its forward activity and the murine Ly49 genes’ expression [456]. A study in 2008 
by Li et al. demonstrated that single nucleotide polymorphisms (SNP) in the KIR’s 
transcription factor binding sites, are responsible of the bi-directional promoters’ functional 
differences, and result in different expression frequencies of the corresponding receptors 
[459]. 
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3.6.2. Ontogeny and NK Cell Repertoire Formation 
During development, the Ly49 receptor expression on murine NK cells starts at low levels 
and progressively rises and reaches, at around eight weeks of age, its definitive levels; more than 
80% of adult mice’s NK cells express at least one Ly49 receptor. This cumulative Ly49 receptor 
expression was demonstrated by Ly49- (Ly49A-C-G2-I-), and single Ly49+ NK cell transfer into 
congenic mice. Following this transfer, both NK cell types (negative or single positive for Ly49 
receptors) were able to mature, acquire other IR, and showed the same expression levels of 
newly acquired receptors [460]. Other in vitro studies demonstrated that the IR acquisition occurs 
in a non-random order during murine NK cell development: Ly49A appears before Ly49G, which 
appears before Ly49I [461, 462]. Such results demonstrate that the Ly49 receptor acquisition is 
sequential (not occurring in a burst), and additive (not subtractive). Human NK cells also present 
sequential expression of their repertoire. During their development, NK cells express NKG2A and 
then KIR molecules at different levels, creating a NK cell repertoire with different receptor 
combinations [463, 464]. 
Different factors, mostly environmental, were found to have an important role in this 
acquisition process. In vitro experiments showed that stromal cells’ MHC class I molecules 
influence the Ly49 expression initiation and cumulative expression [462]. Interleukins have 
distinct effects; while IL-15 (important in NK cell development), had no role in murine Ly49 
expression initiation [465, 466], efficient NK cell receptor acquisition in humans was found to be 
dependent on IL-15 or IL-2, but not IL-7 [463]. On the other hand, CD94/NKG2A expression 
appears to be induced by IL-15 in both humans and mice [466, 467]. 
In extension to the sequential expression of NK cell’s IR, it was proposed that during this 
progressive acquisition, a testing of the receptor’s reactivity with the cognate MHC class I 
molecules could happen in parallel, leading to a termination of the corresponding receptor’s 
expression [468-470]. Once the NK cell acquires the self-specific cognate MHC class I receptor, 
its interaction with the corresponding MHC class I molecule would educate NK cells and stop the 
expression of other IR [471]. A result of such a mechanism would be a random expression of NK 
cell receptor repertoire before the self-specific MHC class I receptor is acquired. This conclusion 
may be highly attractive, but such interactions with MHC class I molecules need to be tested. 
 
3.6.3. MHC Class I Molecules and NK Cell Repertoire Acquisition 
The two most important characteristics of an organism’s NK cell pool is to ensure both 
self-tolerance and effector functions, two features resulting from the NK cell repertoire interaction 
with cognate MHC class I molecules. Although the sequential and additive expression of the NK 
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cell repertoire were demonstrated (cf. chapter 3.6.2. Ontogeny and NK Cell Repertoire 
Formation), the role of MHC class I molecules in this process was proposed, but still not tested. 
In 1997, Raulet et al. suggested that the Ly49 receptors’ expression is stochastic, and that 
“the co-expression probability of two distinct IR is equal to the product of their individual 
frequencies”, namely the “product rule” [469]. Studies in transgenic mice for Ly49C and/or Ly49A, 
analysing the Ly49 receptor repertoire adaptation, showed that once an endogenous Ly49 
receptor is engaged with its ligand, whether the former is self-specific or not, its acquisition is 
limited [472, 473]. The role of MHC class I molecules was to induce the termination of the 
stochastic expression of IR when the NK cell expresses a self-reactive IR [474, 475]. Studies of 
the dose-dependent effect of MHC class I molecules on Ly49 receptors’ expression, showed that 
the acquisition of the specific MHC class I ligand, led to a reduced frequency of NK cells 
expressing more than two IR [476]. MHC class I molecules seem to control the NK cell subsets’ 
size, through inhibitory signals, generating a population of NK cells with a specific IR repertoire 
capable of efficiently detecting missing-self, while being tolerant to the self. Skewing of these 
educated NK cell subsets, which is highly beneficial for the organism, may be due to their specific 
expansion, as demonstrated by their higher ability to proliferate as a response to IL-15 [476]. In 
C57BL/6, MHC class I deficient, and single allele MHC class I mice, the comparison of the 
“observed” with the “expected” (product rule) IR expression’s frequencies revealed deviations, a 
result of both, MHC class I-dependent and independent events [477]. 
The effect of HLA class I molecules on NK cell functions is well established [9, 196, 423, 
425, 478], but their role in NK cell repertoire formation is less clear. While some studies showed 
that NK cell repertoire expression is affected by HLA class I molecules [479, 480], others found it 
to be sequential, random and independent of these latter molecules [481]. Based on a correlation 
between phenotypic studies and statistical analyses, Andersson et al. were able to compare the 
observed KIR co-expression frequencies with the expected ones, and study the effect of self-HLA 
class I molecules on the KIR repertoire expression. Their results, in a KIR haplotype A group of 
individuals, show that HLA class I molecules had the same effect on self- and nonself-KIR’s 
expression. Evidence of an HLA class I mediated control of NK cell subsets’ frequencies exist, 
but appear to be less strong than in the mouse. Schönberg et al. showed that the NK cell KIR 
repertoire, more specifically the HLA-C specific repertoire, is shaped by the cognate HLA class I 
molecules [482]. This process of structural adaptation to HLA class I molecules does not seem to 
be in place during the neonatal period. No bias toward self-HLA class I recognition was detected 
in cord blood (CB) NK cells in both KIR haplotypes A/A and B/B [483]. Functionally, CB NK cells 
were found to degranulate less than adult NK cells, with a higher degranulation for educated NK 
cells compared to the non-educated ones, indicating that both mechanisms, NK cell tuning and 
KIR repertoire adaptation to HLA class I molecules, are uncoupled. 
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Results of MHC class I role in NK cell repertoire formation cannot be extrapolated between 
inbred mice and outbred humans. The differences observed between the two species may be 
induced by inbreeding, in the mice case, which presents allelic variations of both MHC class I 
molecules and Ly49 receptors, thus increasing the specificity and the affinity between these two 
molecules. The KIR/HLA and Ly49/MHC systems comparison should benefit from similar analysis 
platforms (controlled MHC class I expression coupled to high-dimension flow cytometry). The 
engagement failure of an IR with its cognate MHC class I molecule during NK cell development 
does not represent a death sentence for these cells. In healthy donors and in TAP-deficient 
patients (same as in WT and MHC class I KO mice), such NK cells are able to develop, but display 
reduced functional capacities [106, 484]. Such NK cells represent a very good tool to study HLA 
class I molecules’ influence on their receptors’ acquisition. In addition to all the above mentioned 
factors which may influence KIR acquisition, infections, more specifically viral infections, were 
reported to have a high impact on the NK cell repertoire formation. 
 
3.6.4. Viral Infections and NK Cell Repertoire Expression 
During virus infections, NK cells produce a fast response [485, 486], and in mouse CMV 
infections, it is characterised by an expansion, then a contraction by apoptosis of specific subsets 
[487, 488]. With other viruses, like Puumala hantavirus, the expanded NK cell subsets were found 
to last for more than 2 months after the infection [489]. One of these expanded populations was 
the highly mature CD57+ NKG2C+ NK cells, which reached its peak at day 5 post infection, 
explained by the NK cell interaction with infected target cells, known to upregulate the expression 
of HLA-E, the specific ligand for NKG2C. CMV, like other viruses, developed complex 
mechanisms aimed to evade the immune system (cf. chapter 1.4.3.1. Viral Infections) [231, 490-
492], one of which is to keep NK cell IR engaged [253]. The above mentioned expansion of 
NKG2C+ NK cells was also reported in CMV infected patients [493-497], or co-infected with HIV-
1 [498, 499], hantavirus [489], chikungunya [500], HBV and HCV [501], suggesting that infection 
by CMV may shape the NK cell repertoire. Indeed, a detailed analysis of the expanded CD57+ 
NKG2C+ NK cell subset revealed a skewing toward the expression of self-KIR molecules [496, 
501]. This skewing was shown to be time-stable demonstrating the dynamic side of NK cell 
phenotype and functions. Another unexpected result was the expansion of NKG2C-independent 
subsets of NK cells expressing act-KIR, suggesting a role of the latter molecules in NK cell 
response to CMV infection [496]. 
 
Throughout their lifespan, NK cells showed that they are able to adapt to their 
environment, tune their functions, and undergo specific expansions following virus infections. 
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Looking to these findings, one could hypotheses the different theories about HLA class I 
molecules and NK cell KIR repertoire formation, especially after the demonstration that the CMV 
infection status influences NK cell KIR-ome. Still one aspect that all the previous studies have not 
taken in consideration, is studying the NK cell repertoire in a HLA class I deficient (or low-
expressing) environment. 
 
3.7. Trogocytosis 
NK cell functions are controlled by a balance between activating and inhibitory signals 
transmitted through a panel of AR and IR on their cell surface. However, since the description of 
the membrane and protein exchange between NK cells and their surrounding cells, namely 
trogocytosis, NK cell functions proved to be more complex than stated in the basic description 
above. This phenomenon may have high impact on NK cell function and presumes that they can 
react to stimuli from molecules they never expressed, but acquired from the environmental cells. 
  
3.7.1. Characteristics and mechanism 
Trogocytosis is a process in which two cells exchange membrane fragments and proteins 
following an interaction between a receptor, belonging to the cell 1, and its specific ligand, 
belonging to the cell 2. This transfer does not only imply extracellular proteins, but may also 
include patches of membrane as well as intracellular and trans-membrane proteins. 
In 1973, Bona et al. were the first to describe a LPS exchange between lymphocytes [502]. 
This mechanism was later extended to the uptake of antigens, exosomes, nanotube formation 
and finally trogocytosis [503].The first demonstration of trogocytosis in NK cells was provided by 
two independent works which described the transfer of H2-Dd to the Ly49A+ NK cells derived from 
H2-Kb genotype. Ly49A+ NK cells, derived from C57BL/6 mice, were able to acquire H2-Dd from 
the surrounding cells after transfer into Balb/c mice [504], or in a transgenic mouse model 
expressing H2-Dd at different levels [440]. In humans, KIR+ NK cells were also described to be 
able to acquire their HLA class I-specific ligands from surrounding cells [505]. 
Trogocytosis is not restricted to NK cells: CD8+ T cells are able to take up, from APCs, 
peptide-MHC class I molecule complexes, a TCR-mediated capture [506-508]. MHC class II 
molecules were also shown to be captured by CD4+ T cells [509]. Moreover, both CD4+ and CD8+ 
T lymphocytes capture CD80 from the APCs surface in a CD28-dependent manner [507, 510]. 
Using the B cell receptors (BCR), B cells are also able to acquire cell membrane-coupled antigens 
[511]. The transfer of molecules in the opposite direction, from NK cells to the donor cells, in both 
humans and mice, has been shown to be possible [512]. But is this uptake specific? 
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The first two studies describing NK cell trogocytosis demonstrated that the H2-Dd uptake 
by Ly49A on NK cells, was a result of the specific interaction between these two molecules. An 
anti-Ly49A (A1 clone) antibody, or an anti-H2-Dd antibody were able to inhibit the transfer [440, 
504]. In fact, Ly49A can be identified by three different antibodies, JR9-318, YE1-48 and A1, each 
recognising a different epitope. The A1 clone (widely known as Ly49AB6) recognises the epitope 
which binds to H2-Dd, masked when both molecules interact, whereas both epitopes recognised 
by the JR9-318 and YE1-48 clones are always accessible. In a similar way, the transfer of MICA 
and MICB was found to be dependent on their interaction with NKG2D [513, 514]. Other studies 
showed that the uptake of HLA-Cw6 by NK cells was found to be enhanced but not dependant 
on KIR2DL1 [515]. Such results do not have to contradict the former ones, as following 
trogocytosis, the molecule transfer may be accompanied by a membrane transfer, thus passively 
transferring molecules, and if it happens that these molecules are studied, the specificity of the 
trogocytosis is eliminated.  
Following trogocytosis, different situations can be considered regarding the molecules and 
membrane patches transferred to the acceptor cell, but all end with the acquired protein 
internalisation [505]: 
i. Molecules alone may be transferred, without membrane patches. 
This transfer was hypothesized following H2-Dd transfer to Ly49A+ NK cells [504]. Such 
mechanism resembles MHC class I transfer through nanotubes formation, but the involved 
mechanistic and characterisation proofs are still elusive. 
ii. Both molecules and membrane patches can be transferred, but not integrated in the 
acceptor cell membrane. 
Following trogocytosis, the transferred membrane may still be fixed to the acceptor cell 
due to the interaction of the donor cell’s molecule with its ligand on the acceptor cell. 
Evidence of such cases are well illustrated following HLA-C transfer to target cells, 
especially to KIR2DL1+ NK cells, and the transferred membrane removal after a brief acid 
wash [512, 515]. 
iii. The molecules and membrane’s patches are integrated in the acceptor cell membrane 
after transfer. 
This would implicate the integration of the donor cell membrane patches into the acceptor 
cell membrane, in a way that allows the acquired molecules to function properly. There is 
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no demonstration for such a mechanism, but many evidence suggest that it may really 
occur. In the HLA-C transfer to KIR2DL1+ NK cells (stated above), not all the membranes 
were removed by the brief acid wash, indicating that these membranes are not just fixed 
to the acceptor cell by the molecules’ interaction [512]. In another report, a signal 
transduction protein, H-Ras, which is attached to the inner face of the membrane, was 
found equally distributed in the receptor cell cytoplasm after trogocytosis [516]. 
3.7.2. Functional Consequences 
Trogocytosis is a curious phenomenon affecting many cell types of the immune system, 
but what are its functional consequences? In order to answer this question, two different scenarios 
have to be taken in consideration, regarding the transferred molecules’ nature: 
i. The transferred molecule is a Ligand 
In a ligand-type transfer, the acceptor cell has to endogenously express the corresponding 
receptor, and consequently, all the pathway machinery necessary for transducing the 
signal. The only function required from the transferred ligand is to keep its binding 
properties. The best examples for such a scenario is the transfer of MHC molecules to NK 
cells. Indeed, following the H2-Dd uptake by RNK.Ly49A NK cells (RNK-Ly49A is a rat NK 
cell line stably transfected with the inhibitory receptor, Ly49A), a reduced killing of YB2/0 
target cells (a rat myeloma cell line) was observed compared to ones which did not acquire 
H2-Dd [504]. This functional consequence might be due to the cis or trans interactions 
between the ligand, H2-Dd, and its receptor, Ly49A. The HLA-G transfer, following its 
specific interaction with ILT2, affected NK cells (the acceptor cells) functions by reducing 
their proliferation capacities as well as their IL-2 response, abolishing their target killing 
functions, and transformed them into regulatory NK cells, capable of blocking other NK 
cells’ functions [517]. These consequences were abolished after HLA-G and/or ILT2 
blocking, confirming its specificity, as well as after the HLA-G donor cells’ removal, 
confirming its reversibility. Other ligands transfer had similar consequences on NK cells, 
like the MICA acquisition which led to NK cell degranulation [514], and the reduction of 
NKG2D-dependant cytotoxicity following MICB transfer [513]. 
ii. The transferred molecule is a Receptor 
In order to demonstrate functional consequences on the acceptor cell following 
trogocytosis, the transferred receptor has to retain its binding capacities, as well as its 
capability of transducing a signal in the acceptor cell, and lead to a measurable and 
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definable function. In this case of figure, the necessary molecules for the signal 
transduction have to be (i) provided by the acceptor cell, or (ii) transferred alongside the 
receptor molecule from the donor cell. In both cases, the transferred receptor has to be 
well encored in the acceptor cell membrane. Such transfers were observed in both 
directions; from target cells to NK cells, or NK cells to target cells. In a work by 
Vanherberghen et al., Ly49A, was shown to be acquired by the surrounding cells [512]. 
Not only IR, but also AR have been reported to be transferred, with their adaptor 
molecules, to target cells, like 2B4 in association with SAP [518], or NKG2D and its 
adaptor molecules, DAP10 [513]. To date, no functional consequence of a receptor 
transfer has been reported, which might be due to different reasons: (i) the transferred 
receptor did not correctly anchor the acceptor cell membrane, (ii) the receptor cell does 
not have the necessary molecules for the signal transduction, (iii) the resulting function 
was not strong enough to be measurable, and a last reason not to be neglected, (iv) the 
experiment was not set-up to study the receptor transfer, but more the ligand transfer. One 
exception for the (iv)th mentioned reason is the work by Rechavi et al., in 2007, which 
specifically studies the effect of H-Ras transfer from transfected B cells to surrounding 
cells. The authors highlight the enhanced proliferation, cytokine secretion, and ERK 
phosphorylation following the transfer [516]. 
 
As stated above, the importance of the trogocytosis phenomenon is that the transferred 
molecule and membrane patches may endow the acceptor cell with temporary functions of the 
donor cell. This phenomenon can provide a better explanation of some previous works, like the 
work by Elliott et al. in 2010 [429]. Once transferred to a MHC class I positive recipient, MHC 
class I negative (β2m KO) NK cells, may interact with the surrounding MHC class I molecules, 
their IR ligand, and acquire them by trogocytosis, thus becoming educated and functional. 
Trogocytosis in these experiments was not proven, as no MHC class I phenotype was performed 
on the transferred NK cells after their extraction from the recipient animal.  
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AIMS OF THIS STUDY 
NK cells, the third largest population of the circulating lymphocytes, are involved in early 
defence mechanisms against tumours and virally infected cells. Their functions are controlled by 
a balance between activating and inhibitory signals transmitted through their AR and IR 
respectively. NK cell functional competence is acquired through education by the interaction of 
their IR with cognate MHC class I molecules, but the role of the latter molecules in their specific 
receptor repertoire formation is still a debate, especially for human NK cells. Having in our 
possession PBMC derived from TAP-deficient patients, we aimed at studying the interaction 
between HLA class I molecules and their receptors, and its effect on NK cell phenotype and 
functions. 
 
 
Aim of article 1 
 
NK cell KIR Repertoire Acquisition and Maturation are Strongly Modulated by HLA Class I 
Molecules. 
 
In this paper we aimed at studying the influence of HLA class I molecules on their receptor 
repertoire formation and NK cell functions by: 
 
(i) investigating the co-expression pattern of HLA class I receptors (KIR2DL2/3/DS2, 
KIR2DL1/DS1, KIR3DL1, NKG2A and CD8) as well as the maturity marker CD57 in 
seven TAP-deficient patients and a panel of HD. 
(ii) studying the influence of HLA class I expression on NK cell functionality (cytotoxicity, 
degranulation as well as IFN-γ production) towards K562 cell line. 
 
Several studies investigated MHC class I molecules’ influence on their receptors’ 
expression in both human and mice. Murine studies, performed on WT as well as single MHC 
class I expressing and MHC class I deficient NK cells, demonstrated the existing of both MHC 
class I dependent and independent factors regulating NK cell repertoire formation. Human NK 
cell repertoire studies were more complicated and performed only on cells expressing HLA class 
I molecules. Taking advantage of our TAP-deficient PBMC stock, we were able to perform the 
first direct study of HLA class I presence/absence influence on their receptors’ expression on NK 
cells. 
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Aim of article 2 
 
HLA Class I Expression and Its Effect on NK Cell Maturation and Cytotoxicity Gene Profile. 
 
Based on the results published in our above mentioned paper, a parallel study was 
designed, aiming at: 
 
(i) comparing the maturation processes, from CD56bright to CD56dim, between HD and 
TAP-deficient patients by gene profiling. 
(ii) identifying the different pathways implicated in NK cell cytotoxicity which may be  
affected by the presence/absence of HLA class I molecules on NK cell surface. 
 
We previously demonstrated a strong influence of HLA class I molecules on their receptors 
expression as well as NK cells maturation and functionality. In this brief report, we aimed at 
studying by whole genome microarrays the effect of HLA class I molecules on the different 
pathways implicated in NK cell maturation from CD56bright to CD56dim as well as cytotoxicity 
following co-culture with K562 cells.   
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MATERIALS AND METHODS 
 
Solutions and cell culture media. 
FACS Buffer: PBS, 0.5% foetal calf serum (FCS). 
Complete DMEM: DMEM medium supplemented with 100U/mL penicillin, 100µg/mL 
streptomycin, 2mM glutamine, 100µM 2-β-mercaptoethanol, and 10% FCS. 
Complete RPMI: RPMI 1640 medium supplemented with 100U/mL penicillin, 100µg/mL 
streptomycin, 2mM glutamine, and 10% FCS. 
 
Cell lines. 
Human cell lines 
• K562 cells (human myelogenous leukemia line) as well as EBV-immortalised B cells were 
cultured in complete RPMI. 
Fibroblasts: HF-ME primary fibroblasts derived from patient ME (provided by Dr Dewton 
Vasconcelos, Laboratory of Medical Investigation, University of São Paulo School of 
Medicine, Brazil), STF1-169 immortalised fibroblast cell line established from a TAP-1 
deficient patient [72], and STF5-169 immortalised fibroblast cell line derived from a HD (both 
cell lines provided by Prof de la SALLE, University of Strasbourg, France), were all cultured 
in complete DMEM. 
Murine cell lines 
• YAC-1 cells, from a murine T-lymphoma established from a tumour induced by Moloney 
sarcoma virus in an A/Sn mouse, were cultured in complete DMEM. 
• EL4-Dd-GFP cells, an EL4 cell line transfected by a plasmid expressing the H2-Dd molecule 
coupled to GFP [504], were kindly provided by Dr. Petter Höglund, Centre for Hematology 
and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden. EL4-Dd-GFP cells 
were cultured in complete RPMI. 
 
Human subjects and blood samples. 
Peripheral venous blood was obtained from patients with a confirmed TAP-deficiency and from a 
panel of HD, from which PBMC were isolated by Ficoll Hypaque density gradient centrifugation. 
All individuals included in the project gave written informed consent according to the Declaration 
of Helsinki. The study was approved by the National Research Ethics Committee of Luxembourg 
(201109/05). 
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Animals. 
C57BL/6 (WT) were obtained from Harlan, Horst, The Netherlands, and TAP-1 KO (on the 
C57BL/6 background) from the Jackson Laboratories, USA. Mice were kept under specific 
pathogen-free conditions and used at the age of 8-10 weeks. All procedures respected current 
European regulations and were approved by the National Animal Research Authority. 
 
KIR and HLA class I genotyping. 
Genomic DNA was isolated either from fresh blood using a QIAamp DNA Blood Mini Kit (QIAGEN) 
or from EBV-transformed B-lymphoblastoid cells. Both genotypings were performed using PCR 
sequence–specific primers. For HLA-A, HLA-B, and HLA-C, commercial Micro SSPTM plates and 
kits (One Lambda, Canoga Park, CA) were used, according to the manufacturer’s instructions. 
 
Murine cell preparation. 
Spleens were extracted from 8 to 10 weeks old WT and TAP1-KO mice, and passed through a 
40µm sieve. Red blood cells were lysed with ACK lysing buffer (Gibco®), then splenocytes were 
passed through a Nylon wool column to enrich the cell suspension with NK cells. Nylon Wool 
Non-Adherent (NWNA) spleen cells were then used in the different experiments. 
 
Antibodies and flow cytometry. 
For phenotype studies, cells were stained with fluorochrome-conjugated monoclonal antibodies 
(mAb) according to the experiment set up, then measured on a FACSCanto I or a FACSAria 
SORP (both from BD Biosciences). At least 3.105 live cells were acquired per sample. Analyses 
were done with Kaluza® Analysis Software v1.2 (Beckman Coulter). Dead cells and doublets 
were excluded from the analyses. NK cells were identified as CD14- CD19- CD3- CD56dim in 
human samples, and CD3- NK1.1+ in murine samples, and then the percentage of positive cells 
for each studied marker was determined. Co-expression was calculated using the “Boolean” and 
the “Tree” functions. 
 
Functional assays (interferon-γ production and degranulation assay). 
NK cell response following (i) tumour cell encounter and (ii) cross-linking with antibodies, was 
studied. 
In murine NK cell studies, (i) NK cells were negatively purified from NWNA spleen cells using 
Miltenyi NK isolation kit according to the manufacturer’s instructions, then co-cultured with YAC-
1 cells for 6 hours at a ratio of 2:1 in 100µL of complete DMEM and 35U/mL of recombinant 
human interleukin-2 (rhIL-2) (R&D Systems, Abingdon, UK). Negative controls were performed 
  67   
 
with purified NK cells alone. (ii) For antibody cross-linking, flat bottom 96 well plates were coated 
with anti-NK1.1, anti-CD137 (negative control) or anti-IgG2a (isotype control) antibodies at a 
concentration of 10µg/mL. NWMA spleen cells from WT and TAP1-KO mice were incubated for 
6 hours at a concentration of 106 cells in 100µL of DMEM culture medium. 
In human NK cell studies, a total of 106 PBMC was co-cultured with K562 cells at a ratio of 7:1 in 
100µl complete RPMI with 1000U/mL rhIL-2 (R&D Systems, Abingdon, U.K.). Negative controls 
were performed with NK cells alone. 
In both studies, for degranulation measurement, the anti-CD107a mAb was added at the 
beginning of the experiment. After one hour of incubation, monensin and brefeldin A (GolgiStop 
and GolgiPlug, respectively, both from BD Biosciences) were added for a final concentration of 
2µM and 1µM respectively. After another 5 hours of incubation, NK cells were stained for surface 
antigens according to the experiment set up. For IFN-γ assay, cells were fixed and permeabilized 
using Cytofix/Cytoperm solution (BD Biosciences), and then stained with anti-IFN-γ mAb. In both 
cases, dead cell marker (DCM) was used to exclude dead cells. 
 
Cell sorting. 
Human PBMC were stained with the corresponding mAb, and were kept during all the steps in 
complete RPMI. In order to stain and exclude dead and apoptotic cells, Hoechst 33342 
(Invitrogen; 100 ng/mL) was added just before measurement to stain DNA of the permeable cells. 
Cell sorting was performed on a FACSAria SORP (BD Biosciences). NK cells were identified and 
selected as described in the § Antibodies and flow cytometry. 
 
Cytotoxicity assays. 
Prior to the cytotoxicity assays, 2.106 PBMC, derived from TAP-deficient patients or HD, were (i) 
directly used after de-freezing (fresh PBMC), (ii) incubated overnight with 200U/mL of rhIL-2 (R&D 
Systems, Abingdon, UK) (act-ON-PBMC), or (iii) after 5 days of activation with 200U/mL of  rhIL-
2 (act-5d-PBMC). Both NK cells and K562 cells were sorted prior to co-culture. K562 cells were 
stained using a CellTrace CFSE (Molecular Probes) according to the manufacturer’s instructions. 
Hoechst 33342 (Invitrogen; 100ng/mL) was added just before measurement. Live/CFSE+ K562 
cells were sorted and added to previously sorted CD56dim NK cells (c.f § Cell sorting) at different 
NK/K562 ratios and then centrifuged. The pellet was re-suspended in 100µl of complete RPMI in 
96-well V-bottom plates, which were briefly centrifuged before a 5h incubation at 37°C, 5% CO2. 
In parallel, live/CFSE+ K562 cells were incubated alone to calculate their spontaneous death. 
After the incubation, the dead cell marker TO-PRO-3 (Molecular Probes) was added at a final 
concentration of 1mM to identify the percentage of dead K562 cells. After flow cytometry 
measurement, the percentage of specific death was calculated as 
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specific death = [(death - spontaneous death)/(100 - spontaneous death)]x100. 
 
NK cell preparation for microarrays. 
For microarrays, in order to investigate the affected pathways following NK cell activation, CD56dim 
NK cells, derived from 2 TAP-deficient patients [95] and 4 HD were sorted and co-incubated with 
K562 cells according to the cytotoxicity assays protocol, but at a unique ratio of 5/1 (NK/K562). 
After 1h and 5h of incubation, Hoechst 33342 (Invitrogen, 100ng/mL) was added, and live CD56dim 
NK cells were sorted in Trizol LS (Life Technologies Inc.). In parallel, CD56dim and CD56bright NK 
cells, derived from the same sample, were directly sorted (without any prior incubation with or 
without K562 cells) in Trizol LS in order to study the pathways implicated in their maturation from 
CD56bright to CD56dim. 
 
RNA extraction. 
Total RNA was extracted from the sorted CD56bright and CD56dim NK cells (before and after 
activation) according to the standard Trizol chloroform protocol provided by the manufacturer, life 
technologies ®. 
 
Microarrays. 
Samples were prepared according to Affymetrix WT expression kit for Affymetrix Whole Transcript 
Expression Arrays (Life Technologies Inc.). RNA quality and quantity was ensured using the 
Bioanalyzer (Agilent, Inc) and NanoDrop (Thermo Scientific, Inc) respectively. Per RNA labeling, 
80 nanograms of total RNA were used in conjunction with the Affymetrix standard protocol for the 
Human GeneChip 1.0 ST chips (Affymetrix Inc.). 
 
Uptake assays. 
NWNA spleen cells and EL4-Dd-GFP cells, with a maximum of 106 cells of each, were incubated 
at a ratio of 1/1 in 1 mL of complete DMEM for 30 min, 1 hour, 2 hours or 4 hours, at 37°C, 5% 
CO2, or at room temperature. For blocking assays, EL4-Dd-GFP cells were incubated with a 
purified anti H2-Dd antibody during 30 min prior to the uptake assays. Cells were later on stained 
with the corresponding antibodies for flow cytometry analyses. 
 
Statistical analysis. 
Data are represented as mean of the different groups ± SD. Statistical significance of the 
difference in markers’ expression frequencies between two different NK cell groups was 
determined by 2-tailed t-test. ANOVA and a post hoc Tukey test were used to evaluate whether 
KIR molecules are expressed differently in HD and TAP-deficient patients for each combination 
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of two or three of the following markers: CD8, CD57, and NKG2A. In figures, (****p<1.106, ***p<0 
.001, **p<0 .01, *p<0.05 and #p<0.1). Graphs and statistical significance were performed using 
GraphPad Prism or R version 2.15.2.  
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ARTICLES 
Article 1 
NK cell KIR Repertoire Acquisition and Maturation are Strongly Modulated by HLA Class I 
Molecules 
Sleiman M, Brons N.H.C, Kaoma T, Dogu F, Villa-Forte A, Lenoble P, Hentges F, Kotsch K, 
Gadola S.D, Vilches C. and Zimmer J. 
The Journal of Immunology. 2014 Mar 15;192(6):2602-10 
 
Preface related to article 1 
 
Since the discovery of the different NK cell IR by A. and L. Moretta [415-419], NK cell IR 
repertoire acquisition became a subject of extensive study. Different models were developed and 
proposed, but the role of MHC class I molecules in their receptors’ acquisition was not clearly 
established and is still an open debate, especially in human NK cells. While some studies found 
no effect of HLA class I molecules on KIR repertoire formation [481], others demonstrated, on a 
HLA-C repertoire, a bias toward the expression of self-specific KIR molecules on NK cell surface 
[482]. Both studies were undertaken on NK cells derived from HLA class I positive environments, 
making the direct effect of HLA class I molecules on their receptors’ acquisition difficult to study. 
TAP deficiency is a rare disease, with no more than 30 cases described till today [92, 105]. 
These patients present a defect in HLA class I molecules’ surface expression due to a mutation 
in the TAP-1 or TAP-2 gene. Our laboratory has the chance to conserve the biggest stock of 
PBMC derived from these patients, giving us the possibility to study, for the first time, the direct 
effect of HLA class I molecules on their receptors’ acquisition on NK cells. PBMC were provided 
by Dr. Figen Dogu (Pediatric Allergy and Immunology Department, University Faculty of Medicine, 
University of Ankara, Ankara, Turkey), Dr. Alexandra Villa-Forte (Center for Vasculitis Care and 
Research, Rheumatologic and Immunologic Disease Department, Cleveland Clinic, Cleveland, 
OH, USA), Dr. Patrick Lenoble (Departement d’Ophtalmologie, Hopitaux de Mulhouse, France) 
and Prof. Stephan D. Gadola (Novartis, Basel, Switzerland). A multi-colour flow cytometry panel 
consisting of five different HLA class I receptors (CD8, NKG2A, KIR2DL1/DS1, KIR2DL2/3/DS2, 
and KIR3DL1), a maturity marker (CD57), two functionality markers (IFN-γ, CD107a), as well as 
the necessary ones to identify NK cells (CD14, CD19, CD3, CD56, CD16 and DCM), was 
designed with the help of Nicolaas H.C. Brons (Core Facility Flow Cytometry, Public Research 
Center for Health, Luxembourg). PBMC derived from seven TAP-deficient patients and a panel 
of healthy donors (HD) were phenotyped and the co-expression frequencies of the different HLA 
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class I receptors were compared. Statistical analyses were performed by Tony Kaoma (Genomics 
Research Unit, Public Research Center for Health, Luxembourg) HLA class I and KIR genotype 
were performed by Dr. Carlos Vilches (Laboratory of Immunogenetics-HLA, University Hospital 
Puerta de Hierro, Majadahonda, Madrid, Spain), Prof. Katja Kotsch (Surgery Department, Medical 
University Innsbruck, University of Innsbruck, Austria) and Dr. Francois Hentges (Laboratory of 
Immunogenetics and Allergology, Public Research Center for Health, Luxembourg). 
In six of the seven TAP-deficient patients, in comparison to the HD, an increase of KIR 
expression was observed on the CD8+ NKG2A+ NK cell subpopulation, but not on the CD8- 
NKG2A+ subset. This increase suggests a possible novel role of CD8 in NKG2A and KIR 
repertoire acquisition. NK cell maturation was also investigated by combining the analysis of the 
expression of CD57, NKG2A and KIR molecules. TAP-deficient NK cells showed a significant 
accumulation of the NKG2A+ KIR+ NK cells only in the CD57- subset indicating a blockage in the 
NK cell maturation (reduced frequency of CD57+ NK cells). These results demonstrate that in a 
TAP-deficiency, or HLA class I defective surface expression context, HLA class I receptors’ 
acquisition is disturbed by the absence of their ligands. NK cells tend to up-regulate the co-
expression of CD8, NKG2A and KIR molecules, and stop the acquisition of CD57 demonstrating 
a strong influence of HLA class I molecules on their receptors’ repertoire formation as well as NK 
cell maturation. 
Functionally, TAP-deficient NK cell hyporesponsiveness was confirmed, except for one 
patient (patient number 5) whose NK cells exhibited cytotoxic activity toward K562 cells, secreted 
IFN-γ and/or degranulated. No difference in the cytotoxic molecules’ (perforin, granzyme B and 
granulysin), nor HLA-E expression was detected between this patient and the six others. An 
investigation of the HLA class I receptors’ expression on functional NK cells derived from HD 
compared to the TAP-deficient functional outlier revealed differences in their distribution patterns. 
Regardless of the presence or absence of NKG2A and CD57 in TAP-deficient patient 5, NK cells 
that do not express KIR molecules are more functional than ones expressing a single KIR 
molecule. 
  
The Journal of Immunology
NK Cell Killer Ig-like Receptor Repertoire Acquisition and
Maturation Are Strongly Modulated by HLA Class I
Molecules
Marwan Sleiman,*,† Nicolaas H. C. Brons,‡ Tony Kaoma,x Figen Dogu,{
Alexandra Villa-Forte,‖ Patrick Lenoble,# Franc¸ois Hentges,* Katja Kotsch,**
Stephan D. Gadola,†† Carlos Vilches,‡‡ and Jacques Zimmer*
The interaction between clonally distributed inhibitory receptors and their activating counterparts on NK cells and HLA class I
molecules defines NK cell functions, but the role of HLA class I ligands in the acquisition of their receptors during NK devel-
opment is still unclear. Although some studies demonstrated that HLA-C affects the expression of killer Ig-like receptors (KIR),
other studies showed that NK cells acquire their KIR repertoire in a stochastic manner. Only when infected with human CMV is
an expansion of self-specific KIR+ NKG2C+ NK cells detected. To gain more insight into this question, we compared the coex-
pression of different KIR molecules, NKG2A, CD8, and CD57, on NK cells in healthy donors and seven patients with deficient
HLA class I expression due to mutations in one of the TAP genes. Our results show a correlation between the presence/absence of
HLA class I molecules and the coexpression of their receptors. In an HLA class I low-expression context, an increase in KIR
molecules’ coexpression is detected on the NKG2A+ CD8+ subset. In functional assays, hyporesponsiveness was observed for TAP-
deficient NK cells derived from four patients. In contrast, NK cells from patient five were functional, whereas CD107a+ and IFN-g+
CD56dim NK cells presented a different pattern of HLA class I receptors compared with healthy donors. Taken together, our results
provide strong evidence for the role of HLA class I molecules in NK cell maturation and KIR repertoire acquisition. The Journal
of Immunology, 2014, 192: 2602–2610.
N
atural killer cell functions are governed by a balance
between activating and inhibitory signals transmitted
through a large panel of activating receptors and inhib-
itory receptors (IR), respectively. Killer Ig-like receptors (KIR)
bind selectively to some of the HLA-A, HLA-B, andHLA-C alleles.
Furthermore, CD94/NKG2A heterodimers are specific for HLA-E,
which presents peptides derived from the leader sequences of
classical HLA class I molecules (1–3). These IR deliver inhibitory
messages when mature NK cells meet normal autologous targets,
but they also promote normal NK cell education. Only NK cells
expressing at least one IR specific for self-HLA class I molecules
become fully functional in this NK cell–licensing process. In
contrast, in the absence of a self-HLA class I–specific IR, NK cells
remain in a state of hyporesponsiveness. This mechanism allows
the generation of a NK cell repertoire tuned to the optimal de-
tection of “missing-self” (downregulation or absence of autolo-
gous HLA class I molecules) while avoiding autoreactivity (4–6).
A particular scenario for NK cell education exists in patients
with genetic defects in the subunit 1 or 2 of the TAP gene. In these
patients, the surface expression of HLA class I molecules is sig-
nificantly reduced (1–10% of normal levels) (7, 8). NK cells from
these patients were shown to be hyporesponsive ex vivo (low or
absent cytotoxicity against K562 cells) (9–11). Such data support
the above-mentioned models of NK cell education, in which
NK cells remain “unlicensed” as a result of the strongly reduced
interactions between the NK cells expressing IR and a severely
HLA class I–defective environment.
An unanswered question is how NK cells acquire their clonally
distributed repertoire of HLA class I binding molecules and, in
particular, their KIR repertoire, because this is a distinctive phe-
nomenon from NK cell education. An effect of HLA-C on the KIR
repertoire was demonstrated by some investigators (12, 13), whereas
others found the acquisition of KIR molecules to be stochastic (14,
15) except after human CMV infection, which leads to the ex-
pansion of self-specific KIR+ NKG2C+ NK cells (16).
In this study, we dissected the NK cell repertoire in seven TAP-
deficient patients (17–20) and a panel of healthy donors (HD) by
carrying out a detailed analysis of HLA class I receptors (CD8,
NKG2A, KIR2DL1/DS1, KIR2DL2/3/DS2, KIR3DL1) and CD57
expression and coexpression using 14-color flow cytometry. Our
results show an inverse correlation between the presence of HLA
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class I molecules and the coexpression of its receptors, providing
new evidence in favor of a strong role for HLA class I molecules
in NK cell KIR repertoire acquisition.
Materials and Methods
Human subjects and blood samples
Peripheral venous blood was obtained from seven patients with a confirmed
TAP deficiency and from 18 HD (8 males, 10 females; age 25–60 y; mean
age [6 SD]; 36 6 8 y). PBMC were isolated by Ficoll-Paque density
gradient centrifugation. All individuals included in the project gave written
informed consent according to the Declaration of Helsinki. The study was
approved by the National Research Ethics Committee of Luxembourg
(201109/05).
KIR and HLA class I genotyping
Genomic DNAwas isolated either from fresh blood using a QIAamp DNA
Blood Mini Kit (QIAGEN) or from EBV-transformed B-lymphoblastoid
cells. Both genotypings were performed using PCR sequence–specific pri-
mers. For HLA-A, HLA-B, and HLA-C, commercial Micro SSPTM plates
and kits (One Lambda, Canoga Park, CA) were used, according to the
manufacturer’s instructions.
Abs and flow cytometry
For phenotype studies, PBMC were stained for 9- or 14-color flow cy-
tometry with fluorochrome-conjugated mAb (Table I). Stained cells were
measured on a FACSAria SORP (BD Biosciences). At least 3 3 105 live
cells were acquired per sample. Analyses were done with Kaluza Analysis
Software v1.2 (Beckman Coulter). Dead cells and doublets were excluded
from the analyses. NK cells were subsequently identified as CD142 CD192
CD32 CD56dim, and the percentage of positive cells for each studied
marker was determined. Coexpression was calculated using the “Boolean”
and the “Tree” functions (Fig. 1).
Cell sorting
PBMC were stained for five-color flow cytometry sorting with the
corresponding mAb (Table I). During all steps, cells were kept in cell
culture medium (RPMI 1640 supplemented with 10% heat-inactivated
FBS, 10 mM HEPES, 1 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin). Hoechst 33342 (Invitrogen; 100 ng/ml) was
added just before measurement to stain DNA of the permeable cells (dead
or late apoptotic). NK cells were identified and selected as described above.
Cytotoxicity assays
For cytotoxicity assays, both NK cells and K562 cells were sorted prior to
coincubation. K562 cells were stained using a CellTrace CFSE (Molecular
Probes); 106 K562 cells were incubated in 1 ml PBS/0.1% BSA with CFSE
(5 mM) for 15 min at 37˚C, 5% CO2. The excess CFSE was quenched by
addition of five volumes of ice-cold culture medium to the cells and incubated
for 5 min on ice and then cells were washed and resuspended in fresh medium.
Hoechst 33342 (Invitrogen; 100 ng/ml) was added just before measurement.
Live/CFSE+ K562 cells were sorted and added to previously sorted CD56dim
NK cells (see Cell sorting section above) at different NK/K562 ratios (1:1,
5:1, and 10:1) and then centrifuged. The pellet was resuspended in 100 ml fresh
medium in 96-well V-bottom plates, which were briefly centrifuged before
a 5-h incubation at 37˚C, 5% CO2. In parallel, live/CFSE
+ K562 cells were
incubated alone to calculate their spontaneous death. After the incubation,
TO-PRO-3 (Molecular Probes) was added at a final concentration of 1 mM to
identify the percentage of dead K562 cells. After flow cytometry measurement,
the percentage of specific death was calculated as specific death = [(death 2
spontaneous death)/(100 2 spontaneous death)] 3 100.
Functional assays (IFN-g production and degranulation assay)
A total of 106 PBMC was cocultured with K562 cells at a ratio of 7:1
in 100 ml cell culture medium with 1000 U/ml rIL-2 (R&D Systems,
Abingdon, U.K.). Negative controls were performed with NK cells alone.
For degranulation measurement, the anti-CD107a mAb was added. After
1 h of incubation, monensin and brefeldin A (GolgiStop and GolgiPlug,
respectively; both from BD Biosciences) were added. After another 5 h of
incubation, cells were stained with the corresponding mAb (Table I). For
IFN-g assay, cells were fixed and permeabilized using Cytofix/Cytoperm
solution (BD Biosciences) and then stained with anti–IFN-g mAb.
Statistical analysis
A two-tailed t test was used to assess the difference in the expression of
markers by NK cells from HD and TAP-deficient patients. ANOVA and
a post hoc Tukey test were used to evaluate whether KIR molecules are
expressed differently in HD and TAP-deficient patients for each combi-
nation of two or all three of the following markers: CD8, CD57, and
NKG2A. Graphs were constructed and statistical tests were performed
using R version 2.15.2.
Results
Clinically, TAP-deficient individuals, including patients 1–4, 6,
and 7 of our cohort (17–19), present a characteristic association of
chronic inflammation, infection of the airways, and debilitating
Table I. Ab conjugates used for the different NK cell studies (phenotyping, sorting, or functional tests)
Usage
Supplier Clone Ag Conjugated Fluorochrome LaserSorting Functional Phenotyping
X Invitrogen Dead cell marker Hoechst 33342 UV
X X Invitrogen Dead cell marker Blue fluorescent dye UV
X X eBioscience 61D3 CD14 Qdot 605 UV
X BioLegend H4A3 CD107a BV-421 Violet
X BioLegend HCD56 CD56 BV-421 Violet
X X BioLegend HCD56 CD56 BV-510 Violet
X X BioLegend OKT-3 CD3 BV-510 Violet
X X BioLegend UCHT1 CD3 BV-570 Violet
X X BioLegend RPA-T8 CD8 BV-605 Violet
X X BioLegend HCD57 CD57 FITC Blue
X X BioLegend H1B19 CD19 Alexa Fluor 488 Blue
X X eBioscience HP-MA4 KIR2DL1/DS1 PerCP-Cy5.5 Blue
X BioLegend W6/32 HLA-A/B/C PerCP-Cy5.5 Blue
X BioLegend dG9 Perforin PerCP-Cy5.5 Blue
X BioLegend 4S.B3 IFN-g PE Yellow-green
X BioLegend DH2 Granulysin PE Yellow-green
X BioLegend 3D12 HLA-E PE Yellow-green
X X ImmunoTools LT19 CD19 PE-DY647 Yellow-green
X X Beckman Coulter Z199 NKG2A PE-Cy7 Yellow-green
X BioLegend HCD56 CD56 PE-Cy7 Yellow-green
X X Beckman Coulter GL183 KIR2DL2/3/DS2 Allophycocyanin Red
X Invitrogen FGB12 Granzyme B Allophycocyanin Red
X ImmunoTools MEM-15 CD14 Allophycocyanin Red
X X BioLegend DX9 KIR3DL1 Alexa Fluor 700 Red
X X BioLegend 3G8 CD16 Allophycocyanin-Cy7 Red
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skin ulcers. Patient 5 (20) presented the same clinical features but,
more recently, an increase in the severity of the lung infections
and skin ulcers was observed. This was accompanied by facial
lesions, eventually leading to complete destruction of the nasal
cartilage. Because of the patient’s severe illness, the planned bone
marrow transplantation could not be performed. She then developed
a generalized vasculitis with cerebral involvement and seizures. After
a few months in an intensive care unit, unfortunately the patient died.
With regard to NK cell investigations, we previously described
two TAP-deficient patients who expressed KIR and NKG2A at fre-
quencies comparable to HD (9). However, the expression level of
NKG2A on individual NK cells was much higher in the patients (9).
In the current study, we aimed at examining the HLA class I re-
ceptor repertoires in seven TAP-deficient patients and a panel of HD
using 14-color flow cytometry according to the Ab panel in Table I.
NK cells were selected among single/live cells, followed by
gating on CD142CD192CD32 cells and then on the CD56dim popu-
lation (Fig. 1A). These NK cells were examined for expression
of different KIR (KIR2DL1/DS1, KIR2DL2/3/DS2, KIR3DL1),
NKG2A, CD8, and CD57 (Fig. 1B–E), which are present on
donor-dependent subgroups of NK cells (Fig. 2A). Because
only very limited numbers of CD56bright NK cells express KIR (1),
this subset was not considered further in the present work. In the
phenotypic studies, patient 7 was considered an outlier compared
with the others, because his NK cell subsets were similar to the
HD ones.
TAP-deficient CD56dim NK cells exhibit an increase in their
KIR molecules’ coexpression, especially on the NKG2A+
subset
The percentages of NK cells expressing the studied markers varied
between TAP-deficient patients and HD (Fig. 2A), with the ex-
ception of NK cells expressing 0, 1, or 3 KIR, which were not
different between the two groups (only two patients had a higher
frequency of NK cells expressing three KIR). In this patient co-
hort, the most striking difference compared with HD was the very
high percentage of NKG2A+ cells. Conversely, we found a slightly
lower frequency of KIR2 and CD57+ NK cells in the patients. The
percentage of CD8+ NK cells also was significantly increased in
the TAP-deficient individuals.
When analyzing NKG2A2 and NKG2A+ NK cell subsets, we
observed marked differences in KIR expression between TAP-
deficient patients and HD (Fig. 2B). TAP-deficient NKG2A2
and NKG2A+ NK cells exhibited strong variations in their KIR
coexpression distribution pattern, with a much higher percentage
of KIR coexpression on NKG2A+ NK cells compared with
NKG2A2 NK cells. In contrast, the distribution pattern of KIR
coexpression was very similar in NKG2A+/2 subsets in HD, with
a higher percentage of KIR+ NK cells on the NKG2A2 subset.
The comparison of KIR-expressing cells among CD82 and
CD8+ NK cells showed a nonrandom distribution in the patients
(Fig. 2C). Indeed, KIR+ NK cells were more frequent in the
FIGURE 1. Gating strategy used
to study CD57, CD8, NKG2A, and
KIR coexpression on CD56dim NK
cells. (A–C) Results of the pheno-
typing of a representative TAP-de-
ficient patient. The same gating
strategy was used for phenotyping
the six other patients, as well as the
HD. For coexpression of the differ-
ent marker, the “Boolean” and “Tree”
functions were applied to the gating
of (B) and (C). (C) The different KIR
expressions in one of the “Boolean”
combinations of (B): CD572 CD8+
NKG2A+. Four representative dot
plots showing the coexpression of
NKG2A and CD8 on CD56dim NK
cells, as well as KIR2DL2/3/DS2
and KIR2DL1/DS1 on CD572 CD8+
NKG2A+ NK cells derived from one
HD (D) and one TAP-deficient pa-
tient (E).
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CD8+ subset than in the CD82 subset, which was not the case for
the HD.
Next, we studied the influence of the maturation marker CD57
on the distribution of KIR molecules (Fig. 2D). As expected, and
as previously described (21, 22), the majority of HD KIR2 cells
was contained in the CD572 population, whereas the KIR+ NK
cells were better represented among the CD57+ subset. Re-
garding the TAP-deficient NK cells, they followed the pattern of
HD cells in the CD572 population. However, among the CD57+
NK subset, the frequency of cells expressing one KIR was sig-
nificantly lower than in HD.
HLA class I molecules strongly influence their receptors’
acquisition and NK cell maturation
We compared the different combinations of these markers to ex-
plore the coinfluence of CD8 and NKG2A on KIR repertoire
shaping in a HLA class I low-expression environment (Fig. 3A).
The greatest difference in the percentages of KIR+ NK cells be-
FIGURE 2. The expression of KIR molecules
is influenced by the presence of NKG2A when
comparing CD56dim NK cells from HD and TAP-
deficient patients. Box plots represent the fre-
quency of CD56dim NK cells expressing (A) or
coexpressing (B–D) the studied markers in HD
(n = 9 when CD57 is implicated; n = 18 when
CD57 is not implicated) and six TAP-deficient
patients. Circles represent TAP-deficient pa-
tient 7, who was considered an outlier. (A) By
comparing NK cells from HD and TAP-deficient
patients, significant differences are observed in
the expression of CD8, NKG2A, and two KIR.
When dissecting NK cells considering NKG2A
(B), CD8 (C), or CD57 (D) expression, it appears
that the presence of NKG2A and CD57 (indi-
vidually) on HD NK cells has no effect on KIR
distribution (horizontal dashed line). In TAP-
deficient patients, KIR distribution is strongly
affected by NKG2A [(B) horizontal gray line] but
much less by CD57 [(D) horizontal gray line].
****p , 1 3 1026, ***p , 0.001, **p , 0.01,
*p , 0.05, #p , 0.1.
FIGURE 3. HLA class I molecules strongly influence their receptors’ acquisition and NK cell maturation. Box plots represent the frequency of CD56dim
NK cells coexpressing the studied markers in HD (n = 9 when CD57 is implicated; n = 18 when CD57 is not implicated) and six TAP-deficient patients.
Circles represent TAP-deficient patient 7, who was considered an outlier. (A) With regard to the effect of the coexpression of CD8 and NKG2A, no
significant differences were observed between HD and TAP-deficient patients for the single-positive cells (CD82 NKG2A+ or CD8+ NKG2A2). The
presence or absence of both markers together seems to affect the expression of KIR molecules on NK cells in an HLA class I low expression context. (B)
With regard to the effect of CD57 and NKG2A on KIR distribution on CD56dim NK cells, significant differences were only observed for the single-positive
cells for these two markers (CD572 NKG2A+ and CD57+ NKG2A2). ****p , 1 3 1026, ***p , 0.001, **p , 0.01, *p , 0.05, #p , 0.1.
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tween the two donor groups was found in the CD8+ NKG2A+ and
CD82 NKG2A2 fractions compared with the single-positive
subsets (CD82 NKG2A+ and CD8+ NKG2A2). The major differ-
ence between KIR-expressing NKG2A+ NK cells in the patients
compared with HD was confirmed only in the CD8+ NKG2A+ subset
and not among the CD82 NKG2A+ cells, which is consistent with
a synergistic influence of both CD8 and NKG2A on the KIR reper-
toire of the patients.
When combining the two markers CD57 and NKG2A (Fig. 3B),
it appeared that more KIR+ NK cells are present in the CD572
NKG2A+ subset from the patients than the HD. The CD572
NKG2A2 population showed the lowest amount of KIR+ CD56dim
NK cells. Likewise, KIR2 NK cells represented the majority in the
CD572 NKG2A+ subtype. When focusing on CD57+ NK cells, we
observed that there were more KIR+ cells within the NKG2A2
population of the HD, whereas this was not true for the patients’
NK cells. KIR+ cells were relatively rare in the CD57+ NKG2A+
subset in both HD and patients. Nevertheless, the HD had more
KIR2 cells than the patients, with the inverse observed for
NKG2A+ cells expressing two KIR.
To complete the phenotypic studies, we looked at the triple
combination of CD57, CD8, and NKG2A (Supplemental Fig. 1).
NK cells from TAP-deficient patients and HD showed some dif-
ferences, in particular among the NKG2A+ cells, as well as in
the CD572 CD82 NKG2A2 population. A higher percentage of
CD572 CD81 NKG2A1 KIR1 NK cells was observed in patients
compared with HD, indicating a block of CD57 acquisition, but
not for KIR molecules, in the patients.
TAP-deficient CD56dim NK cells exhibit hyporesponsiveness
against K562 cells but express cytotoxic molecules and HLA-E
In our first study of TAP-deficient NK cells, we demonstrated that
they have, in the absence of IL-2–mediated activation, no natural
cytotoxic activity against the target cell line K562 or against HLA
class I–deficient EBV-transformed B cell lines (no missing self
recognition) (9). This result was confirmed in cytotoxicity assays
using nonactivated, but purified, NK cells from four of the seven
patients as effectors and K562 cells as targets (Fig. 4A). Indeed,
NK cells from three patients (patients 1, 2, and 3) were not cy-
totoxic. Interestingly however, NK cells from one patient (patient
5) killed K562 cells to a significant degree, although not to the
same extent as HD NK cells, suggesting that NK cells from this
patient were able to overcome the missing education due to the
lack of HLA class I molecules.
The lack of cytotoxic activity in NK cells from patients 1–3
was paralleled by the absence of a significant degranulation in
the presence of K562, measured in terms of the percentages of
CD107a+ NK cells, which were extremely low in patients 1–4. As
expected, NK cells from patient 5 degranulated upon stimulation,
albeit less strongly than did NK cells from most HD. A similar
hyporesponsiveness was shown for IFN-g production by NK cells
from the patients, again with the exception of patient 5 (Fig. 4B).
KIR and HLA genotyping were performed on PBMC from the
seven patients (Supplemental Table I), hoping to find a unique or
different genotype for the functional outlier, patient 5. KIR ge-
notypes were identified according to Pyo et al. (23). The three
possible KIR haplotype compositions were found among the seven
patients (homozygous haplotype A for patient 2; heterozygous
haplotypes AB for patients 1, 6, and 7; and homozygous haplotype
B for patients 3, 4; and 5, Supplemental Table II). Among the
three patients exhibiting haplotype B, characterized by the ex-
pression of activating KIR, only patient 5 had functional CD56dim
NK cells. Unfortunately, such results do not explain the functional
differences in NK cells from patient 5.
One explanation for the hyporesponsiveness of TAP-deficient
NK cells could be the absence of the cytotoxic molecules con-
tained in the granules normally released upon sensitive target cell
encounter, although this would not explain the absence of IFN-g
production. Therefore, we analyzed the presence of granulysin,
granzyme B, and perforin in normal and TAP-deficient NK cells
(Fig. 4C). Although perforin was present in all NK cells from both
cohorts, we found a slightly reduced percentage of TAP-deficient
NK cells expressing granzyme B compared with HD. A more
striking difference was observed for granulysin, which was present
in only ∼30–50% of patients’ NK cells compared with 70–90% in
most HD. Nevertheless, the three molecules are clearly present in
TAP-deficient NK cells, so that the missing cytotoxic activity of
these cells is probably not due to a lack of such factors.
The fact that most of the NK cells from the patients are NKG2A+
prompted us to check for expression of HLA-E (Fig. 5A). We
hypothesized that patient 5 might exhibit stronger expression of
HLA-E, which would interact with NKG2A and lead to a potential
education of her NK cells. The phenotyping showed that all seven
patients expressed HLA-E on their NK cells, which was reduced
FIGURE 4. TAP-deficient CD56dim NK cells exhibit hyporesponsive-
ness toward K562 cells, although they express cytotoxic molecules. (A)
The gray line represents HD, the dashed lines represent TAP-deficient
patients 1, 2, and 3; and the bold line represents TAP-deficient patient 5. (B
and C) Box plots showing the frequency of CD56dim NK cells derived from
seven HD and six TAP-deficient patients. Outliers do not represent the
same patient in (B) and (C): patient 5 is the outlier in (B) (solid dots), and
patient 7 is the outlier in (C) (open dots). (A) Cytotoxicity assays were
performed with purified CD56dim NK cells and K562 target cells incubated
together for 5 h. NK cells show hyporesponsiveness for patients 1, 2, and 3
in contrast to patient 5, who presents cytotoxic CD56dim NK cells. (B) To
confirm these results, PBMC from seven HD and five TAP-deficient patients
(patients 1, 2, 3, 4, and 5) were incubated with K562 cells (ratio 7:1) and
1000 U/ml of IL-2 for 6 h. The percentage of CD56dim NK cells expressing
CD107a or IFN-g was determined, showing hyporesponsiveness for the
studied patients with the exception of patient 5, represented as an outlier. (C)
The percentage of CD56dim NK cells expressing granulysin, granzyme B, or
perforin was determined. TAP-deficient NK cells showed no major differ-
ence compared with normal NK cells except for granulysin (circles represent
patient 7, considered an outlier). ***p , 0.001, **p , 0.01, #p , 0.1.
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30–50% compared with HD (50% for patient 5). In contrast, as
expected and as previously shown (7–11), expression of the
classical HLA class I molecules (HLA-A, HLA-B, and HLA-C)
was decreased significantly in all patients (Fig. 5B), between 95
and 99% reduction compared with HD (96% for patient 5).
Different patterns for functional CD56dim NK cells with regard
to their HLA class I receptors in HD and TAP-deficient patient 5
We then investigated which subpopulations of NK cells from HD
preferentially degranulated and/or produced IFN-g. With regard to
the patients, this analysis only made sense for patient 5 (repre-
sented as an outlier in the box plots in Fig. 6). First, we observed
that most of the degranulating TAP-deficient NK cells were
NKG2A+ and CD8+, whereas only ∼20% of the degranulating
cells were CD57+ (Fig. 6A). With regard to IFN-g–producing NK
cells (Fig. 5B), patient 5 presented the same pattern as HD, with
the exception of CD8: 70% of IFN-g+ CD56dim NK cells were
positive for this marker.
Next, we analyzed the functionality, with respect to KIR ex-
pression, of NKG2A+ NK cells compared with NKG2A2 NK cells
(Fig. 6C, 6D). A significant percentage of HD KIR+ NK cells were
reactive to stimulation, regardless of the presence or absence of
NKG2A, but KIR2 NK cells from the NKG2A+ subpopulation
were best represented among the functional cells. Only very few
NKG2A2 KIR+ NK cells from patient 5 could respond to K562,
whereas most of the functional cells were NKG2A+. Interestingly,
20% of the IFN-g+ NK cells from the patient were NKG2A2
KIR2, and this percentage was twice as high as in the HD.
With respect to CD8 (Fig. 6E, 6F), the overall pattern was that,
in CD82 cells, a higher number of KIR2 NK cells were functional
compared with KIR+ cells, and this phenomenon was even more
pronounced in the patient. When CD8 was expressed, NK cells
without a KIR or with only one KIR were the most responsive to
stimulation, with a slightly higher fraction of TAP-deficient cells
compared with the cohort of HD. With regard to KIR2 NK cells
from the patient, the percentage of functional cells was in the same
range in the presence or absence of CD8.
Cells expressing one KIR were the most functional among the
CD57+ population, whereas the KIR2 NK cells were predomi-
nantly reactive among the less mature CD572 subset (Fig. 6G,
6H). There were more CD572 KIR2 cells among the functional
NK cell subset from patient 5 than all other populations, including
CD571 cells.
The investigation of CD8 and NKG2A together (Fig. 7A, 7B)
added little to the overall picture, but it confirmed that NKG2A2
cells from patient 5 were not functional and that, in the CD8+
NKG2A+ population, a higher percentage of patient 5’s NK cells
were reactive compared with normal NK cells, with KIR absent or
present.
When analyzing CD57 and NKG2A together, we found the
same pattern among the CD572 NKG2A+ NK cells but not the
CD57+ NKG2A+ NK cells (Fig. 7C, 7D). No major differences
between normal and TAP-deficient NK cells were noticed when
three markers (CD57, CD8, NKG2A) were compared, with the
exception that, again, a higher percentage of functional cells
among the CD572 CD8+ NKG2A+ subpopulation was found in
patient 5 compared with HD (Supplemental Fig. 2).
An overall conclusion is that, for TAP-deficient patient 5, func-
tional NK cells are more represented among the CD572 CD8+
NKG2A+ KIR2 CD56dim subpopulation.
Discussion
We show in this study of a cohort of seven TAP-deficient patients
that the NK cell phenotype regarding KIR and NKG2A expression
is significantly different in six of the seven patients compared with
a panel of HD. Our results clearly identify that HLA class I
FIGURE 5. HLA-E and HLA-A, HLA-B,
and HLA-C expression on HD and TAP-defi-
cient CD56dim NK cells. HLA-E (A) and HLA-
A, HLA-B, and HLA-C (B) expression on
CD56dim NK cells for three HD and seven TAP-
deficient patients. The same expression was
observed for CD3+, CD19+, and CD14+ cells.
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molecules exert a strong effect on their receptors’ (CD8, NKG2A,
and KIR molecules) acquisition on NK cells. From a functional
point of view, four of the five patients had hyporesponsive NK
cells, whereas NK cells from the fifth patient were cytotoxic to-
ward K562 and produced IFN-g, although slightly less than the
majority of HD. No major defect in TAP-deficient NK cells’ cy-
totoxic molecules (granzyme B and perforin) was found, in con-
trast to a reduced expression of granulysin.
The fact that TAP-deficient NK cells are hyporesponsive was
reported by us and other investigators in both human and mouse
(7–11, 24). In particular, natural cytotoxic activity ex vivo was
completely absent in the first two patients that we described (not
included in this study) (9). According to the current models of
NK cell education, only those NK cells that express at least one
IR specific for self-HLA class I molecules become functional,
whereas cells lacking such receptor(s) will not become licensed
for cytotoxicity and cytokine production (4, 5). Following this
model, NK cells from patients with TAP deficiency, in whom HLA
class I expression is greatly reduced, are expected to remain
hyporesponsive.
An exception to this rule is the nonclassical class I molecule
HLA-E, which was reported to be subnormally expressed by TAP-
deficient hematopoietic cells (25), although this was not confirmed
in another patient (26). Because NK cells from one of our patients
were functional, we checked for the presence of HLA-E at the cell
surface and expected a higher level of this molecule on the NK
cells (as representatives of lymphocytes) from patient 5. This
hypothesis was based on the possibility that NK cells from this
patient could have been educated through the interaction of
NKG2A with its ligand HLA-E. However, HLA-E was present on
the NK cells and other hematopoietic cells from the seven
patients, although at reduced levels compared with HD (30–50%
reduction compared with HD). Thus, if NKG2A had educated NK
cells from patient 5, it would not have done so in the other
FIGURE 6. KIR molecules and NKG2A, CD8, and CD57 expression and coexpression differ in functional CD56dim NK cells between HD and TAP-
deficient patients. Box plots represent the frequency of different markers on CD107a+ and IFN-g+ CD56dim NK cells derived from seven HD. The outlier
represents patient 5 (encircled black dots), who has functional CD56dim NK cells. When comparing NK cells from HD and TAP-deficient patient 5,
differences are observed in the expression of CD8, CD57, and NKG2A on CD107a+ cells (A) but only in the expression of CD8 on IFN-g+ CD56dim NK
cells (B). (A and B) No differences are observed for the expression of KIR molecules. When considering the KIR distribution following the expression of
NKG2A (C, D), CD8 (E, F), or CD57 (G, H) on CD56dim NK cells, it appears that patient 5’s NK cell marker distribution on CD107a+ and IFN-g+ CD56dim
NK cells does not follow the same patterns as in HD. For TAP-deficient patient 5, zero KIR NK cells are always more functional than ones expressing at
least one KIR, despite the presence of NKG2A or CD57.
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patients, despite comparable expression levels of its ligand HLA-
E. One possible reason for the responsiveness of these NK cells is
that HLA-E molecules of the patient present TAP-independent
peptides, which is indeed possible (27, 28), and that the combi-
nation of HLA-E with these given peptides would allow recog-
nition by NKG2A, whereas this would not be the case for the other
patients with a different set of TAP-independent peptides. Another
hypothesis is that HLA-E levels are suboptimal and still too low to
educate NK cells through NKG2A, but they are not higher in
patient 5 than in the hyporesponsive individuals.
A more “basic” explanation may be a strong in vivo preactivation
of NK cells through HLA class I–independent mechanisms and,
in particular, by inflammatory cytokines. Indeed, the patient
was heavily infected at the time of blood drawing and had the
most severe symptoms in our cohort, as briefly described in the
Introduction.
Phenotypically, at the first level of analysis, a significantly higher
proportion of patient NK cells than HDNK cells expressed NKG2A
and CD8. The most striking difference was the significantly higher
frequency of NKG2A+ KIR+ NK cells in the patients compared
with the panel of HD. These results suggest that, in the absence of
classical HLA class I molecules, a significant fraction of NK cells
continues to “desperately” express HLA class I–specific receptors
to encounter sufficient “educating” amounts of matched ligands,
which can actually never occur in TAP deficiency.
Our analysis of CD57 expression revealed that KIR+ NK cells
were more frequent among the CD57+ population and that KIR2
NK cells were predominant among the CD572 subset. There were
no major differences between normal and TAP-deficient NK cells
in this regard. An interesting result was that, in the patients,
significantly more KIR+ cells were found among the CD572/
NKG2A+ subset than in the HD. This might suggest that a portion
of the TAP-deficient NK cells acquire KIR in earlier stages of
differentiation or, alternatively, that their maturation is blocked in
a significant fraction of the NK cells before CD57 becomes
expressed.
Because it was established that the CD8a/a homodimer, the
only form of CD8 expressed by NK cells, can recognize HLA
class I molecules (29, 30), we decided to integrate CD8 into the
list of HLA class I ligands and to investigate its potential influence
on the expression of other HLA class I ligands present in NK cells.
Addison et al. (31) showed that CD8+ NK cells are more cytotoxic
and less prone to target cell–induced apoptosis than are their
CD82 counterparts. The majority of the functional TAP-deficient
NK cells in our study were CD8+, which would be in favor of this
claim. In contrast, CD8 by itself is not sufficient to make NK cells
functional, as seen in the other patients. In any event, there is no
CD8 ligand expressed on K562 target cells, so that CD8 might
“only” be a phenotypic marker of the strongly cytotoxic NK cells
but not functionally implicated at this level. However, it seems to
play a role in the development of the KIR repertoire, at least in
TAP deficiency.
With regard to the acquisition of the KIR repertoire by NK
cells, two models have been proposed: the “stochastic” model (14)
and the “ligand-instructed” model (13). The latter claims that,
although initially stochastic, the repertoire later becomes biased
toward self-specific KIR. Scho¨nberg et al. (12) demonstrated that
the “instruction” process is not yet in place in the neonatal period
but appears later in life. This might explain why KIR repertoires
are different among individuals, because the repertoire is shaped
by the personal history of infections. However, we found a very
similar KIR expression among HD NKG2A+ subsets, suggesting
the existence of common acquisition rules, at least for some NK
subpopulations. Recently, Be´ziat et al. (16) showed that the bias
toward self-specific KIR is characteristic of patients with a history
of CMV infection but not other common herpes virus infections.
This might be an explanation in many cases and would validate
both the “stochastic” model (initially and in the absence of CMV
infection) and the “ligand-instructed” model (bias due to CMV
infection). In a humanized mouse model (mice lacking Ly49
ligands but transgenic for HLA-Cw3 and a KIR B haplotype), van
Bergen et al. (32) found that, in the presence of HLA-Cw3, the
FIGURE 7. Coexpression pattern of CD57, CD8,
and NKG2A on CD107a+ and IFN-g+ CD56dim NK
cells from HD and TAP-deficient patient 5. Box
plots represent the frequency of the combinations of
different markers on CD107a+ (A, C) and IFN-g+ (B,
D) CD56dim NK cells derived from seven HD.
Encircled black dots represent patient 5, who has
functional CD56dim NK cells. Differences in the
frequency of the different combinations of mark-
ers are observed between the two NK cell types.
For patient 5, functional NK cells are more fre-
quent in the NKG2A+CD8+ population (A, B) and
the CD572 subset (C, D) compared with HD.
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corresponding IR KIR2DL2 was reduced both in frequency and in
expression level.
With regard to the expression of NKG2A and KIR in TAP
deficiency, the acquisition rules are likely to be disturbed by the
very low number of HLA class I molecules in the environment.
Nevertheless, among NKG2A+ cells, KIR molecules are present
at higher levels than in HD. This could reflect that, under phys-
iological conditions, KIR acquisition is stopped once enough
“matching” IR–HLA class I interactions are attained by the in-
dividual NK cell, whereas the process continues in TAP defi-
ciency because the limiting partner is absent. However, the reason
why not all TAP-deficient NK cells express NKG2A and several
KIR remains unknown. Thus, our results suggest that HLA class I
molecules have a strong influence on KIR expression and point
toward the existence of additional NK cell–intrinsic, HLA class I–
independent factors that prevent KIR overexpression. In the con-
text of the increasing use of NK cells in clinics, the fact that HLA
class I molecules have a strong impact on the acquisition
of their receptors could become important from a translational
perspective.
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 Supplemental Figure 1: Influence of the combination of CD57, CD8 and NKG2A 
on KIR molecules expression in CD56dim NK cells derived from healthy donors 
and TAP-deficient patients. 
TAP-deficient (n=7) and HD (n=9) NK cells were phenotyped according to the 
antibody frame (Table 1). Boxplots represent the frequency of CD56dim NK cells co-
expressing CD57, CD8, NKG2A and KIR molecules in nine HD (white boxes) and 
six TAP-deficient patients (grey boxes). The comparison of the different markers’ 
distribution shows that CD57- CD8+ NKG2A+ KIR+ NK cells are more present in 
TAP-deficient patients compared to HD, suggesting a block of CD57, but not HLA 
class I receptors’ acquisition in the patients. Circles represent the TAP-deficient 
patient 7 considered as an outlier. In figures, (****P<1x10-6, ***P<0 .001, **P<0 
.01, *P<0 .05 and #P<0 .1).   
 
 
 
 
 
Supplemental Figure 2: Co-expression pattern of CD8/NKG2A and 
CD57/NKG2A on CD107a+ and IFN-γ+ CD56dim NK cells from healthy donors 
and TAP-deficient patient 5.  
TAP-deficient (n=7) and HD (n=9) NK cells were phenotyped according to the 
antibody frame (Table 1). Boxplots represent the frequency of different markers’ 
distribution on CD107a+ (A, C) and IFN-γ+ (B, D) CD56dim NK cells derived from 
seven HD. Circles represent the TAP-deficient patient number 5 which presents 
functional CD56dim NK cells. When combining CD8 and NKG2A or CD57 and 
NKG2A for the analysis of KIR molecules distribution among CD107a+ (A) and IFN-
γ+ (B) CD56dim NK cells, healthy donors and TAP-deficient patient 5 present different 
distribution patterns; zero KIR NK cells being more functional than one KIR NK cells 
in TAP-deficient patient 5 compared to HD. 
  
Supplemental Table I: KIR and HLA class I genotype of the seven TAP-deficient patients included in this study. 
KIR and HLA class I genotypes of the 7 TAP-deficient patients were determined by SSP-PCR (see section “Materials and Methods”, “KIR and 
HLA class I genotyping” §) showing that they are all homozygous for HLA Class I molecule genes. 
 
 
 
 
 
 
 
Patient nb HLA class I genotype 
KIR genotype 
2DL1 2DL2 2DL3 2DL4 2DL5 3DL1 3DL2 3DL3 2DS1 2DS2 2DS3 2DS4 2DS5 3DS1 2DP1 3DP1 
1(20) A*24 B*14 C*08 pos - pos pos pos pos pos pos pos - - pos pos pos pos pos 
2(20) A*24 B*14 C*08 pos - pos pos - pos pos pos - - - pos - - pos pos 
3(17) A*26:01 B*49:01 C*07:01 pos pos - pos pos pos pos pos pos pos pos pos pos pos pos pos 
4(17) A*26:01 B*49:01 C*07:01 pos pos - pos pos pos pos pos pos pos pos pos pos pos pos pos 
5(18) A*01 B*08 C*07 pos pos pos pos pos - pos pos pos pos - - pos pos pos pos 
6(19) A*26 B*38 C*12 pos pos pos pos - pos pos pos - pos - pos - - pos pos 
7(19) A*26 B*08 C*07 pos pos pos pos pos pos pos pos - pos pos pos - - pos pos 
Patient nb Deduced centromeric KIR haplotypes¶ Deduced telomeric KIR haplotypes¶ Summary 
1(20) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DS1-2DL5-2DS5-2DS1-3DL2 (tB01) 
AB 
2(20) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
AA 
3(17) 
3DL3-2DS2-2DL2-2DL5-2DS3-2DP1-2DL1-3DP1- (cB01) 
3DL3-2DS2-2DL2-3DP1- (cB02) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DS1-2DL5-2DS5-2DS1-3DL2 (tB01) 
BB 
4(17) 
3DL3-2DS2-2DL2-2DL5-2DS3-2DP1-2DL1-3DP1- (cB01) 
3DL3-2DS2-2DL2-3DP1- (cB02) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DS1-2DL5-2DS5-2DS1-3DL2 (tB001) 
BB 
5(18) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
3DL3-2DS2-2DL2-3DP1- (cB02) 
-2DL4-3DS1-2DL5-2DS5-2DS1-3DL2 (tB01) 
-2DL4-3DS1-2DL5-2DS5-2DS1-3DL2 (tB01) 
BB 
6(19) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
3DL3-2DS2-2DL2-3DP1- (cB02) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
AB 
7(19) 
3DL3-2DL3-2DP1-2DL1-3DP1- (cA01) 
3DL3-2DS2-2DL2-2DL5-2DS3-2DP1-2DL1-3DP1- (cB01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
-2DL4-3DL1-2DS4-3DL2 (tA01) 
AB 
 
Supplemental Table II: TAP-deficient patients’ KIR haplotype analysis. 
Using KIR genotypes (Supplemental Table I), the corresponding haplotypes were determined according to Pyo et al. (23) showing that the three 
KIR haplotypes (AA, AB and BB) are found among the seven TAP-deficient patients. In table, ¶cA01, cB01, tA01, etc stand for the centromeric 
(c) and the telomeric (t) segments of common KIR A- and B-haplotypes, respectively. 
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Discussion related to article 1 
 
NK cell IR specific interaction with MHC class I molecules is essential for these cells’ 
functions, making the IR repertoire formation of great interest for NK cell studies. Works on mice 
IR repertoire, by D. Raulet and others, led to the proposal of a stochastic sequential acquisition 
model. Ly49A is the first murine IR to be expressed, followed by Ly49G then Ly49I, creating the 
different IR repertoire combinations present in the NK cell pool [461, 462]. MHC class I molecules’ 
role in this process was suggested to be responsible of the NK cell reactivity testing and the 
repertoire acquisition termination. Later studies on MHC class I-deficient or single allele 
expressing mice, based on the comparison of “observed” versus “expected” IR frequencies, 
demonstrated the existence of MHC class I-dependent and MHC class I-independent factors 
regulating the NK cell repertoire formation [477]. 
Human NK cell KIR repertoire formation studies proved to be more complex. Statistical 
and phenotypical analyses by Andersson et al. demonstrated an absence of HLA class I 
molecules’ effect on KIR repertoire formation in a HLA-C-specific setting. NK cell KIR molecules 
are acquired stochastically and not affected by cognate HLA class I molecules [481]. On the 
contrary, Schönberg et al. showed that the NK cell repertoire formation is shaped by the cognate 
HLA class I molecules. A bias toward self-specific KIR molecule expression was observed in adult 
NK cells [482], but not during the neonatal period. NK cell KIR repertoire is initially acquired 
stochastically, then adapted to the cognate HLA class I molecules [483]. The differences between 
the above mentioned studies were later on explained by Beziat et al. works in which they 
underlined the effect of CMV infections on the KIR repertoire adaptation [495, 496, 501]. An 
expansion of NKG2C+ self-specific KIR+ NK cell population was observed in CMV infected 
individuals. These results may explain the NK cell KIR repertoire bias toward cognate HLA class 
I molecules described in Schönberg et al. studies (where no information was presented 
concerning the CMV status of the studied subjects). 
All the available studies on human NK cell repertoire formation were performed in a HLA 
class I positive context, so the direct effect of the presence/absence of these molecules on their 
specific receptors’ expression could not be studied. Our work presents, for the first time, a direct 
correlation between the HLA class I status and their receptors’ repertoire expression on NK cells. 
An in-depth phenotypic study of TAP-deficient NK cells showed an increase in their NKG2A, 
KIR2DL1/DS1, KIR2DL2/3/DS2, and KIR3DL1 molecules’ co-expression on the CD8+ but not the 
CD8- NK cell subset. Although CD8 function on T cells is well established (its expression is 
essential for T cell receptor (TCR) recognition of MHC class I molecules), its expression on NK 
cells is not well studied. NK cell CD8α/α homodimers were found to recognise HLA class I 
molecules [519], and CD8+ NK cells were previously shown to be more cytotoxic and less prone 
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to apoptosis than their CD8- counterparts [355, 356]. Our results present a novel effect of CD8 on 
HLA class I receptors’ expression on NK cells, and indicate that in a HLA class I-defective surface 
expression context, CD8 can synergise with NKG2A and have a strong effect on KIR repertoire 
formation. 
Different NK cell markers were attributed to NK cell maturation, including CD57 which was 
found to correlate with a unidirectional differentiation process leading to highly mature NK cells 
[361]. In this maturation/differentiation process, NK cells tend to lose NKG2A and gain KIR 
expression, a phenomenon uncoupled to their education [362]. The study of CD57 in addition to 
NKG2A and KIR molecules in TAP-deficient NK cells, showed a blockage in the NK cell 
maturation process. TAP-deficient NK cells show an increase of NKG2A and KIR molecules’ co-
expression on the CD57- NK cell subset indicating that the NK cell differentiation process is 
affected by the defective surface expression of HLA class I molecules. NKG2A continues to be 
expressed during (and after) KIR molecule acquisition, contrary to CD57 acquisition which seems 
to be blocked. 
 
Different studies have demonstrated the hyporesponsiveness of human and mouse TAP-
deficient NK cells toward tumour cells [92, 105, 106, 109, 520, 521]. In our study, this 
hyporesponsiveness (after 5 hours of contact with K562 cells) was confirmed for three patients in 
cytotoxicity assays, and in four patients (the last three plus one) who did not produce IFN-γ nor 
degranulated (no CD107a expression). In contrast, patient number 5 exhibited cytotoxic NK cells, 
which were able to secrete IFN-γ and/or degranulate following their encounter with K562 cells. 
KIR haplotype analyses were not able to explain this TAP-deficient functional outlier as it was not 
the only representative of the B/B KIR haplotype among the seven patients. Another explanation 
was also eliminated as all the patients expressed cytotoxic molecules: perforin and granzyme B 
levels were similar to HD, only granulysin levels were lower (40% for TAP-deficient patients 
compared with 80% for HD), but that did not seem to affect the functionality of patient 5 NK cells. 
NK cell responsiveness and functionality are a result of their education by MHC class I 
molecules. Educated functional NK cells have to express at least one IR specific for cognate MHC 
class I molecules. Following this hypothesis, TAP-deficient NK cells are expected to be 
hyporesponsive, which was demonstrated in our work and by others before us [92, 105, 106, 109, 
520, 521]. The fact that the frequency of NKG2A+ NK cells was significantly higher in the patients 
compared to the HD, led us to check the expression of its specific ligand, the non-classical HLA 
class Ib molecule, HLA-E. The latter is known to present on the cell surface, peptides resulting 
from the leader sequences of HLA class Ia molecules (HLA-A, -B, and -C) [19], and to bind the 
NKG2 molecules (NKG2A, B and NKG2C) [199]. The expression of HLA-E in TAP-deficient 
patients is still a debate. While Furukawa et al. reported an expression comparable to HD [522], 
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Matamoros et al. found it to be highly reduced on PBMC derived from another TAP-deficient 
patient [100]. In our cohort, HLA-E was present on the lymphocytes of all the patients, but its 
expression was reduced from 30% to 50% compared to the level in HD. If the interaction of 
NKG2A with its ligand HLA-E could educate NK cells from patient 5, it would have been possible 
for the other patients too, especially that the functional outlier had the lowest HLA-E surface 
expression level, 50% reduction compared to HD. 
Another plausible explanation of the exceptional NK cell functionality of TAP-deficient 
patient 5 would be the peptides presented by HLA-E molecules. Such peptides can be TAP-
dependent or TAP-independent and may differ between the individuals [523, 524]. Our functional 
outlier’s NK cells may have their HLA-E coupled to a peptide conferring them educational 
characteristics, thus making them functional. Only a peptide elution test would give us the answer 
to this question, but the patient unfortunately passed away after severe lung infections and a 
generalised vasculitis with cerebral involvement and seizures. Considering the heavy infections 
and health conditions at the time of the blood sampling, an in vivo activation of NK cells by 
secreted cytokines like IL-15 and IL-2 is possible, and could be the explanation for her 
functionality and severe condition. 
The exceptional functionality of TAP-deficient patient 5 NK cells led us to investigate the 
HLA class I receptors’ expression pattern on IFN-γ+ or CD107a+ NK cells. HD functional NK cells 
exhibited a normal pattern of KIR and NKG2A expression: NK cells expressing 1 KIR molecule 
were among the most functional ones in the absence of NKG2A or presence of CD57, whereas 
NK cells with no KIR molecules on their surface were among the functional cells in the presence 
of NKG2A. TAP-deficient patient 5 functional NK cells did not follow the same pattern: in the 
presence or absence of NKG2A and/or CD57, NK cells expressing no KIR molecules were among 
the most functional ones. Such a pattern could not be a result of education by HLA-E or the low 
expressed HLA class I molecules. In order to check if the possible in vivo IL-2 activation could 
lead to such results, TAP-deficient NK cells derived from patient 1 and 2 were activated for 12 
hours with 200U/mL of rhIL-2 then co-incubated with K562 cells according to the same conditions 
in [525]. After 5 hours of co-incubation with K562 cells no IFN-γ production was observed but 15% 
of activated TAP-deficient CD56dim NK cells degranulated (data not shown). Their HLA class I 
receptors’ expressing pattern was different from the HD and the TAP-deficient patient 5. These 
results may indicate that our functional outlier’s NK cells are not activated by in vivo secretion of 
IL-2. Further analyses of the different IL present in the patient’s blood may have given us more 
insight to her unique NK cell functionality, but unfortunately this patient’s materials are no longer 
available. 
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According to the different NK cell education models, the interaction of a self-specific IR 
with cognate MHC class I molecules educates NK cells giving them their full functionality. In 
accordance to this process as well as our presented results, it would be tempting to suspect a 
role of the inhibitory signals in NK cell KIR repertoire formation. Once a self-specific IR is acquired, 
its interaction with cognate MHC class I molecules (in cis or trans) would lead to an inhibitory 
signal educating NK cells, but also stopping the acquisition of other IR and down-regulating 
NKG2A. In a HLA class I-defective expression context, the expression of self-specific IR would 
lead to none of the above mentioned processes, as their interaction with the cognate HLA class I 
molecules can never occur. No inhibitory signal can be transmitted, leading to an accumulation 
of HLA class I receptors especially in the CD57- NK cell subset, a sign of a blockage of NK cell 
maturation. 
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Article 2 
HLA Class I Expression and Its Effect on NK Cell Maturation and Cytotoxicity Gene Profile 
Sleiman M, Kaoma T*, Bernardin F*, Brons N.H.C, Lenoble P, Vallar L. and Zimmer J. 
* Contributed equally 
In preparation 
 
Preface 
 
Our paper dealing with HLA class I molecules’ effect on NK cell KIR repertoire acquisition 
[525] demonstrated an overall hyporesponsiveness of TAP-deficient NK cells toward the K562 
cell line, as well as a blockage in their maturation process demonstrated by an accumulation of 
CD8+ NKG2A+ KIR+ NK cells in the CD57- subset. In this brief report we aimed at determining the 
different pathways, affected by the very low surface expression of HLA class I molecules, which 
are implicated in (i) NK cell maturation from CD56bright to CD56dim, and (ii) NK cell response toward 
tumour cells, more specifically the K562 cell line. In both parts, (i) and (ii), two TAP-deficient 
patients (patient 1 and 2 according to Sleiman et al. [525], provided by Dr. Patrick Lenoble, 
Departement d’Ophtalmologie, Hopitaux de Mulhouse, France ) and four HD were chosen, from 
whom CD56bright and/or CD56dim NK cells were sorted (by Nicolaas H.C. Brons, Core Facility Flow 
Cytometry, Public Research Center for Health, Luxembourg  and myself) and then whole genome 
microarrays or functional tests followed by whole genome microarrays were performed by 
François Bernardin (Genomics Research Unit, Public Research Center for Health, Luxembourg). 
Statistical analyses were performed by Tony Kaoma (Genomics Research Unit, Public Research 
Center for Health, Luxembourg). 
In the present version of the brief report, we will quickly expose analyses and discussion 
of the results as work is still ongoing to better understand the study’s outcome. 
 
 
Results and discussion 
 
Human NK cells can be sub-divided into two main populations according to their surface 
expression of CD56: CD56bright and CD56dim. These two NK cell sub-populations were shown to 
be different phenotypically and functionally [6, 119, 336, 377], and several studies have 
demonstrated that CD56bright NK cells are the progenitors of the CD56dim subset [362, 378-381]. 
From the transcriptomic side, studies by Hanna et al. revealed differences in the gene expression 
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profile between CD56bright CD16- and CD56dim CD16+ NK cells derived from a panel of healthy 
donors [526]. Having demonstrated a maturation blockage in TAP-deficient NK cells due to the 
defective surface expression of HLA class I molecules [525], we aimed in this work at examining 
the different pathways implicated in this maturation process in both statuses (HD and TAP-
deficient) as well as NK cell cytotoxicity. 
The individual comparison of each NK cell subset (CD56bright or CD56dim) derived from the 
two statuses (HD vs TAP-deficient) showed considerably high numbers of differentially expressed 
genes (1730 and 1395 respectively) which encode mainly transcription factors and phenotypic 
markers (Fig. 1). When comparing the gene expression profile between the two NK cell subsets 
(CD56bright vs CD56dim) in the same status (HD or TAP-deficient), only 700 and 638 genes 
respectively were found to be differentially expressed. Cluster analysis of these genes did not 
reveal any significant difference between the two cell types [(HD CD56bright vs CD56dim) vs (TAP-
deficient CD56bright vs CD56dim)]. TAP-deficient and HD NK cells seem to follow the same paths 
while maturating form CD56bright to CD56dim. The defective expression of HLA class I molecules 
seems to affect the CD56bright and CD56dim NK cell gene expression, but not their maturation 
process, at least from the transcriptomic side. 
In a previous work, TAP-deficient NK cell hyporesponsiveness was broken after 11 days 
of activation with rhIL-2 allowing them to efficiently kill K562, DAUDI and RAJI cells, and perform 
ADCC [106]. Similar results were observed for the two TAP-deficient patients investigated in this 
study. Initially hyporesponsive (Fig. 2A), after 12 hours of activation with 200U/mL of rh-IL2, NK 
cells sorted from the two TAP-deficient patients were able to kill K562 cells (Fig. 2B) as well as 
degranulate (15% of CD107a+ NK cells for both patients), but no IFN-γ production was detected 
(data not shown). This activity increased considerably after 5 days of activation (200U/mL of rhIL-
2) and exceeded a 90% killing of K562 cells (Fig. 2C). TAP-deficient NK cells express normal 
levels of perforin, granzyme B, but reduced levels of granulysin [525]. Activation with rhIL-2 broke 
these cells’ hyporesponsiveness, demonstrating that they have the necessary machinery to kill 
tumour cells but are not able to trigger it in normal conditions. 
The second part of this study aimed at examining the different genes and pathways 
implicated in the NK cell cytotoxicity and which are affected by the defective surface expression 
of HLA class I molecules. To do so, CD56dim NK cells derived from HD and the two TAP-deficient 
patients were sorted, incubated with K562 cells at a ratio of 5/1 (NK/K562), then resorted for whole 
genome microarrays. The incubation times were chosen in order to study the early induced genes 
(1 hour) and the late induced genes (5 hours) resulting from K562 co-incubation. Considering 
TAP-deficient NK cell hyporesponsiveness, as well as the differences in the expressed gene 
profiles at t=0h (Fig. 1), we expected to have completely different profiles at 1 hour and 5 hours 
of incubation. 
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Three different methods were used in analysing the gene profiles generated in this study: 
(i) static data set comparison, when considering each NK cell subset in the two statuses (ex. 
CD56dim HD vs TAP-def, blue in Fig. 3), (ii) time-series expression data set, when comparing in 
the same status two different time points (ex. HD 1h vs 5h, red in Fig. 3), and (iii) comparative-
time-series expression data set, when comparing two different time points in the two statuses (ex. 
[HD 1h vs 5h] vs [TAP 1h vs 5h], mauve in Fig. 3). 
The gene expression differences between HD and TAP-deficient CD56dim NK cells was 
already demonstrated in the paper’s first part. A static data set comparison after 1 hour of 
incubation showed less differences between the two statuses: only 352 genes (belonging to 6 
different functional clusters) are differentially expressed, compared to 1395 genes and 22 
functional clusters before tumour co-incubation (Fig. 3A, B). Following 5 hours of co-incubation, 
an identical gene profile is observed for the two NK cell types. TAP-deficient and HD NK cells are 
similarly induced although they are functionally different. Such unexpected results led us to 
consider a different approach: time-series expression data set analysis combined to a 
comparative-time-series expression data set analysis. Although “HD 0h vs 1h” profile showed 
significantly higher differentially expressed genes compared to “TAP-deficient 0h vs 1h” (1252 
and 66 genes respectively), when performing a comparative-time-series expression data set 
analysis, only 12 genes (with no specific functional cluster) were found. Similar results were found 
for the two other comparative-time-series expression data set analysis. 
The phenotypic differences between HD and TAP-deficient NK cells, like: the absence of 
IFN-γ production in TAP-deficient NK cells and the increase of CD69 expression in HD NK cells 
after 5 hours of K562 co-incubation, as well as all the cytotoxicity pathways, are not reflected in 
the gene profile. Such results were not expected in the light of a complete hyporesponsiveness 
of TAP-deficient compared to a normal responsiveness of HD NK cells toward the tumour cell line 
K562. Different hypotheses can be drawn in order to explain these results, but the most plausible 
one would be that the necessary genes in cytotoxicity pathways were not expressed at the right 
time in TAP-deficient NK cells. IFN-γ mRNA, as well as other molecules produced upon tumour 
cell encounter, were detected in TAP-deficient NK cells, but their corresponding proteins were 
absent. Increasing the studied time-points between 0 hour and 1 hour of incubation, coupled to a 
protein-array-analysis, could complete the whole-genome-microarrays performed in this study, 
but the availability of the biological material (TAP-deficient PBMC) is the limiting factor. In order 
to circumvent this problem, another analysis approach is being performed. The differentially 
expressed genes in Fig. 3, can be subdivided into three different clusters: (i) genes which have 
similar expression levels between the two statuses at t=0h, and are similarly affected by tumour 
co-incubation, (ii) genes which are different between both statuses at t=0h and do not change in 
expression by tumour co-incubation time, and (iii), the most interesting cluster; the genes which 
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are initially different between the two statuses and are affected by the tumour co-incubation. 
These last genes are not numerous, but are under detailed analyses for the time being. 
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Figure legends 
 
Figure 1: Gene profile comparison between CD56bright and CD56dim NK cells derived from 
HD and two TAP-deficient patients. 
Experimental conditions: NK cells (CD56bright and CD56dim) were sorted from freshly defrosted 
PBMC derived from 4 HD and 2 TAP-deficient patients, before performing whole genome 
microarrays. Differentially expressed genes were determined using a p-value (FDR) < 0.05, and 
no Fold Change abs(FC). (A) Heat maps represent the differentially expressed genes between 
the two NK cell types (HD and TAP-deficient) and the 2 differentiation stages (CD56bright and 
CD56dim). (B) Scheme represents the differentially expressed gene numbers in the 5 different 
combinations when comparing the 2 cell types (HD and TAP-deficient), and the 2 stages 
(CD56bright and CD56dim). In parenthesis are indicated the differentially-expressed-gene clusters 
with an enrichment score > 2, calculated with Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7, available on http://david.abcc.ncifcrf.gov/. Blue numbers 
indicate the punctual comparisons (HD CD56bright vs TAP-deficient CD56bright, and HD CD56dim vs 
TAP-deficient CD56dim). Red numbers indicate the gene numbers when comparing the 2 NK 
stages in the same cell type (CD56bright and CD56dim in HD or TAP-deficient), and mauve numbers 
represent the difference when comparing [CD56bright vs CD56dim in HD] vs [CD56bright vs CD56dim 
in TAP-deficient patients]. 
 
Figure 2: Fresh TAP-deficient NK cells exhibit hyporesponsiveness toward K562 cells, but 
increase their activity after activation with IL-2. 
In the graphs, black lines represent the cytotoxicity of HD NK cells, the blue lines represent the 
cytotoxicity of TAP-deficient patient’s 1 NK cells, and the red lines are for TAP-deficient patient’s 
2 NK cells. NK cell cytotoxicity experiments were performed according to the protocol in [525] 
using the ratios 1:1, 5:1 and 10:1. For HD, n=6 in (A), and n=3 in (B and C). (A) Fresh TAP-
deficient NK cells are hyporesponsive toward K562 cells, contrary to the ones derived from HD. 
(B) After overnight activation with 200U/mL of rhIL-2, HD NK cell cytotoxicity significantly 
increased, and TAP-deficient patient NK cells were able to kill K562 cells, but less than HD. (C) 
Following 5 days of activation with rhIL-2, both NK cell types were highly cytotoxic and were able 
to kill between 90% and 99% of K562 cells. 
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Figure 3: Gene profile comparison between fresh, 1h activated and 5h activated CD56dim 
NK cells derived from HD and 2 TAP-deficient patients. 
Experimental conditions: CD56dim NK cells were sorted from freshly defrosted PBMC derived from 
4 HD and 2 TAP-deficient patients, co-incubated with sorted live K562 cells during 1 hour or 5 
hours, then sorted again before performing whole genome microarrays. Differentially expressed 
genes were determined using a p-value (FDR) < 0.05, and no Fold Change abs(FC). (A) Heat 
maps represent the differentially expressed genes between the 2 NK cell types (HD and TAP-
deficient) and the 3 incubation times (0h, 1h and 5h). (B) Scheme represents the differentially 
expressed gene numbers in the 11 different combinations when comparing the 2 cell types (HD 
and TAP-deficient), and the 3 incubation times (0h, 1h and 5h). In parenthesis are shown the 
differentially-expressed-genes’ clusters with an enrichment score > 2, calculated with Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.7, available on 
http://david.abcc.ncifcrf.gov/. Blue numbers indicate the punctual comparisons (0h HD vs 0h TAP-
deficient, 1h HD vs 1h TAP-deficient, and 5h HD vs 5h TAP-deficient). Red numbers indicate the 
gene numbers when comparing 2 incubation times in the same cell type (0h vs 1h, 1h vs 5h, and 
0h vs 5h in HD, or in TAP-deficient), and mauve numbers represent the differences when 
comparing ([0h vs 1h in HD] vs [0h vs 1h in TAP-deficient patients], [1h vs 5h in HD] vs [1h vs 5h 
in TAP-deficient patients], [0h vs 5h in HD] vs [0h vs 5h in TAP-deficient patients]). 
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Figure 2 
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Letter 1 
Clinical and Immunological Remarks about TAP Deficiency 
Zimmer J, Sleiman M, Hentges F. and Gadola SD. 
Journal of Biological Chemistry. 2012 Aug 3;287(32):27047 
 
Comment on: 
Role of Metalloproteases in Vaccinia Virus Epitope Processing for Transporter 
Associated with Antigen Processing (TAP)-Independent Human Leukocyte 
Antigen (HLA)-B7 Class I Antigen Presentation. 
Lorente E, García R, Mir C, Barriga A, Lemonnier FA, Ramos M. and López D. 
Journal of Biological Chemistry. 2012 Mar 23:287(13):9990-10000 
  
Abstract 
The transporter associated with antigen processing (TAP) enables the flow of viral 
peptides generated in the cytosol by the proteasome and other proteases to the 
endoplasmic reticulum, where they complex with nascent human leukocyte antigen 
(HLA) class I. Later, these peptide-HLA class I complexes can be recognized by 
CD8(+) lymphocytes. Cancerous cells and infected cells in which TAP is blocked, as 
well as individuals with unusable TAP complexes, are able to present peptides on HLA 
class I by generating them through TAP-independent processing pathways. Here, we 
identify a physiologically processed HLA-E ligand derived from the D8L protein in TAP-
deficient vaccinia virus-infected cells. This natural high affinity HLA-E class I ligand 
uses alternative interactions to the anchor motifs previously described to be presented 
on nonclassical HLA class I molecules. This octameric peptide was also presented on 
HLA-Cw1 with similar binding affinity on both classical and nonclassical class I 
molecules. In addition, this viral peptide inhibits HLA-E-mediated cytolysis by natural 
killer cells. Comparison between the amino acid sequences of the presenting HLA-E 
and HLA-Cw1 alleles revealed a shared structural motif in both HLA class molecules, 
which could be related to their observed similar cross-reactivity affinities. This motif 
consists of several residues located on the floor of the peptide-binding site. These data 
expand the role of HLA-E as an antigen-presenting molecule. 
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LETTER
Clinical and Immunological Remarks about
TAP Deficiency
We read with interest the article by Lorente et al. (1) describing the
presentation of TAP-independent antigens from vaccinia virus by
TAP-deficient cells. Their findings offer a mechanistic explanation
for the fact that TAP-deficient patients are not particularly suscep-
tible to viral infections and for why adult patients often have nor-
mal CD8 T-cell numbers (2–4). Conversely, severe viral infec-
tions might occur early in life, preparing the grounds for the
usually observed recurrent bacterial infections. TAP-independent
peptides might be generated during most viral infections. How-
ever, the presentation of these peptides to CD8 T-cells to gener-
ate efficient antiviral immune responses is still likely to be depen-
dent on the patient’s HLA haplotype. Interestingly, HLA-A*02, the
most common HLA class I allele in Europe, has been previously
shown to present diverse TAP-independent peptides to CD8
T-cells (5) but has not been found in the clinically immunodefi-
cient patients. Thus, HLA-A*02 homozygous TAP-deficient peo-
ple might be protected from severe clinical manifestations, thereby
“escaping” diagnosis.
We suggest slightly modifying the statement that “TAP-deficient
patients live normal life spans with only a limited susceptibility to
chronic respiratory bacterial infections.” Although we agree that this
is possible, patients often suffer from widespread bronchiectasis and
respiratory insufficiency. Many develop mutilating granulomatous
skin ulcers in the mid-face and on the extremities (2–4). Importantly,
treatment with immunosuppressive drugs leads to progression of
bronchiectasis, respiratory failure, and complications such as brain
abscesses.
A question arising is whether TAP plays a role in the presentation of
bacterial antigens. Future studies might examine the efficiency of this
pathway in TAP-deficient patients.
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Letter 2 
TAP Deficiency is Also a Cause of Bronchiectasis 
Zimmer J, Sleiman M, Poli A, Michel T. and Hentges F. 
Thorax. 2013 May;68(5):490-1 
 
Comment on: 
Immunity and Bacterial Colonisation in Bronchiectasis. 
Whitters D. and Stockley R. 
Thorax. 2012 Nov:67(11):1006-13 
 
Abstract 
BACKGROUND: Non-cystic fibrosis bronchiectasis is characterised by irreversibly 
dilated bronchi usually associated with chronic sputum production, bacterial 
colonisation of the lower respiratory tract, inflammation and frequent exacerbations. 
Irrespective of the underlying cause, this represents failure of the host defence to 
maintain sterility of the respiratory tract. 
OBJECTIVE: To review the interactions and associations of non-cystic fibrosis 
bronchiectasis with the innate and adaptive immune systems with particular emphasis 
on known failure of local defences established deficiencies of the adaptive immune 
system. In addition we wished to explore potential subtle changes in the host defence 
which can lead to bacterial colonisation together with bacterial factors that aid 
colonisation of the lower respiratory tract and impair antibiotic response. This latter 
concept is considered with particular reference to Pseudomonas aeruginosa, which is 
often found in the airway secretions of patients with non-cystic fibrosis bronchiectasis 
and may act as a model for other organisms. 
METHODS: An extensive literature review was undertaken to provide a 
comprehensive review of immunity and bacterial colonisation in non-cystic fibrosis 
bronchiectasis, with focus on in vitro studies examining bacterial factors which may 
facilitate colonisation together with potential implications for management. 
CONCLUSION: These themes provide a review of the current understanding of non-
cystic fibrosis bronchiectasis together with areas for future research and potential 
therapeutic strategies.  
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TAP deﬁciency is also a cause
of bronchiectasis
We read with interest the recent bronchi-
ectasis review by Whitters and Stockley.1
The authors provide a comprehensive
overview of the changes in the immune
response that might favour bacterial colon-
isation of the lower airways and in a
second step initiate the vicious cycle
leading to chronic inﬂammation and recur-
rent infections. Their description of the
innate immune system in the lung includes
antibacterial peptides, neutrophils and toll-
like receptors. Although this is correct,
Natural Killer (NK) cells might also be
mentioned, as their role in the immune
response to bacteria (besides their antiviral
and antitumor functions) has been
repeatedly documented.2 3 NK cells par-
ticipate in innate immune defence mechan-
isms through (i) the release of cytotoxic
granules containing, among others, the
antibacterial factors granulysin,
α-defensins and cathelicidin,2 and (ii) cyto-
kine production that stimulates both
innate and adaptive immunity. In addition,
they have immunoregulatory properties
able to limit excessive immune responses.3
Thus, it is highly likely that NK cells are
one of the actors participating in the
pathogenesis of bronchiectasis. The same
may hold true for the more recently dis-
covered (non NK) innate lymphoid cells,
but more work will be necessary to estab-
lish this.
Another important point of the review
is the useful list of the causes of bronchi-
ectasis in which transporter associated
with antigen processing (TAP) deﬁciency
is however missing. TAP proteins are
crucial for peptide loading on newly
synthesised Human Leukocyte Antigen
(HLA) class I molecules, and the conse-
quence of TAP deﬁciency is a very low
cell-surface expression of these HLA class
I molecules.4 5 Clinically, besides skin
ulcers, the patients suffer from chronic
bacterial infections of the upper and
lower airways with bronchiectasis.4 5
Although the known cases of this immune
deﬁciency are rare (around 30 patients
reported in the literature), there might be
much more, as the diagnosis of idiopathic
bronchiectasis might be made in most
instances without having checked for TAP
deﬁciency (by staining of patients’ periph-
eral blood mononuclear cells with an
anti-HLA class I antibody which reveals
by ﬂow cytometry a very low expression
level compared to healthy control donors,
and/or the absence of HLA class I mole-
cules by serotyping).
In our opinion, it is important to detect
TAP deﬁciency as soon as possible in
order to optimise the treatment of the
patients, and thus it should be systematic-
ally included in the diagnostic algorithms
applied to the exploration of chronic
respiratory infections and bronchiectasis.
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COLLABORATIONS AND ONGOING PROJECTS 
NK cell capacities to kill tumour and virally infected cells made them of high and 
continuous interest in the immunology field. During my thesis work, and taking the advantage 
of our developed flow cytometry facility as well as our knowledge in primary 
immunodeficiencies (more specifically TAP-deficiency), we had the chance to start different 
collaborations aiming at better understanding NK cell functions in different disease contexts. 
i. Role of NKG2C in TAP-deficient individuals 
Aiming at studying the role and function of NKG2C in the TAP-deficiency context, a 
collaboration with Prof Karl-Johan Malmberg, from the Centre of Infection Medicine 
(CIM) Karolinska Institutet, Stockholm, Sweden, was launched. The first set of 
experiments was performed by Dr Vivien Béziat Centre of Infection Medicine (CIM) 
Karolinska Institutet, Stockholm, Sweden) on PBMC derived from two TAP-deficient 
patients. This collaboration was later on extended with Oslo medical hospital where Dr 
Jodie Goodridge is performing experiments on TAP-deficient fibroblasts. 
ii. NK cells in Multiple Myeloma (MM) 
Multiple Myeloma (MM) is a haematological malignancy responsible of 2% of deaths 
related to cancer. Its annual incidence, which is increasing by time, is partially balanced 
by an improvement of the patients’ survival rate especially due to immunomodulators 
use in treatment. Interest on the effect of these immunomodulators on the immune 
system function is increasing, especially in the NK cell field. Willing to better 
understand the NK cell/plasma cell interaction in MM, a collaboration was started with 
Dr Nassera Aouali (Laboratory of Experimental Hemato-Oncology, CRP-Santé 
Luxembourg). The project was presented for funding to the “Cancer Research 
Foundation in Luxembourg” and is awaiting approval.  
iii. Identification of two potential new TAP-deficient patients 
TAP-deficiency is a very rare disease unfamiliar to medical doctors. During my PhD 
studies, we tried to get in contact with many doctors around the world hoping to identify 
new cases allowing us to better study NK cell functions in this particular context. As a 
result, we started two collaborations in order to identify two potential new cases of 
TAP-deficiency. 
iii.a - Case number 1: a woman living in Brazil and presenting the common symptoms 
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of TAP-deficient patients, as well as a defective surface expression of HLA class I 
molecules, was identified by Dr Dewton Vasconcelos. The mutation responsible of her 
surface-expression deficiency of HLA class I molecules has not yet been identified, but 
we were able to perform phenotypic and functional tests on her NK cells. 
iii.b - Case number 2: till today, all the reported cases of TAP-deficiency were 
identified in consanguineous families which resulted in a homozygous TAP1 or TAP2 
mutation. Dr Steven Holland, from the Laboratory of Clinical Infectious Diseases, 
NIAID, NIH, U.S.A, identified a new patient (27 years old man) with a defective surface 
expression of HLA class I molecules. Genetic tests showed a heterozygous mutation 
in TAP2 exon 4. The patient’s biological material was sent to our laboratory in order to 
find the second mutation and perform phenotypic and functional tests on his NK cells. 
iv. NK cell education by IR:MHC class I cis interactions 
In June 2010 I started my PhD thesis at the Laboratory of Immunogenetics and 
Allergology (LIGA) in order to study the molecular mechanisms implicated in murine 
NK cell education by MHC class I molecules. Using TAP1-KO NK cells following their 
H2-Dd uptake form environmental cells by trogocytosis, we were planning to study the 
effect of the Ly49A:H2-Dd cis interaction on NK cell education. To do so, a collaboration 
was launched with Dr Petter Höglund (Center for Hematology and Regenerative 
Medicine, Karolinska Institutet, Stockholm, Sweden), who provided us with the EL4-
Dd-GFP cell line [504]. All the preliminary experiments were successfully performed, 
but this project had to be postponed as the commercialisation of the major antibody 
used in the experiments (Ly49A-JR9-318) was stopped. In this thesis chapter we will 
present the experiments’ results and propose a possible continuation of this project. 
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Role of NKG2C in TAP-Deficient Individuals 
Collaboration with Prof Karl-Johan Malmberg 
Centre of Infectious Medicine, Karolinska Institutet, Stockholm, Sweden 
 
The role of HLA class I in NK cell education and functions is well established, and our 
most recent paper demonstrated these molecules’ strong effect on KIR repertoire formation 
[525]. In the last few years, many studies underlined the effect of CMV infection on NK cell 
KIR repertoire adaptation; an expansion of the NKG2C+ self-specific-KIR+ NK cell population 
was found in CMV+ patients [495, 496, 501]. In parallel to the HLA-E phenotype performed 
during our paper’s experiments [525], NKG2C expression frequency was determined. Results 
showed heterogeneity in TAP-deficient NK cell profile: NKG2C was expressed on NK cells 
derived from three out of seven patients. As patients’ CMV status in unknown, no conclusion 
concerning the NKG2C+ NK cell population can be drawn. 
In the light of these results, a collaboration was launched with Pr. Karl-Johan Malmberg 
(Centre of Infectious Medicine, Karolinska Institutet, Stockholm, Sweden) to whom PBMC 
derived from two TAP-deficient patients (presenting the highest frequency of NKG2C+ NK 
cells) were sent, and experiments were performed by Dr Vivien Béziat. The aim of this work 
was to study NKG2C in TAP-deficient patients: co-expression profile of a large KIR panel on 
NKG2C+ NK cells and role of this activating receptor in patients’ NK cells. 
In depth KIR phenotypic studies revealed strong differences between CMV+ HD NK 
cells and ones derived from the two TAP-deficient patients (Fig. 1A). While NKG2C+ NKG2A- 
(but not NKG2C- NKG2A+ and NKG2C- NKG2A-) NK cells showed a bias toward self-specific 
KIR expression in the CMV+ HD (Fig. 1B), no bias in KIR expression was observed in the three 
former NK cell subpopulations of TAP-deficient patients (Fig. 1C, D). 
To assess the functionality of NK cells expressing exclusively NKG2A or NKG2C, IFN-
γ and TNF-α production, as well as degranulation (CD107a expression) toward 721.221-AEH 
(721.221 cell line presenting the HLA-E epitope recognised by NKG2A leading to NK cell 
inhibition, or NKG2C leading to NK cell activation) cells and P815+anti CD16 were performed 
(Fig.2). As expected, both HD NK cells (NKG2A+ NKG2C- and NKG2A- NKG2C+) performed 
rADCC following P815+anti CD16 co-culture, whereas TAP-deficient NK cells exhibited low to 
very low response. NKG2A+ NKG2C- NK cell co-culture with 721.221-EAH cells did not result 
in any response for both statuses (healthy and TAP-deficient); NKG2A being an inhibitory 
receptor. On the other hand, NKG2A- NKG2C+ HD NK cells were activated by 721.221-EAH 
cells. NKG2C was engaged in an interaction with its ligand leading to NK cell activation. On 
the contrary, both patients’ NK cells (NKG2A- NKG2C+) had very low response toward 
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721.221-AEH cells. NKG2C does not seem to act like an activating receptor in TAP-deficient 
individuals. This conclusion was confirmed in receptor crosslinking experiments where NK 
cells were incubated in plates coated with the different combinations of NKG2C, 2B4 and 
DNAM-1 antibodies (Fig. 3). Compared to CMV+ HD, neither NKG2C nor the combination of 
2B4 and DNAM-1 were able to activate TAP-deficient NK cells. Only combinations of NKG2C 
with another antibody (2B4 or DNAM-1) lead to TAP-deficient NK cell degranulation, patient 1 
NK cells being more functional than the ones derived from patient 2. These results clearly 
demonstrate that NKG2C does not act as an activating receptor in TAP-deficient NK cells but 
more like an activating co-receptor. 
In HD, engagement of NK cell AR, including NKG2C, induces a signal transduction 
through their adaptor molecule DAP12 leading to a series of protein phosphorylation by SYK 
and ZAP-70 resulting in Ca2+ signalling and NK cell degranulation. On the contrary, 2B4, 
DNAM-1 and NKG2D engagement with their ligand is not sufficient for activating NK cells, two 
signals need to synergise in order to efficiently phosphorylate the lymphocyte cytosolic protein 
2 (SLP-76) thus leading to an activating signal pathway. Investigating the expression and the 
phosphorylation of the different molecules implicated in these pathways should allow us to 
better elucidate this functional difference. 
In order to give more insight to the role of CMV infection on HLA class I (HLA-A, -B 
and -C) and HLA-E expression, a collaboration was launched with Oslo Medical Hospital, 
where Dr Jodie Goodridge is working on infecting TAP-deficient fibroblasts with CMV. 
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Figure legends 
 
Figure 1: KIR co-expression frequency on NKG2C+ NKG2A- TAP-deficient NK cells. 
(A) Shown is the frequency of NKG2C+ NKG2A- CD56dim NK cells in seven TAP-deficient 
patients [525] and a panel of healthy donors. Only three patients (1, 2 and 5) exhibited high 
levels of NKG2C+ NKG2A- CD56dim NK cells. The expression frequency of seven different KIR 
molecules was determined on NKG2C- NKG2A-, NKG2C- NKG2A+, and NKG2C+ NKG2A- 
CD56dim NK cells in one healthy donor (B) and TAP-deficient patients 1 and 2 (C and D 
respectively). The presence of one KIR in a combination is represented by a colour code below 
the graph: 2DL1 (dark blue), 2DL2/S2 (purple), 2DL3 (red), 2DS1 (light blue), 2DS4 (orange), 
3DL1 (green), 3DL2 (black). Data in (A) were analysed with Kaluza analysis software v1.2 
(Beckman Coulter), and in (B) with the Boolean gate algorithm of Flow Jo Version 9.6 
(TreeStar). Pestle software Version 1.6 was used to remove the background. 
 
Figure 2: Functional characterization of NKG2C+ NKG2A- NK cells in TAP-deficient 
patients. 
Polyfunctional assays were performed on thawed PBMC, rested overnight and stimulated by 
HLA-E expressing 721.221.AEH cells or P815 coated with 1µg/mL anti-CD16 (3G8 clone). 
Cells were stained with mAbs for CD107a (degranulation), and intracellular expression of IFN-
γ and TNF-α. Pie charts show the frequency of NK cells positive for 0, 1, 2, or 3 responses 
(CD107a, IFN-γ, and TNF-α). The color-coded arcs depict the frequency of cells positive for 
CD107a, IFN-γ, and TNF-α. Data were analysed with the Boolean gate algorithm of Flow Jo 
Version 9.6 (TreeStar). Pie charts were generated using the Spice software Version 5.3 (NIAI 
Freeware). 
 
Figure 3: NKG2C is an activating co-receptor in TAP-deficient patients. 
Degranulation assays were performed on thawed PBMC, rested overnight and stimulated by 
coated antibodies corresponding to the eight possible combinations of NKG2C, DNAM-1 and 
2B4. White histograms represent a panel of healthy donors, grey histograms represent TAP-
deficient patient 1, and black histograms represent TAP-deficient patient 2. Data were 
analysed with the Boolean gate algorithm of Flow Jo Version 9.6 (TreeStar). Histograms 
represent the mean ± SD.  
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NK Cells/plasma cells interactions in Multiple Myeloma (MM) 
Collaboration with Dr Nassera Aouali 
Laboratory of Experimental Hemato-Oncology, CRP-Santé Luxembourg 
 
Multiple Myeloma (MM) is a type of haematological cancer distinguished by high 
proliferation levels of clonal plasma cells in the BM. Plasma cells are differentiated B 
lymphocytes responsible of Ig production that play a major role in humoral adaptive immune 
response [527]. Hence, due to malignant plasma cell accumulation, the smooth production of 
platelets, erythrocytes and leukocytes is disturbed. Ig production is also affected and 
overproduction of a non-functional protein (Ig) takes place, also known as paraprotein or 
monoclonal protein (M protein or M Ig) [528]. 
MM diagnosis is based on different criteria which includes symptoms of bone disease, 
renal failure, anaemia, bleeding, recurrent bacterial infections, and laboratory tests such as 
plasma hyperviscosity, raised erythrocyte sedimentation rate and over production of M serum 
protein or globulin. When MM is suspected, further verification of the disease should be carried 
out by BM aspiration plasma cells count [529] and infiltration assessment by 
immunohistochemistry on a trephine section biopsy of 20mm length [530]. Normal levels of 
plasma cells in HD BM is around 2%, and can reach to 10% in early stages of the disease. 
MM evolution can be divided into four different stages: two asymptomatic stages which could 
evolve to multiple myeloma (MM), monoclonal gammopathy of undetermined significance 
(MGUS) and smoldering multiple myeloma (SMM), MM could be progress in plasma cell 
leukaemia (PCL). In the last stages of the disease, plasma cells pass from the BM to the blood 
and constitute more than 20% of blood lymphocytes. The median age of individuals presenting 
MM is approximately 70 years. The annual incidence of newly diagnosed cases of MM is 
increasing, but the survival rate is improving by time [531] especially thanks to a new class of 
drugs used in MM treatment, the immunomodulators. 
Immunomodulators, currently used in MM treatment, include “Lenalidomide”. These drugs 
lead to an increase or reduction of the immune system response, in this case towards plasma 
cells. The immunomodulators’ implications on the immune system, more specifically in the 
MM context, is growing by time [532-535]. The aim of this study is to better understand the 
mechanisms behind MM resistance to NK cell killing throughout the disease evolution, and 
study the effect of the different immunomodulators on NK cell functions. To do so, blood and 
BM sampling will be carried out on patients from the different stages of the disease; MGUS, 
SMM, MM and PCL, followed by deep NK cell phenotype and functional tests. 
Immunomodulators’ combinations cytotoxicity will be also studied on both plasma cells and 
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NK cells. Results should give us more information about the interactions between plasma cells 
and NK cells in the MM context and help us propose more adapted clinical treatments. 
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Identification of Two New TAP-deficient Patient 
 
During my PhD thesis work, we were able to get in contact with two doctors who 
identified patients presenting defective surface expression of HLA class I molecules. Our main 
part of the collaboration was to identify the mutation and perform different NK cell studies. In 
this chapter, we will present two different case studies on which work is still ongoing. 
 
Case study I: 
Collaboration with Dr Dewton Vasconcelos, 
Laboratory of Medical Investigation, University of São Paulo School of Medicine, Brazil 
 
TAP-deficient cases are very rare: 30 cases were described till today. This study aims 
at investigating a new patient presenting a HLA class I surface expression defect by: 
(i) sequencing the genomic DNA region of TAP-1 and TAP-2, hoping to find a 
mutation explaining the patient’s phenotypic status. 
(ii) performing a detailed phenotypic and functional study on NK cells (based on the 
experiments in Sleiman et al. 2014 [525]) in order to compare this new patient’s 
results to the former ones. 
 
In this case report we describe a potential new TAP-deficient patient, from Brazil, with 
a confirmed defective expression of HLA class I molecules (94% reduction of HLA class Ia, 
and 75% reduction for HLA-E) (Fig. 1A). She represents the common symptoms of TAP 
deficiency: granulomatous skin ulcers and recurrent upper airways’ infections. In collaboration 
with Dr Carlos Vilches (University Hospital Puerta de Hierro, Madrid, Spain) KIR and HLA 
class I genotyping were performed, showing a homozygous HLA profile correlating with her 
parents’ consanguineous marriage (Table 1A, B). Primers situated in the 5’ and 3’ intronic 
sequences of TAP-1 and TAP-2 exons were designed, and their sequencing is ongoing in 
collaboration with Prof Claude Müller and Dr Jonathan Turner (CRP-Santé, Department of 
Immunology, Luxembourg). 
To assess the HLA  class I defective expression impact on their receptors’ expression 
and co-expression, in-depth phenotypic studies were performed as described in [525] (Fig. 
1B, C and D). Surprisingly, no differences were observed in CD8, NKG2A, CD57 and KIR co-
expression frequency between patient Case I and HD (Fig. 1B). A co-expression frequency 
study of CD8/NKG2A/KIR (Fig. 2C) and CD57/NKG2A/KIR (Fig. 2D) confirmed these 
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similarities. Patient Case I presents the same expression frequencies as HD, and constitutes 
the second outlier in our 8 patients with HLA class I defective surface expression. Only an 
over representation of NKG2A- 0 KIR NK cells was observed in the CD57+ NK subpopulation.  
 
Regardless of the patient’s mutation (which is still not identified), her NK cells were 
found to be hyporesponsive toward K562 cells: low cytotoxicity (Fig. 2A), and no IFN-γ 
production nor NK cell degranulation were observed (data not shown). The presence of 
cytotoxic molecules (granzyme B, perforin and granulysin) was analysed, and their expression 
frequency in CD56dim NK cells was similar to both HD and the former 6 TAP-deficient patients 
described in our previous paper [525]. 
 
In this study, we describe a new patient presenting the typical clinical symptoms of 
TAP-deficiency. Her NK cells exhibit hyporesponsiveness towards K562 cells, but no major 
differences in their HLA class I receptor expression frequency compared to HD were observed. 
While working on identifying the mutation causing her HLA class I phenotype, further studies 
on her NK cells could give us more information on her repertoire formation and NK cell 
functions. 
 
Case study II: 
Collaboration with Dr Steven Holland, 
Laboratory of Clinical Infectious Diseases, NIAID, NIH, USA 
 
Till today, the described cases of TAP-deficiency, resulting from consanguineous 
parents, were all homozygous for the TAP-1 or TAP-2 mutations as well as for their HLA 
genotypes. Two years ago, Dr Steven Holland (Laboratory of Clinical Infectious Diseases, 
NIAID, NIH, USA) identified a new patient (29 years old male) presenting a chronic progressive 
granulomatous dermatitis on his upper left arm. This patient is of Northern European descent 
born to non-consanguineous parents, and is CMV negative. Different therapies were used in 
treating his skin granulomatous dermatitis, like complete excision and grafting of the affected 
skin, as well as treatment with systemic and topical corticosteroids, without any success. 
PBMC staining showed a defective expression of HLA class I molecules (67% reduction 
compared to HD). Following the sequencing of TAP-1 and TAP-2 mRNA, a mutation was 
found in exon 4 of TAP-2 resulting in a premature STOP codon (c.817C>T). Another mutation, 
in the exon 8 region of TAP-2 is suspected but still not identified. 
Our laboratory was contacted in order to help finding the second mutation and perform 
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NK cell studies. Due to a transport technical problem, PBMC were received in a bad condition, 
so NK cell studies were postponed to the next annual patient’s blood sampling. The patient’s 
KIR and HLA genotyping, in collaboration with Dr Carlos Vilches (University Hospital Puerta 
de Hierro, Madrid, Spain) confirmed his HLA heterozygous profile (Table 1). Studies are still 
ongoing, hoping to identify the second TAP-2 mutation. 
 
 
Figure legends 
 
Table 1: KIR and HLA class I and class II genotype of the case I and case II patients 
 
Figure 1: Case I patient expresses low levels of HLA class I and a HLA class I receptor 
expression pattern different form HD and other TAP-deficient patients. 
(A) Shown is the HLA-A, -B and -C expression on CD56dim NK cells derived from one HD 
and the Case I patient. The same expression was observed on all PBMC. (B, C and D) box 
plots represent HD and TAP-deficient patients (reused from [525]) and red dots the patient 
Case I. When comparing the different markers expression and co-expression in A, B and C, 
patient Case I presents the same expression frequencies as HD except for NK cells that are 
NKG2A- 0KIR in the CD57+ subpopulations. In figures, ****p<1x10-6, ***p<0 .001, **p<0 .01, 
*p<0 .05 and #p<0 .1. 
 
Figure 2: Patient Case I exhibits hyporesponsive NK cells although they express 
cytotoxic molecules. 
In (A) the black line represents HD and the red dashed line patient Case I. In (B) box plots 
represent HD and TAP-deficient patients (reused from [525]) and red dots the patient Case I. 
(A) cytotoxicity assays were performed on purified CD56dim NK cells and K562 cells co-
incubated for 5 hours. Hyporesponsiveness, compared to HD, is observed for patient Case I. 
(B) The percentage of CD56dim NK cells expressing granulysin, granzyme B and perforin was 
determined. Patient Case I does not show major difference compared to HD NK cells. In 
figures, **p<0 .01, *p<0 .05 and #p<0 .1. 
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Figure 2: 
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NK cell education by IR:MHC class I cis interactions  
The study of IR:MHC class I cis interaction on NK cell education was the main aim of 
this project. In order to give more insight to the mechanism behind these interactions, we: 
(i) characterised phenotypically and functionally C57BL/6 and TAP1-KO NK cells 
(ii) investigated the membrane transfer (trogocytosis) in both murine NK cell types 
(iii) planned to compare NK cell functionality in both NK cell statuses (C57BL/6 and 
TAP1-KO) before and after trogocytosis. 
 
Preface 
 
NK cell education is an adaptive process resulting from MHC class I molecule 
interaction with their specific NK cell IR. Educated, thus functional NK cells have to express at 
least one IR specific for cognate MHC class I molecules. The interaction between the two 
former molecules can occur in: (i) trans, when each molecule is on a different cell surface, or 
(ii) cis, when both molecules are expressed on the same cell surface. Different models have 
been developed trying to give more insight to the NK cell education/tolerance mechanism 
(licensing, disarming, or rheostat models), neglecting the IR:MHC class I cis interactions. 
In 2001, three independent studies demonstrated for the first time the existence of a 
membrane transfer mechanism in NK cells, named trogocytosis [440, 504, 505]. In this 
phenomenon, following a specific interaction of a NK cell receptor with its corresponding ligand 
expressed on surrounding cells, the NK cell is able to acquire this ligand and express it on its 
cell surface (cf. chapter 3.7. Trogocytosis). The result of this uptake is a NK cell surface cis 
interaction between the receptor and its newly acquired ligand. Here we aimed at studying the 
influence of IR:MHC class I cis interaction on NK cell education by performing Ly49A:H2-Dd 
uptake. The different experiments are described in the chapter Materials and Methods. 
This project was the main subject of my PhD project on which I worked during the first 
18 months of my thesis. The key antibody of this study is Ly49A (JR9-318) which allows us to 
identify the trogocytosed Ly49A+ NK cells. Due to the stopping of its production by “Becton 
Dickinson”, trogocytosis studies had to be postponed. In this chapter we will present the results 
we were able to obtain, and propose possible experiments which could help to complete them. 
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Results 
 
C57BL/6 and TAP1-KO NK cells show differences in some of their IR expression, but not in 
their maturation. 
 
NK cells derived from C57BL/6 (WT) and TAP1-KO splenocytes were selected among 
the live/CD3- NK1.1+ cells, then the expression frequency of the different receptors was 
determined (Fig. 1A). Differences were only observed for KLRG1 which was significantly less 
expressed in TAP1-KO NK cells, and Ly49F, Ly49C/I and NKG2A/C/E which were 
overexpressed in the same NK cell type. NK cell maturation statuses were assessed by 
measuring the CD27/CD11b expression pattern (Fig. 1B). Both NK cell types presented the 
same subsets’ distribution according to the four stages of maturation: CD11b- CD27-, CD11b- 
CD27+, CD11b+ CD27+, and CD11b+ CD27-, indicating no maturation disturbance in TAP1-KO 
NK cells compared to WT ones. 
 
 
TAP1-KO NK cells are hyporesponsive compared to WT NK cells, although they express 
granzyme A. 
 
When analysing granzyme A expression, no differences were observed by comparing 
both NK cell types (WT and TAP1-KO), or their education status (Fig. 2A). Edu+ NK cells being 
Ly49C/I+ NKGE2A/C/E+ and Edu- NK cells are Ly49C/I- NKG2A/C/E-. Both NK cell types, 
independent of their education status, express granzyme A, so they have part of the necessary 
machinery to kill target cells. Following activation with coated NK1.1 antibody, WT NK cells 
degranulated significantly higher than TAP1-KO ones (Fig. 2B). No response was observed 
for CD137 (negative control) nor IgG2a (isotype control), indicating that the response is 
specific for NK1.1 stimulation. Similar results were observed when TAP1-KO and WT 
negatively selected NK cells were co-cultured during 6h with YAC-1 target cells, ratio 2:1 with 
35U/mL of rhIL-2 (Fig. 2C, D). TAP1-KO NK cells showed complete hyporesponsiveness: 
neither IFN-γ production nor degranulation (CD107a expression), contrary to WT NK cells 
which produced IFN-γ and degranulated when in contact with tumour cells. In the latter NK 
cell type, educated ones were more responsive than the non-educated ones. 
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TAP1-KO and WT NK cells take up H2-Dd from donor cells following Ly49A:H2-Dd interaction. 
 
It was previously shown that Ly49A+ NK cells are able to take up H2-Dd from 
surrounding cells and express it on their surface. Using the EL4-Dd-GFP cell line (EL4 cell line 
transfected with a plasmid expressing H2-Dd coupled to GFP [504]), we investigated the ligand 
uptake by NK cells. Both NK cell types expressed Ly49A (JR9-318) (18% ± 2% expression 
frequency) but no H2-Dd was detected (Fig. 3A1, A2). Following 1 hour of incubation with EL4-
Dd-GFP cells (donor cells) at a ratio of 1/1 (NWNA spleen cells/donor cells), 97%-99% of 
Ly49A+ NK cells acquired the ligand and became positive for H2-Dd (Fig. 3 B1, B2). In order 
to investigate the specificity of the interaction, donor cells were incubated with anti-H2-Dd 
antibody prior to the trogocytosis in order to block the ligand interaction site. Following co-
incubation of NK cells with these donor cells, no double Ly49A H2-Dd double positive cells 
were found (Fig. 3 C1, C2). The H2-Dd transfer from donor cells to Ly49A+ NK cells was 
inhibited as the interaction site is blocked, demonstrating the specificity of the ligand uptake. 
Ly49A molecules present different epitopes recognised by three different antibodies: JR9-318, 
YE1-48 and A1. In order to investigate which epitope interacts with H2-Dd and is responsible 
for the ligand acquisition, trogocytosis assay was performed followed by Ly49A staining with 
each of the three different Ab. The JR9-318 epitope (Fig. 3 B1, B2) was able to detect all 
Ly49A+ NK cells, same as YE1-48 (data not shown). On the contrary, following trogocytosis, 
no Ly49A+ (A1) NK cells were found, whereas 18% ± 2% of NK cells were H2-Dd+, 
corresponding to the Ly49A (JR9-318)+ NK cell percentage (Fig. 3 D1, D2). These results 
clearly indicate that Ly49A1 epitope was masked following trogocytosis and could not be 
recognised by its Ab. H2-Dd uptake by Ly49A+ NK cells is the result of the specific ligand 
interaction with the Ly49A1 epitope. 
 
 
Discussion and perspectives 
 
Protein exchange between lymphocytes was first described in 1973 by Bona et al. 
[502]. Later studies demonstrated an uptake of MHC class I and class II molecules by CD8+ 
and CD4+ T cells respectively, affecting their functions and immune response [507-509]. Such 
ligand uptakes were also reported in NK cells. Murine H-2Dd- Ly49A+ NK cells were able to 
take up H2-Dd from surrounding cells after transfer to Balb/c mice [504], or in a transgenic 
mouse model expressing different levels of H2-Dd [440]. In this study, we aimed at examining 
H2-Dd uptake in TAP1-KO NK cells and study the effect of the resulting cis interaction between 
the receptor and the ligand on NK cell functions. 
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A phenotypic characterisation of both WT and TAP1-KO NK cells showed significant 
differences only in a few surface receptors. As previously reported [536, 537], Ly49C/I (the 
specific receptor of H2-Kb, the cognate MHC class I molecules of C57BL/6 mice), presented 
an over-expression in TAP1-KO spleen NK cells. Similar results were also found for 
NKG2A/C/E, specific receptors of Qa-1, a non-classical MHC class I molecule. KLRG1 was 
associated with a mature NK cell phenotype and a reduction of IL-15 induced-proliferation 
[538]. Its significantly reduced expression on TAP1-KO NK cells compared to WT ones 
demonstrates a lack in the former cells’ maturity, which was not confirmed by the CD27/CD11b 
expression pattern; both NK cell statuses presented the same distribution of the four 
CD27/CD11b populations. In TAP-deficient NK cells, CD27/CD11b expression evolution can 
take place as in WT ones, but NK cell maturation is not completed due to the low expression 
of MHC class I molecules. These results go in the same line as our finding on human NK cells 
which are able to progress from CD56bright to CD56dim, but the expression of CD57, a maturity 
marker, is reduced [525]. 
Functionally, TAP1-KO NK cells showed hyporesponsiveness following Ab activation 
and YAC-1 co-culture. On the contrary, WT NK cells produced IFN-γ and/or degranulated in 
both activation cases, and educated (Ly49C/I+ NKG2A/C/E+) NK cells were more functional 
than non-educated ones (Ly49C/I- NKG2A/C/E-) corroborating the hypothesis that NK cells 
need to express at least one IR specific for cognate MHC class I molecules in order to become 
functional [421]. 
Ligand uptake from surrounding cells was previously described in NK cells derived 
from C57BL/6, β2m-KO and MHC class I transgenic mice [440, 504]. Trogocytosis following 
TAP1-KO NK cell co-incubation with donor cells were similar to the former results. Ligand 
uptake was independent of whether or not the NK cell expressed MHC class I molecules; both 
WT and TAP1-KO Ly49A+ NK cells were able to acquire H2-Dd from donor cells. This uptake 
proved to be a molecular mechanism independent of temperature or the cell medium in which 
NK cells and donor cells are co-cultured. Following a 30 min, 1h, 2h or 4h of co-incubation in 
complete DMEM or PBS, at 4°C, room temperature or 37°C 5% CO2, 97%-99% of Ly49A+ NK 
cells acquired H2-Dd (data not shown). Trogocytosis specificity was demonstrated by inhibiting 
the uptake after H2-Dd block in donor cells by an anti-H2-Dd Ab. Ly49A1 masking following 
trogocytosis clearly demonstrates that H2-Dd uptake by NK cells is a result of the specific 
interaction of the ligand with the A1 epitope of the Ly49A receptor. 
 
Sjöström et al. have demonstrated that RNK.Ly49A NK cells (a rat NK cell line stably 
transfected with the Ly49A) showed a reduced killing of YB2/0 target cells (a rat myeloma cell 
line) following the H2-Dd uptake. Killing was abolished when target cells expressed H2-Dd 
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molecules, implicating that even after H2-Dd uptake, Ly49A+ NK cells can still receive inhibitory 
signals through trans interactions [504]. These results cannot be extrapolated to TAP1-KO NK 
cells as RNK.Ly49A NK cells are initially functional, contrary to our TAP-deficient murine NK 
cells. H2-Dd acquisition following trogocytosis may have different consequences when taking 
the recipient cell status in consideration. 
The next step in our study was to investigate the functional consequences of the newly 
acquired Ly49A:H2-Dd cis interaction on murine TAP1-KO NK cells following trogocytosis. 
Separating both cell lines after co-incubation was necessary in order to eliminate the possible 
trans interactions between the ligand and its receptor which may interfere in the experiment’s 
outcome. Different methods were tested, but none was a success. After co-incubation, NK 
cells not only acquire H2-Dd from donor cells, but also membrane patches which included CD3 
(EL4 cells are CD3+), so following negative selection, H2-Dd+ NK cells were retained in the 
column alongside donor cells. FACS sorting did not solve the problem either, as sorted NK 
cells were very fragile and died shortly after, not giving us the possibility to test trogocytosis 
effect on their functions. Adding to this the production stop by “BD Biosciences” of the Ly49A 
(JR9-318) Ab, the continuation of our project was postponed. 
 
 
Figure legends 
 
Figure 1: Phenotypical characterisation of C57BL/6 and TAP1-KO NK cells. 
Histograms represent the expression percentage mean with SD of each of the studied markers 
on NK cells, n=6 (A) Black histograms represent C57BL/6 mice, and light grey histograms 
represent TAP1-KO mice. NK cells (NK1.1+ CD3-) derived from C57BL/6 and TAP1-KO mice 
spleens were phenotyped for different markers including inhibitory and activating receptors. 
(B) NK cell maturation was also studied using CD27 and CD11b (MAC-1). ***p < 0.001, 
**p < 0.01, *p < 0.05. 
 
Figure 2: Functional characterisation of C57BL/6 and TAP1-KO NK cells following 
activation with NK1.1 Ab or YAC-1 cells. 
Histograms represent the expression-percentage mean of each marker on NK cells. n=2 in A, 
C and D, and n=3 in B. In (A) and (B), black histograms represent WT NK cells and light grey 
histograms represent TAP1-KO NK cells. In (C) and (D), grey histograms represent all NK 
cells, grey histograms with diagonal lines represent educated (Edu+) NK cells (Ly49C/I+ 
NKG2A/C/E+), and grey histograms with horizontal lines represent non-educated (Edu-) NK 
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cells (Ly49C/I- NKG2A/C/E-). (A) Shown is the granzyme A expression frequency on C57BL/6 
and TAP1-KO NK cells. (B) Histograms represent NK cell degranulation following antibody 
crosslinking activation. NK1.1 is the Ab of interest, CD137 the negative control, and IgG2a the 
isotype control. (C, D) Shown is the NK cells’ IFN-γ production and CD107a expression 
following co-incubation with YAC-1 cells, ratio 2:1 (NK:YAC-1), 35U/mL of rhIL-2, 6h at 37°C, 
5% CO2. **p < 0.01. 
 
Figure 3: TAP1-KO and C57BL/6 NK cells can specifically take up H2-Dd from the 
surrounding cells. 
Shown are eight dot plots representing the co-expression status of Ly49A (JR9-318 clone, 
columns A, B and C, or A1 clone, column D) and H2-Dd on C57BL/6 (first line, A1, B1, C1 and 
D1) and TAP1-KO (second line, A2, B2, C2 and D2) NK cells. (A1, A2) NK cells were stained 
for Ly49A (JR9-318) before trogocytosis, (B1, B2) after trogocytosis, (C1, C2) or after 
trogocytosis following H2-Dd block in donor cells by an anti-H2-Dd Ab. (D1, D2) Ly49A epitope 
interaction-specificity was tested by staining NK cells with anti-Ly49A1 after trogocytosis. 
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Figure 1 
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Figure 2 
 
Figure 3  
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CONCLUSION 
 
Since their discovery in 1974-1975, NK cells became a subject of intensive study. Their 
capacity to spontaneously kill tumour and infected target cells, secrete a wide range of 
cytokines and regulate other immune cell functions, made them of great potential importance 
in several disease treatments. In this study work, we aimed at giving more insight to the above 
mentioned mechanisms and pathways. Better understanding NK cell education and receptor 
repertoire formation and adaptation can lead to a safer and wider clinical application. 
Taking advantage of our TAP-deficient biologic material stock, and starting 
collaborations with local and international scientific teams, we were able to shed more light on 
HLA class I molecules’ effect on NK cell phenotype, maturation and functions. 
In a close collaboration with the flow cytometry core facility, managed by Nicolaas 
Brons, we developed an 18-color flow cytometry panel giving us the ability to simultaneously 
study NK cell functionality as well as IR and maturity markers’ expression in TAP-deficient 
patients compared to healthy donors. In-depth phenotypic analyses showed that in a low 
surface HLA class I molecules’ expression context, NK cells tend to increase the co-
expression of their HLA class I receptors (KIR, NKG2A and CD8) especially on the less mature 
CD57- sub-population. Functionally, TAP-deficient NK cell hyporesponsiveness was 
confirmed, except for one patient. 
Based on these results, and willing to identify the different NK cell maturation and 
cytotoxicity pathways affected by the low surface expression of HLA class I molecules, whole 
genome microarrays were performed. Analysis showed that the surface expression level of 
HLA class I molecules does not seem to have an impact on NK cell maturation from CD56bright 
to CD56dim. A time-series gene profile comparison following 0, 1 and 5 hours of co-incubation 
with K562 cells demonstrated a different gene expression evolution for each of the two NK cell 
statuses, leading to an identical profile at the final time point. These results contradict the 
significant functionality difference between healthy and TAP-deficient NK cells and raise 
questions on how an identical gene induction can lead to such a significant phenotypic and 
functional difference. Are the genes induced at the right time in TAP-deficient NK cells, as the 
similarity between the two statuses was already significant at the 1 hour time point? What 
about mRNA translation in TAP-deficient NK cells, how is it regulated? Do microRNAs play a 
role in this regulation, as IFN-γ mRNA is detected at the same level in both NK cell types, but 
only expressed as a protein in healthy NK cells? A more detailed time-point analyses (between 
0 and 1 hour co-incubation) completed by a protein array may contribute to better understand 
the results we obtained. 
In the past few years, several studies mainly by M. Lopez-Botet and K. Malmberg 
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teams underlined the effect of CMV infections on NK cell repertoire adaptation. A time-stable 
expansion of NKG2C+ self-specific KIR+ NK cell population was observed. Among our TAP-
deficient patients’ cohort, only three presented an NK cell expression of NKG2C (15%-25%). 
In the light of these results, a collaboration was started with Prof K. Malmberg to whom PBMC 
derived from two patients were sent (presenting the highest percentage of NKG2C+ NK cells). 
Experiments performed by Dr V. Béziat demonstrated that contrary to CMV+ individuals, 
NKG2C+ NK cells in TAP-deficient patients did not present any skewing toward self-specific 
KIR expression. Unfortunately as patients’ serology is not available, no connection could be 
done with CMV. Functional tests (rADCC and response towards 721.221-AEH cells) showed 
that NKG2C does not act as an AR in TAP-deficient individuals, but as an activating co-
receptor. Only its combination with a 2B4 or DNAM-1 signal was efficient in activating one of 
the two studied patients’ NK cells. 
 
Our thesis work, combined with our collaborations’ results, lead to new fundamental 
findings in HLA class I molecules’ effect on NK cell functional properties and repertoire 
formation. These findings should allow us to better understand NK cells mechanisms and 
maybe reconsider some of their features while designing new immunotherapies. The low 
surface expression of HLA class I molecules seems to have a strong impact on NK cell 
repertoire and AR functions’ pathways. The department of stem cell transplantation (Texas 
University) in collaboration with Massachusetts Institute of Technology (MIT) and 
SangamoBioscience are investigating the possibility towards eliminating HLA class I 
expression and generate universal cells from allogeneic donors. Why not imagining using 
TAP-deficient NK cells in future immunotherapies? Only the limited amount of TAP-deficient 
PBMC makes further experiments difficult to perform. 
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